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Abstract 
Microbial diversity encompasses the whole of the Earth’s biosphere and is incredibly vast. 
The microbial diversity of three disparate micro-environments using two culture-independent 
techniques (denaturing gradient gel electrophoresis (DGGE) and 454-pyrosequencing) were 
revealed. Five commercially available DNA polymerase (pol) enzymes were assessed in 
determining the bacterial community generated in sandy soil. The V3 region of the 16S rRNA 
gene was targeted for amplification by polymerase chain reaction (PCR). Using a PCR-
DGGE approach, different DNA pols exhibited differences in the DGGE profiles produced. 
Both high-fidelity DNA pols Ex Taq™ Hot Start (HS) and Platinum® Pfx detected greater 
microbial diversity present within sandy soil than the other DNA polymerase enzymes. 
We employed Ex Taq™ HS to characterise the microbial communities present in two 
chronic respiratory tract diseases, non-cystic fibrosis bronchiectasis (nCFBR) and chronic 
obstructive pulmonary disease (COPD). Seventy individuals expectorated sputum, and using 
16S and 28S rRNA PCR-DGGE polymicrobial communities were revealed. From the 70 
patients investigated, 20 presented with symptoms consistent with an exacerbation, the 
remainder being clinically stable. Demographic and culture data were used in constrained 
ordination analyses to identify any significant associations between these data and changes in 
the sputum microbiota. The data presented indicates that bacterial lung communities in adult 
nCFBR patients have distinct differences between exacerbating and clinically stable episodes. 
Persistent colonisation by Pseudomonas aeruginosa is significantly associated with reduced 
lung function, and is negatively correlated with Haemophilus influenzae carriage. Bacterial 
communities seem to be predominantly assembled by stochastic processes. Fungal taxa 
present were scarce. 
Stable COPD populations have been previously investigated using culture-dependent 
techniques. Eleven clinically stable COPD patients had a bronchoalveolar lavage (BAL) fluid 
taken from the right lower lobe. Both 16S and 28S rRNA PCR-DGGE was performed on all 
clinical samples from extracted DNA. Co-migration of bands was then compared to a 16S 
and 28S standard ladder consisting of pure cultivars. Additionally, execution of 454-
pyrosequencing and interrogation of the V3-V5 region of 16S rRNA genes resulted in 1799 
unique OTUs being identified. Dominant bacterial genera identified were Streptococcus, 
Arthrobacter, and Staphylococcus respectively. Bacterial taxa identified were then subjected 
to multivariate statistical analysis to identify relationships between the microbial 
communities and patient phenotypes. Metagenomic analysis demonstrated that heterogeneous 
bacterial populations exist in all eleven individuals. This preliminary study shows that the 
lungs of COPD sufferers are colonised with multiple species of bacteria and demonstrate that 
a complex microbial community is present. Furthermore, bacterial phylotypes resolved to 
class-level indicated three potential drivers of community structure within the COPD lung 
microbiome: lung function, moderate and severe COPD progression, and smoking status in 
cohort. The identification of a greater number of bacterial taxa was also apparent in culture-
negative patients using both PCR-DGGE and 454-pyrosequencing approaches. 
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SL:  standard ladder(s) 
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SSCP:  single strand conformation polymorphism 
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Chapter One: General introduction 
1.1 A global view of micro-organism biodiversity 
The biosphere of Earth is absolutely dependent on micro-organisms since they are 
required to sustain almost every form of life on the planet and are also key drivers in almost 
all geochemical cycles (Madigan et al., 2009). Since the landmark paper published by Woese 
and Fox in 1977, followed by subsequent developments in molecular biology in the 1980s, 
microbial diversity on Earth is recognised as being greater than microbiologists had ever 
envisioned. Over evolutionary time, diversity has led to the successful proliferation and 
colonisation of micro-organisms across an extensive range of habitats. Environments such as 
soil, the ocean, the subsurface, and indeed macro-organisms including humans, harbour an 
extraordinary number of prokaryotes (Whitman et al., 1998). In addition, the many 
prokaryotic phyla have species capable of colonising a multitude of environments 
inhospitable to other forms of life for example: hot springs situated in Yellowstone Park 
(Hugenholtz et al., 1998b), the high temperatures and extremely low pH niche of the 
thermoacidicphilic euryarchaeon Picrophilus torridus (Futterer et al., 2004), the deep sea 
(DeLong et al., 1994), hydrothermal vents (Huber et al., 2000), the sea ice of the Antarctic 
(Thomas and Dieckmann, 2002), and even in the permanent ice both in Lake Bonney and 
Lake Vostok (Christner et al., 2001, Gordon et al., 2000, Priscu et al., 1999). 
Estimates of the total number of prokaryotes on Earth are in the order of 4-6 × 10
30
 cells 
with a biomass of 350-550 Pg of carbon (1 Pg = 10
15
 g) (Whitman et al., 1998). Owing to the 
inconceivable numbers of bacterial cells present in our biosphere, their rapid growth and 
ability to demonstrate physiological and genetic adaptability this group of organisms has 
incredible genetic diversity (Hindré et al., 2012). Putting these numbers into perspective is 
indeed a daunting task, it has been estimated that one ton of soil contains at least 4 × 10
6
 
different taxa (Curtis et al., 2002). Quoting Pace, et al., “we are only scratching the surface of 
a vast reservoir of microbial diversity” (Pace et al., 2012). 
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1.2 The origins of modern molecular microbiology 
A sobering aspect to consider in terms of the many species of bacteria that inhabit the 
Earth is that estimates of only 1 % of all microbial species have been identified and 
characterised by classical culture-based techniques (Amman et al., 1995, Staley and 
Konopka, 1985). Historically, before the advent of molecular sequence-based phylogenetics 
much of microbial life (and its genetic diversity) was alluded to and previous hypotheses 
regarding the kingdoms of life constituted five: animals, plants, fungi, protists, and monera 
(protozoa and bacteria respectively) (Whittaker, 1969). This model was adopted primarily on 
the previous knowledge of the macro-organisms around us within the biosphere, and rather 
ignorantly, bacteria themselves were thought to be unimportant; the term “prokaryote” itself 
was defined rather negatively in comparison to their eukaryotic counterparts in the 1960s 
(Stainer and van Niel, 1962). The advances in molecular biology in the next decade made 
possible the inference of phylogenetics across all the kingdoms of life by comparison of 
ribosomal ribonucleic acid sequences. In addition to the seminal work carried out by Pace 
and collaborators using these techniques enabled a reconstruction of the history of life and 
proposed a new model consisting of the now-recognised three primary lines of evolutionary 
descent as opposed to the initial standard two in the universal tree of life (Woese, 1987, 
Woese and Fox, 1977, DeLong and Pace, 2001, Olsen et al., 1986). These are now formally 
designated “urkingdoms” or “domains” represented by the Eucarya (eukaryotes), Bacteria 
(initially termed the eubacteria) and Archaea (initially termed archaebacteria) (Fig. 1.1) 
(Woese et al., 1990). 
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Fig. 1.1: The universal tree of life (ToL) representing the three known domains, 
Archaea, Bacteria, and Eucarya. These domains or kingdoms were phylogenetically 
reconstructed using partially or fully sequenced ribosomal ribonucleic acid sequences 
(rRNAs) from both the 16S (ubiquitous in archaeal and bacterial species) and 18S 
(exclusive to the Eucarya domain) ribosomal small subunits. Phylum levels indicated 
are shown by the branches in each kingdom, whereas at the bases of each 
phylogenetic tree there are unresolved branching orders (blue circles) (Pace, 2009). 
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1.3 Culture-dependent microbiology 
Classical culture-based microbiological techniques pioneered by Beijerinck, Koch, 
Pasteur, van Leeuwenhoek, and Windogradsky maintained and developed microbiological 
research for centuries (Keller and Zengler, 2004). Culture-dependent microbiology is crucial 
if one is to characterise and gain a significant understanding of a bacterial species or micro-
organism, its physiology, or access to its metabolic pathways via genes dispersed throughout 
its genome (Keller and Hohn, 1997, Palleroni, 1997, Yu et al., 2002). However, using 
traditional enrichment and cultivation techniques accepts the issue that such techniques are 
highly selective and biased towards the growth of specific bacterial species. 
This facet of traditional culture-based microbiology is no more apparent than in the 
modern clinical microbiology laboratory where these techniques are used in conjunction with 
modern molecular-based methodologies for the routine isolation of potentially pathogenic 
micro-organisms (PPMs) from patient specimens (i.e., the detection of aetiological agents by 
providing conditions they require to grow in vitro (Rogers et al., 2009a)). Indeed, using 
selective media for effective isolation requires that the PPMs in question must grow to at 
least 10
5
 cells in density in order for these bacterial colonies to be visualised (Keller and 
Zengler, 2004). One must also bear in mind that for isolation of the aetiological agent(s), the 
selective media employed biases in favour of fast-growing and high density forming micro-
organisms that have the capacity to withstand high concentrations of nutrients and have the 
ability to grow in isolation (Keller and Zengler, 2004). A great number of traditional 
cultivation techniques fail to isolate many micro-organisms from most natural habitats, 
including humans. A major contributing factor of this, is that the traditional cultivation 
techniques employed such as selection and isolation of specific microbes utilise conditions 
for growth in vitro that are completely different to the natural environment from which many 
of these micro-organisms originate from (Eilers et al., 2000, Torvisk et al., 2002). 
The major limiting factor in using culture-based microbiology to isolate aetiological 
agents is that culture-based techniques do not consider the role of polymicrobial infections or 
the vast numbers of microbial taxa that colonise the human host. Indeed, bacteria infecting 
human tissues are often part of mixed bacterial communities, in particular when mucosal 
barriers have been compromised (Brogden et al., 2005). Contextually, we sometimes need to 
consider infection as a complex microbial milieu (Rogers et al., 2009a). This is very 
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important if appropriate treatment regimens are to be adopted and tailored to the individual 
patient infected with one or more pathogenic organisms. The advent of culture-independent 
techniques has revealed these microbial communities within the human host in greater detail 
than ever before and also enables investigators to appreciate the magnitude of the task 
involved in characterising these communities. 
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1.4 Culture-independent microbiology 
Culture-independent techniques have revealed a vast world of microbial diversity 
remaining to be discovered and placed microbes, once thought to be insignificant, firmly 
back into their respective positions in the universal tree of life (Pace et al., 2012). Molecular 
fingerprinting methods such as denaturing gradient gel electrophoresis (DGGE), temperature 
gradient gel electrophoresis (TGGE), terminal restriction fragment length polymorphism (T-
RFLP), single strand conformation polymorphism (SSCP), and denaturing high-performance 
liquid chromatography (DHLPC) have enabled researchers to analyse microbial communities 
from several ecosystems; these techniques are collectively known as microbial profiling 
(Nocker et al., 2007). These fingerprinting techniques have usually targeted the 16S rRNA 
gene(s) (Hugenholtz et al., 1998a, Pace et al., 1986) or sometimes functional genes encoding, 
for example, ammonium mono-oxygenase (amoA) (Horz et al., 2000, Yeager et al., 2005), 
nitrogenase (nifH) (Rosado et al., 1998, Widmer et al., 1999), and RNA polymerase B (rpoB) 
(Adékambi et al., 2008, Ormeno-Orrillo et al., 2006, Renouf et al., 2006) for the analysis of 
sub-populations that exhibit certain functional properties within a community (Nocker et al., 
2007). Total community DNA is extracted and used as a template for PCR amplification of 
the 16S rRNA gene(s), PCR fragments are then either analysed by electrophoresis (DGGE, 
TGGE, SSCP, and T-RFLP) or chromatography (DHLPC) (Nocker et al., 2007). Resolution 
of the different bacterial species within the community is achieved as a function of DNA 
sequence variation within the amplified 16S rDNA fragments as these are usually of similar 
size (Hamady and Knight, 2009, Nocker et al., 2007). Finally, from the community profiles 
generated, one can analyse the banding patterns or clustering of specific bands using 
statistical techniques such as Principal Co-ordinates Analysis (PCoA) (Dollhopf et al., 2001). 
More recently, the next-generation sequencing (NGS) analysers developed by Roche, 
Illumina®, and Applied Biosystems™ have taken sequencing to the next level via 
deployment of multiple platforms and different sequencing technologies paving the way for 
the era of metagenomics that we now live in. This ‘next level’ can be further defined as what 
is commonly known as ‘deep sequencing’, i.e., massively parallel sequencing ― the 
simultaneous sequencing of several hundred thousand DNA fragments with read lengths 
exceeding that of 100 base pairs (bp) (McPherson, 2009). The term metagenomics is defined 
as “culture-independent studies of the collective set of genomes of mixed microbial 
communities and applies to explorations of all microbial genomes in consortia that reside in 
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environmental niches, in plants, or in animal hosts (Petrosino et al., 2009). Using 454-
pyrosequencing as an example of a NGS platform; briefly, DNA pyrosequencing or 
sequencing synthesis is based on the detection of released inorganic pyrophosphate (PPi) 
during DNA synthesis. Visible light (i.e., photons) is generated by a cascade of enzymatic 
reactions and the amplitude of each light signal is proportionally represented by the 
incorporation of nucleotides (Fig. 1.2) (Novais and Thorstenson, 2011). In metagenomic 
studies using massively parallel sequencing technology, DNA pyrosequencing targets 
hypervariable regions within bacterial 16S rRNA genes amplified by PCR. By using millions 
of single-stranded DNA fragments from isolated genomic DNA (gDNA) as sequencing 
templates attached to beads in emulsion PCR, amplification occurs within each emulsion 
droplet. Each bead carrying millions of copies of unique DNA templates are all denatured 
and every bead attached to a single-stranded DNA (ssDNA) clone are deposited into tiny 
chambers before being exposed to another set of smaller beads carrying immobilised 
enzymes which are responsible for DNA pyrophosphate sequencing. Nucleotide composition 
of each ssDNA fragment is elucidated by the associative release of PPi and generation of 
photons (Margulies et al., 2005). Exploitation of 16S rRNA gene(s) in culture-independent 
studies of the microbiota of metazoan subjects and the environment has enabled microbial 
ecologists to not only infer the phylogenetic relationships of the bacterial communities but to 
also detect uncultivable species of bacteria from many taxa using modern sequencing 
technologies coupled with molecular fingerprinting methodologies. From the original 11 
phyla described by Woese and colleagues nearly 30 years ago (Woese et al., 1985), the 
bacterial phyla now number 53 thanks in part to the impact of 16S rRNA gene sequencing 
from uncultivable bacterial species (Rappé and Giovannoni, 2003). 
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Fig. 1.2: Principals of DNA pyrosequencing. 1.) Single-stranded DNA (ssDNA) in PCR amplicon 
serves as template for hybridisation of a sequencing primer incubated with four enzymes, DNA 
polymerase, adenosine triphosphate (ATP) sulphurylase, luciferase, and apyrase in addition to the 
substrates adenosine 5′ phosphosulphate (APS), and luciferin. 2.) Addition of the first 
deoxyribonucleoside triphosphate (dNTP) into the reaction results in catalysis of this dNTP by the 
DNA polymerase enzyme via insertion into the DNA strand but only if it is complementary to the 
base in the template strand. Incorporation of these complementary bases is associated with the 
release of inorganic pyophosate (PPi). Subsequently, the amount of PPi released is related to the 
amount of incorporated nucleotides in the reaction, i.e, in equimolar quantities. 3.) Conversion of 
PPi to ATP is executed by the enzyme ATP sulphurylase in the presence of APS. The generation 
of photons proportional to the amount of ATP released from the primary conversion from PPi to 
ATP is from the ATP product itself driving the luciferase-mediated conversion of luciferin to 
oxyluciferin. Detection of photons in the luciferase-catalysed reaction is achieved by a charge 
coupled device chip and is visualised by a peak in the program (i.e., raw data output). The light 
signal produced is proportional to the number of nucleotides incorporated. 4.) The nucleotide-
degrading enzyme, apyrase, continuously degrades unincorporated nucleotides and ATP. 
Subsequent addition of nucleotides only occurs once this degradation process is complete. 5.) 
The complementary DNA strand is synthesised continually by the sequential addition of dNTPs in 
which the nucleotide sequence data is determined by the signal peaks visualised in the program 
output and then annotated appropriately (Novais and Thorstenson, 2011, Qiagen). Abbreviations: 
ADP, adenosine diphosphate; AMP, adenosine monophosphate; dNDP, deoxyribonucleoside 
diphosphate; dNMP, deoxyribonucleoside monophosphate. 
1 
5 
4 
3 
2 
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In particular, culture-based microbial identification to nucleic acid sequencing is now 
becoming more commonplace in diagnostic microbiology laboratories. In the past this 
approach has been infrequently adopted due to the technical expertise needed to perform 
DNA sequencing using Sanger technologies (Petrosino et al., 2009). Developments using 
Sanger-sequencing showed that 16S rRNA genes contain 9 hypervariable regions, V1-V9, in 
which ~ < 500 bp of the 16S rDNA coding sequence was required in order to generate genus- 
and species-level pathogen identification (Kolbert and Persing, 1999, Lane et al., 1985). The 
hypervariable V1-V9 regions (50-100 bases in size) situated within the 16S rRNA genes in all 
bacteria are interspersed between highly conserved regions (Fig. 1.3); indeed, all 16S rRNA 
vary in their nucleotide sequence composition, but the conserved regions remain as they 
were, unchanged, conserved invariant through time across nearly all bacterial species due to 
their essential functions within the bacterial cell (van de Peer et al., 1996, Jonasson et al., 
2002). This key property coupled with the inherent nature of 16S rRNA in addition to high 
information content and universal distribution reveals why 16S rRNA is utilised for 
phylogenetic analysis, microbial community profiling, and more recently, metagenomic 
studies using NGS technology. 
 
  
Fig. 1.3: Conserved and hypervariable regions within the 16S rRNA gene. The conserved regions 
interspersed throughout this gene are indicated in grey (C1-C9), whereas the hypervariable 
regions (V1-V9) are represented by different colours. Each hypervariable region ranges from ~ 50-
100 base pairs in length. The V4 subregion, as an example, shows PCR amplification using 
primers that target the hypervariable region of interest (pink circles in full length 16S rRNA gene 
and pink arrows representing primer-binding sites) and the sequencing primer site (blue bottom 
arrow). Metagenomic sequencing using 454-pyrosequencing technologies utilise multiple 
hypervariable regions of the 16S rRNA gene to generate greater read lengths and sequence 
coverage in microbial identification (Petrosino et al., 2009). 
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The V1-V9 regions themselves have been shown to demonstrate different efficacies in 
terms of the species or genus phylotypes resolved within the microbial community analysed 
and their respective environments sampled. A study by Chakravorty et al., has shown that the 
V2 and V3 regions were the most effective at independent genus identification (Chakravorty 
et al., 2007); in particular is the application of the V3 hypervariable region in microbial 
community profiling PCR-DGGE mediated studies in which Yu, et al, (2004)  showed that 
amplification of the V3 region within rrs genes generated better DGGE profiles than the 
other hypervariable regions amplified and analysed (Yu and Morrison, 2004). 
In summary, culture-independent techniques have been an indispensable aid in describing 
the many microbial consortia in the biosphere of planet Earth and in us, human beings. In the 
following section we will demonstrate that we are collectively as a species intimately 
involved and indeed in contact with a characteristic microbiota incorporating bacteria, 
viruses, archaea, protozoans, and fungi (Foxman et al., 2008). 
1.5 The bacterial ribosome and 16S rRNA 
The constant manufacturing processes involved in protein biosynthesis occur on the 
ribosome and these play a key role in a bacterium’s ability to proliferate in the environment, 
providing implications for bacterium-host interactions and crucially pathogenicity (Moss et 
al., 2007). This massive macro-molecular protein, 21 nm in size is comprised of both the 30S 
and 50S subunits which associate together via self-assembly forming the intact 70S bacterial 
ribosome (Ramakrishnan, 2002). Several publications of the three-dimensional structure of 
the ribosome have revealed the 30S and 50S subunits in great detail (Ban et al., 2000, Cate et 
al., 1999, Schluenzen et al., 2000, Schuwirth et al., 2005, Wimberly et al., 2000). Both 
subunits contain rRNA; the smaller 30S subunit comprising of 16S rRNA (1542 nt) and 21 
ribosomal proteins (termed r-proteins), the larger 50S subunit is composed of two rRNAs, 
23S (2904 nt) and 5S (120 nt) rRNA and 33 proteins (Noller and Nomura, 1996). 
Within the rrnB operon (Fig. 1.4) downstream from both promoters P1 and P2, the 16S 
rRNA is encoded by the rrs genes; these express the formation of the small subunit (SSU) 
16S rRNA ubiquitous in all bacterial species (one copy of this gene is always present in the 
bacterial genome ― although copy number can vary between bacterial species; e.g., model 
organisms such as Bacillus subtilis, Clostridium perfringens, Escherichia coli, and 
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Lactococcus lactis have been previously shown to possess 10 (both in B. subtilis and C. 
perfringens) (Garnier et al., 1991, LaFuci et al., 1986), 7 (Kiss et al., 1977), and 6 (Beresford 
and Condon, 1991, Tulloch et al., 1991) rrn operons respectively) (Kaczanowska and Rydén-
Aulin, 2007). Assembly of the prokaryotic ribosome is extremely complex and an in depth 
discussion of its assembly and multiple functions is beyond the scope of this thesis. 
 
  
Fig. 1.4: The rrnB operon showing nucleolytic processing of the rrnB primary transcript. 
Downstream promoters P1 and P2 in the rrnB operon encode the formation of both 16S and 23S 
rRNA species and their associated ribosomal proteins (r-proteins) (not shown). Both the 5′ and 3′ 
sites are indicated in addition to the promoter and termination regions (P1, P2, T1, and T2 
respectively). Also indicated are the processing sites of RNase III (III), RNase G (G), RNase E (E), 
RNase P (P), RNase T (T), and unknown RNases (?). These RNases process and chemically 
modify the pre-mature rRNA species in the positions shown above generating mature 16S and 
23S rRNA species (Kaczanowska and Rydén-Aulin, 2007). 
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1.6 The human microbiome 
In humans, estimates of the total amount of bacteria that colonise the gastrointestinal tract 
(GIT) outnumber our ‘own’ cells by up to 10-fold (Poxton, 2010). Acquisition of many 
bacterial taxa present in the gut is due to the early colonisation of these bacteria when the 
neonate first passes through the birth canal during labour (Palmer et al., 2007). The gut is not 
the only microbial ecosystem located in the human body, the skin, urogenital tract, and 
indeed the upper respiratory tract, have significant and complex bacterial communities 
(Gonzalez et al., 2011, Turnbaugh et al., 2007). These ubiquitous micro-organisms are an 
essential part of human evolution. In particular, mutual bacterial colonisation of the human 
mucosal surface interface forms a co-evolutionary relationship which benefits both the 
numerous bacterial species which inhabit these regions and the host; e.g., the upper 
respiratory tract (URT) and GIT plays host to ~ 600 and 1,000 unique species of bacteria 
respectively; identified as either permanent residents, others as transiently colonising these 
mucosal sites (Aas et al., 2005, Manson et al., 2008). 
The Human Microbiome Project (HMP) of the National Institutes of Health (NIH) was 
launched in 2007 in a venture to begin to understand and characterise the human-associated 
microbiota and microbiome factors; i.e., collectively, the microbes that inhabit us and the 
genes in all of these micro-organisms (Gonzalez et al., 2011). We are only beginning to 
appreciate the full impact of the human microbiota in health and disease and the genetic 
diversity that encompasses the human microbiome in chronic diseases such as obesity 
(Turnbaugh et al., 2009), Crohn’s disease (Eckburg and Relman, 2007) and other metabolic 
disorders (Spencer et al., 2011). Indeed micro-organisms are absolutely essential for human 
health offering beneficial effects such as the maintenance of pH in the oral and vaginal 
cavities, stimulation of the immune system, both innate and cellular, the prevention of 
invasion by PPMs, digestion of ingested foods through phase III metabolism processes, and 
finally providing nutrients vital to our health (Foxman et al., 2008). Most research is 
presently centred around bacterial diversity, whether this is through NGS or molecular 
fingerprinting methodologies, of the human microbiota, and several studies on bacterial 
diversity have been published on the GIT (Eckburg et al., 2005, Qin et al., 2010, Zoetendal et 
al., 1998), skin (Fierer et al., 2008, Gao et al., 2007), female urogenital tract (Brown et al., 
2007, Zhou et al., 2007) URT (Charlson et al., 2010), and lungs (Hilty et al., 2010) of 
individuals amongst others. However, the human microbiome is not only comprised of 
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bacteria, other studies looking at both fungal and viral metagenomics (termed mycobiome(s) 
and virome(s) respectively) in human hosts have also recently been published looking at both 
diseased and non-diseased cohorts (Ghannoum et al., 2010, Reyes et al., 2010, Willner et al., 
2009). 
1.7 Microbial ecology 
How does one make sense or comprehend this mass of genomic information contained 
within the human microbiome? In the GIT alone, it has been hypothesised that the entire gene 
complement of the intestinal microbiota was ~ 150 times larger than our own, many of these 
genes being uniquely encoded within this microbial assemblage (Qin et al., 2010). One way 
to tackle the increasing amounts of data and begin to model the numerous interactions within 
this abundance of microbes is to use microbial ecology hypotheses, i.e., looking at the 
microbial communities that make up the human microbiome from an ecological perspective. 
Using a microbial ecological framework provides microbiologists and the biomedical 
community powerful schemes for hypothesis testing of the HMP datum (Dethlefsen et al., 
2007, Robinson et al., 2010). Microbial community ecology arose from macro-ecology, i.e., 
the ecological frameworks used to study both the plant and animal kingdoms defined as 
“multi-species assemblages, in which organisms live together in an environment and interact 
with each other” (Knoopka, 2009). Using these frameworks enables microbial ecologists to 
better elucidate the way in which microbial communities that are part of the human 
microbiome contiguously interact within environmental niches inside the human body over 
space and time (Gonzalez et al., 2011). In addition, the investigation of the micro-
environment within and its concurrent effects on the distribution and abundance of microbial 
species will provide a better understanding of the communities that inhabit us (Gonzalez et 
al., 2011). Adapting these theories and applying them to the microbial world has taken time, 
but nevertheless two studies in 2006 combined the metagenomic strategies with microbial 
ecology modelling for the datum generated; the first investigated the metagenomics of the 
microbial community in water from an iron mine in Minnesota (Edwards et al., 2006). 
Subsequently, a second study elaborated the metagenomics of rare members of several 
microbial communities using massively parallel pyrotag sequencing (Sogin et al., 2006). 
With this data, ecological measurements of richness, diversity, and similarity were all used 
for data analysis. 
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In essence, microbial diversity within sample types analysed, can be performed using three 
measures: alpha, beta, and gamma diversity indices defined by Whittaker in which (i), alpha 
diversity quantifies the richness of the species (number of taxa) in a niche; (ii), beta diversity 
compares the diversity between environments thus describing how disparate communities are 
structured in different niches; and (iii), gamma diversity in which both the alpha and beta 
diversity of communities from different landscapes and geographical regions are measured 
(Whittaker, 1972, Whittaker, 1969). In the microbial world, the definition of the term species 
is pragmatic (Amman et al., 1995). Conceptually speaking the term species encompasses 
those individuals as a group interbreeding within a species but isolated from other groups 
(i.e., other species) by genetic recombination barriers (Mayr, 1957). However, bacteria and 
some eukaryotes are asexual, contradicting this assumption, thus not forming ecologically 
distinct species defined genetically (Amman et al., 1995). Nevertheless, bacterial species are 
still defined by the use of operational taxonomic units (OTUs), i.e., the binning of coding 
nucleotide sequences from 16S rRNA genes to form species-level OTUs at a phylogenetic 
distance of 0.03, equivalent to 97 % nucleotide similarity against reference species sequence 
databases (Robinson et al., 2010). In addition to species diversity, other factors implicated in 
microbial ecology are biological divers of community structure, spatial patterning and 
temporal dynamics. All of these factors are hypothesised to affect the human microbiota. 
1.8 Microbial biofilms 
It has been recognised for some time now that microbes very rarely exist in isolation in 
natural, industrial, and medical habitats; microbes, and in particular bacteria, tend to form 
aggregated complex three-dimensional structures (Stickler, 1999). These aggregated bacterial 
cells are embedded within a hydrated matrix of extracellular polymeric substances (EPS) 
termed biofilms (Costerton et al., 1999, Donlan and Costerton, 2002). A polymicrobial 
biofilm therefore can be further defined as an eclectic assortment of fungi, bacteria, and 
viruses, attached to biotic and abiotic sites within the human host (Peters et al., 2012). Studies 
conducted on polymicrobial biofilm communities within the oral cavity enabled an initial 
understanding of the properties of biofilms. 
Using bacteria as an example, the formation of biofilms is a result of an ancient adaptation 
(Hall-Stoodley et al., 2004) that prokaryotes utilise as a mode of growth in hostile 
environments, enabling the colonisation of new niches via dispersal mechanisms (Hall-
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Stoodley and Stoodley, 2005, Mai-Prochnow et al., 2008, Purvedorj-Gage et al., 2005). 
Polymicrobial biofilm formation is through sequential attachment mechanisms termed co-
aggregation, in which one species of microbe attaches itself to an appropriate substrate and 
then subsequently becomes a scaffold for other micro-organisms to facilitate adherence and 
biofilm formation (Rickard et al., 2003). Microbial biofilms are important both in healthy and 
diseased individuals due to several characteristics such as (i), phenotypic heterogeneity (ii), 
cell-cell communication via quorum sensing (QS), (iii), recalcitrance against antimicrobial 
compounds and (iv), resistance to both host phagocytic defences and antibodies (Hall-
Stoodley and Stoodley, 2009). All of these properties enable biofilm infections to persist in 
the host despite administration of antimicrobial therapies and sustained host innate and 
cellular immune responses. Microbial biofilms are also beneficial to the host; specifically 
speaking, the abundance of conserved bacterial genera in the oral cavity has been previously 
shown using implanted sterile enamel chips into the mouths of human volunteers 
demonstrating the early colonization (~ 4 h) of Streptococcus spp. in addition to other genera 
such as Actinomyces, Gemella, Granulicatella, Neisseria, Prevotella, Rothia, and Veillonella 
(Diaz et al., 2006). Changes in this conservation of specific bacterial genera, whether over a 
rapid or slower time, has been hypothesised to promote disease-associated phenotypes within 
the human host; one example of this is the administration of broad-spectrum antibiotics 
which can severely affect the global bacterial populations within the community in the gut, 
i.e., reducing the protective properties of the polymicrobial commensals, thus allowing the 
proliferation of more invasive and resistant bacterial species in the site affected (Dethlefsen et 
al., 2008). 
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1.9 Polymicrobial infections 
Just as polymicrobial biofilms are comprised not only of bacteria, but also viruses and 
fungi, polymicrobial infections can be defined as acute and chronic diseases caused by 
various combinations of viruses, bacteria, fungi, and also parasites (either protozoan or 
metazoan in origin) (Brogden et al., 2005). Further to this definition, polymicrobial infections 
are hypothesised to play a significant role within the human host and can manifest themselves 
via three distinct processes, although these processes could be all in unison (Brogden et al., 
2005): 
1. The generation of an environmental niche inside the human host due to the 
presence of one microbial species facilitates the colonisation of this niche by 
other PPMs. 
2. When one species of microbe is present, this predisposes the host to subsequent 
colonisation by other micro-organisms. 
3. Two or more non-pathogenic microbes are present and cause disease through 
synergistic effects in the host. 
Some of the above concepts have been touched on recently, especially in relation to the 
theoretical concepts presented in microbial ecology, a key point here is that in polymicrobial 
infections, microbe-microbe interactions such as microbial interference can actually suppress 
the proliferation of other micro-organisms in the environmental niche generated, this 
interference can occur between PPMs or between probiotic microbes and pathogens (Bogaert 
et al., 2004). Synergistically, an environmental niche is generated by one microbe, as in 
periodontal disease, and this leads to subsequent colonisation by other PPMs (Palmer et al., 
2001). Bacterial-viral synergism also plays a strong role in polymicrobial infections, for 
example, the isolation of human metapneumovirus (HPMV) in a range of debilitating 
respiratory tract conditions in conjunction with other viruses such as severe acute respiratory 
syndrome, with coronavirus, and bronchiolitis with respiratory syncytial virus (RSV) (Chan 
et al., 2003, Greensill et al., 2003). Infection with the measles virus also greatly pre-disposes 
the host to secondary infections with bacterial agents (Slifka et al., 2003); these secondary 
bacterial and viral infections can be attributed to the primary viral infection exhibiting and 
inducing an immunosuppressive effect within the host thus leading to, but not always, severe 
detrimental results. Additionally, infection with respiratory tract viruses can greatly pre-
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dispose the host to colonisation or subsequent infection with a secondary micro-organism via 
destruction of the epithelial lining of the respiratory tract thus increasing bacterial adhesion 
and up-regulation of bacterial cell-surface receptors with the immunosuppressive properties 
of the viral infection which can lead to bacterial super-infections (Peltola and McCullers, 
2004). 
What is the basis for polymicrobial interactions in the human host and their origin? In all 
humans there is a co-evolutionary relationship between the host and their microbiome, this 
co-evolution has developed over time for thousands of years and has consequently resulted in 
species-specific physical and chemical interactions between microbes; these microbe-microbe 
interactions are employed due to the large variety and concentration of micro-organisms 
present and relatively minute amount of physical space available within us (Peters et al., 
2012). Microbe-microbe interactions can be expressed variously within the host such as 
immunomodulation, augmented virulence phenotypes in trans, colonisation enhancement 
factors, cell-cell communication via QS, and contact-dependent attachment (Peleg et al., 
2010). 
Indeed, polymicrobial infections within human hosts are being increasingly recognised 
both in nosocomial and community settings as these several conditions imply: (i), human 
deficiency virus-acquired immunodeficiency syndrome (HIV-AIDS) patients in Africa are 
co-infected with malarial protozoan parasites and/or with Mycobacterium tuberculosis in 
addition to other micro-organisms (Lawn, 2004), (ii), bacterial vaginosis infection in women 
involves the increase in the mixed bacterial populations of Gardnerella vaginalis, Gram-
positive anaerobic cocci and Gram-negative anaerobic rods such as Peptostreptococcus spp. 
and Prevotella spp. respectively, in addition to Mycoplasma hominis and Ureaplasma 
urealyticum as the Lactobacillus sub-populations rapidly decline (Hill, 1993, Persson et al., 
2009, Pybus and Onderdonk, 1999), (iii), dental caries in the oral cavity is an extremely 
common condition affecting most of the adult population and younger children in which the 
hard enamel, dentin, and cementum surface surrounding the soft dental pulp is broken down 
(Holst, 2005). Breakdown of the hard dental surface is first by the creation of a polymicrobial 
biofilm ― i.e., dental plaque ― and secondly, the fermentation of carbohydrate sugars such 
as sucrose and fructose into lactic acid by several species of bacteria such as Actinomyces 
viscosus, Lactobacillus acidophilus, Nocardia spp., Streptococcus mutans, and the yeast 
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Candida albicans (Kinke et al., 2009, Minah and Loesche, 1977), (iv), chronic lower 
respiratory tract (LRT) infections in cystic fibrosis (CF) and chronic obstructive pulmonary 
disease (COPD) individuals are now thought to be polymicrobial in nature due to extensive 
studies, especially in CF where culture-independent techniques were employed (Erb-
Downward et al., 2011, Harris et al., 2007, Hilty et al., 2010, Rogers et al., 2005a, Rogers et 
al., 2004, Rogers et al., 2003, Sethi et al., 2009, Sethi and Murphy, 2008, Sibley et al., 2006, 
Veeramachaneni and Sethi, 2006). 
1.10 The respiratory tract 
The respiratory system in humans is categorised into two separate components, the upper 
and lower respiratory tract, both operate in unison for the effective and efficient distribution 
of air, from the external environment into the internal environment of the lungs. The URT 
serves to warm and moisten the air when inspiration occurs protecting the LRT from PPMs 
and other foreign particles such as allergens, but also enabling for effective gaseous 
exchange. The LRT is responsible for the gaseous exchange of diatomic oxygen (O2) in the 
alveoli to the peripheral blood capillaries that line the connecting tissues. Here O2 diffuses 
across the membrane and enters erythrocytes, initially binding to haemoglobin in the process, 
that are circulating in the blood capillaries before releasing O2 to the tissues and cells around 
and within the body where required. In humans, the process of respiratory function is an 
essential physiological process; it is the gaseous exchange of diatomic oxygen and carbon 
dioxide between blood and the external atmosphere (Bourke, 2002, Marieb and Hoehn, 
2007). 
The lung is the major interface between the internal and external environment of the 
human host, inspired air is abundant with opportunistic and pathogenic bacteria, viral and 
fungal micro-organisms (Bourke, 2002). Despite this constant exposure to potentially harmful 
particles, the health of an individual is maintained by sophisticated and complex host defence 
mechanisms (Stockley, 1998, Wilson et al., 1996). Defences such as the mucocilliary 
escalator which inhibits adherence and facilitates particle removal are dependent on bronchial 
epithelium integrity (Stockley, 1998). In addition, are antimicrobial agents such as lysozyme 
and lactoferrin that inhibit bacterial replication, secretory immunoglobulin A (IgA), and 
scavenging macrophages (Stockley, 1998). 
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1.10.1 Chronic respiratory tract diseases 
Chronic respiratory tract diseases are of major global importance; they are increasing in 
incidence worldwide and are now classified by the World Health Organisation (WHO) as 
non-communicable diseases (NCDs) in addition to cardiovascular disease, cancer, and 
diabetes, collectively they account for the highest rates of mortality on a global scale than all 
other causes combined (Reardon, 2011). Chronic respiratory diseases encompass conditions 
such as CF, COPD, non-cystic fibrosis bronchiectasis, and asthma amongst others. Asthma 
and COPD present problems worldwide, both in terms of morbidity and mortality, but also in 
economic costs on healthcare resources. Asthma is a chronic inflammatory airway disease in 
which individuals suffer from exacerbations which result in chest tightness, wheezing, cough 
and dyspnoea, all symptoms associated with airway obstruction (Jarjour and Kelly, 2002). In 
the Western world, asthma is the most common chronic respiratory disease affecting 10 % of 
adults and 30 % of children, in the U.S. alone, 1.75 million asthma-related emergency 
department visits and 456 000 asthma-related hospitalisations were recorded contributing 
towards one-third of the total $14.7 billion annual U.S. asthma-related health care 
expenditure (Akinbami et al., 2011, American Lung Association). Chronic obstructive 
pulmonary disease is primarily induced by cigarette smoking and is characterised by 
irreversible airflow limitation and chronic inflammation in the LRT (Pauwels et al., 2001). 
COPD is an increasingly leading cause of morbidity and mortality globally, but woefully 
under-recognised (Pauwels and Rabe, 2004); from 1990 to 2020, the 30 year projection of 
COPD ranking will be a rise from sixth to third most common cause of mortality and fifth in 
the cause of disability worldwide (Lopez and Murray, 1998). Economically, in the U.K., 
£500 million is spent annually through direct healthcare costs relating to COPD in addition to 
24 million working days also wasted (British Lung Foundation, 2006). 
Cystic fibrosis is the most common recessive autosomal genetic disorder affecting 
individuals of Caucasian descent, ~ 1:2,500 children are afflicted with the condition from 
birth and ~ 70,000 adults and children are thought to be affected with CF worldwide (Cystic 
Fibrosis Foundation, World Health Organization, 2002) Genetically, CF is caused by a 
mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on 
the long arm of chromosome 7, encoding for a membrane-bound cyclic-adenosine 
monophosphate (cAMP)-regulated chloride channel (Kerem et al., 1989, Riordan et al., 1989, 
Rommens et al., 1989). Mutations of the CFTR gene vary tremendously, and > 1,500 
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mutations and sequence variants have been identified presently and deposited into the Cystic 
Fibrosis Genetic Analysis Consortium. Although many of these mutations are rare, only four 
occur at > 1 % frequency, in particular, the most frequent mutation F508del exists in the 
region of DNA within the CFTR gene that encodes for one of two nucleotide-binding 
domains (NBDs), i.e., NBD1 (Döring and Ratjen, 2005). The mutation in NBD1 results in 
abnormal transport of chloride and sodium ions affecting water transport across mucus-rich 
epithelial tissues inducing systemic pathophysiological effects in CF individuals where the 
CFTR gene is expressed in various organs such as the respiratory, gastrointestinal, and 
reproductive tracts, the pancreas, and liver (Tizzano and Buchwald, 1995). Physiological 
dysfunction in the respiratory tract is the leading cause of morbidity in CF individuals as ~ 90 
% die of respiratory failure due to this CFTR defect consequently leading to several 
cascading factors; dehydration of the airway mucous, reduced mucocilliary clearance, 
mucous retention, and predisposition of the CF patient to recurrent chronic lung infections 
(Boucher, 2002, George et al., 2009). 
One of the main defining clinical features in CF and COPD is bronchiectasis; an abnormal 
dilatation of the bronchi and bronchioles due to repeated cycles of respiratory tract infection 
and subsequent inflammation (Barker, 2002, O'Donnell, 2008). Bronchiectasis is a highly 
debilitating disease which can cause premature mortality and chronic morbidity in some 
instances due to severe pulmonary infections and lung function impairment (Alzeer et al., 
2007, King et al., 2005). The paradigm relating to chronic infection in bronchiectasis is a 
vicious circle of continual transmural infection and inflammation followed by mediator 
release, the retention of inflammatory secretions and micro-organisms in the LRT cause 
further lung tissue damage thus accelerating pulmonary obstruction and recurrent chest 
infection (Cole, 1986). Patients with CF present with a very severe form of bronchiectasis, 
but increasingly, other individuals are now being diagnosed with an idiopathic variant of this 
disease, termed non-CF bronchiectasis (nCFBR). The term idiopathic arises from the initial 
diagnosis of nCFBR in many patients in which the aetiology of the disease is unknown. The 
increasing frequency in the diagnosis of nCFBR is due to the widespread use of high-
resolution chest computed tomography (HRCT) scanning (Cohen and Sahn, 1999), although 
the prevalence of nCFBR globally is unknown (O'Donnell, 2008). However, a recent study 
conducted in the U.S. alone revealed that 110,000 individuals may be receiving treatment for 
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nCFBR with an annual cost to the U.S. healthcare system of $630 million respectively 
(Weycker et al., 2005). 
Most, if not all, individuals who are afflicted with asthma, COPD, CF, and nCFBR suffer 
from punctuated episodes of exacerbations, i.e., a worsening of symptoms which induce 
airway obstruction in these patients clinically presented as dyspnoea, cough, chest pain, and 
wheeze. Exacerbations can be triggered by several factors, including a secondary infection of 
both the URT and LRT of several aetiologies, but they also vary in their severity and 
frequency in the chronic respiratory disease briefly described above. In summary, chronic 
respiratory tract diseases play a significant role in the morbidity, mortality, and economies 
not only in the Western world, but increasingly in the developing world. 
Cough, breathlessness, wheeze, chest pain, and sputum production, all major symptoms of 
respiratory disease may be indicative of acute or chronic respiratory tract infection (Leach, 
2007). As the respiratory tract is a continuous entity, via the nose to the alveoli, respiratory 
tract infections (RTI) are distinguished by diagnoses of the ‘preferred focus’ of the infectious 
agent, either in the URT or LRT, although there can be at times ambiguity concerning this 
issue; for instance, the parainfluenza virus can infect the nasopharynx, larynx, trachea, and 
occasionally the bronchi and bronchioles resulting in the common cold, laryngotracheitis 
(croup), bronchitis, bronchiolitis, or pneumonia respectively (Goering et al., 2008). The 
aetiology of respiratory tract infection may be bacterial, viral or fungal in origin. Some 
patients may already present with an underlying lung disease such as nCFBR, CF, and 
COPD, of which infection in the upper and lower respiratory tract is a secondary disease, but 
nevertheless a critical contributing factor to the morbidity and mortality of the individual in 
question. For the purposes of the investigative work contained herein, the author will focus 
primarily on lower respiratory tract infections in non-CF bronchiectasis and COPD. 
1.10.2 Respiratory tract defence mechanisms 
Approximately 14,000 L of air is processed on a daily basis by the human lungs, of which 
contact between the external and internal environments is in constant flux, the integrity of the 
thin alveolar membrane must be maintained at all times to ensure efficient O2 and CO2 
gaseous exchange within the host; thus the recognition, and conduct, of particulate matter 
without resulting in excessive inflammation is critically important (Valdivia-Arenas et al., 
2007). The fragile alveolar epithelial layer itself is protected by non-specific factors such as 
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the cough reflex mechanism, ciliary beat, and mucocilliary escalator, in addition to several 
complex host innate defences comprising of both pulmonary cellular and humoral elements. 
Pulmonary innate cellular components are mediated by the airway and alveolar epithelial 
cells, but also leukocytes, both resident and recruited, including natural killer cells (NKCs), 
dendritic cells (DCs), cytotoxic T cells, macrophages, and neutrophils; antimicrobial products 
secreted into the epithelial lining fluid such as collectins, defensins, lysozyme, lactoferrin, 
secretory IgA, and cathelicidins are all constituents of the pulmonary humoral innate system 
(Zass and Schwartz, 2005). All of the above factors mitigate a collective role in the innate 
immune system including initial defence mechanisms against micro-organisms and clearance, 
but also crucially, subsequent activation of the adaptive immune system (Medzhitov and 
Janeway, 1997). 
Recognition of PPMs in the respiratory tract is achieved by cell-surface conserved 
signature pathogen-associated molecular patterns (PAMPs) which are then mediated in turn 
by pattern-recognition receptors (PRRs) lining the airway epithelium, present in secretory 
components of the innate immune system and the cell-surface of leukocytes. Patter-
recognition receptors are able to facilitate recognition of micro-organisms because of several 
common characteristics in that PAMPs are highly conserved and therefore critical to micro-
organism subsistence, PPRs themselves are expressed constitutively within the host thus 
enabling detection of pathogens irrespective of life-cycle stage (Akira et al., 2006). The goal 
in the recognition of PPMs via PAMP-PPR mediation in the respiratory tract is two-fold; (i), 
to allow effective and efficient recognition of said PPMs by macrophages consequently 
leading to phagocytosis and induction of inflammatory mediators (Bals and Hiemstra, 2004), 
and (ii), to allow for discrimination between non-pathogenic and pathogenic elements that 
may come into contact with the airway epithelium in which the high specificity of PAMP-
PPR interactions confer for these actions (Zass and Schwartz, 2005). 
Toll-like receptors (TLRs) are an evolutionary conserved group of type I integral 
membrane glycoproteins characterised by their extracellular leucine-rich-repeat (LRR) motifs 
and COOH-terminal cytoplasmic signalling domains homologous to the interleukin 1 (IL-1) 
receptor in which the primary function of TLR molecules is that of PRRs (Baus and Fenton, 
2004, Bowie and O'Neil, 2000). Twelve mammalian TLRs to date have been identified in 
mammalian hosts, TLR-2 and TLR-4 are the most extensively studied of the TLR families, 
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but all recognise related PAMPs from viral, bacterial, and fungal origins via highly specific 
binding to microbial ligands mediated by the variable LRR domain and intracellular 
signalling carried out by the conserved COOH-terminal intracellular tail (Armstrong et al., 
2004). For example, TLR-2 and TLR-4 have all been shown to primarily bind to lipoteichoic 
acid (LTA) and lipopolysaccharide (LPS), both constitutive components of bacterial Gram-
positive and Gram-negative cell wall composition respectively (Akira et al., 2006, Bals and 
Hiemstra, 2004, Zass and Schwartz, 2005); in addition, TLR2 has also been shown to bind to 
mycobacterial lipoarabinomannan, suggesting a defensive role in Mycobacterium 
tuberculosis infection and other atypical mycobacterial agents (Drennan et al., 2004, Reiling 
et al., 2002, Weiland et al., 2004). Molecular display of TLRs is not only limited to the 
respiratory tract epithelial cells and leukocytes but also DCs, B cells, and T cell subtypes, 
including extracellular (e.g., TLR-2 and TRL-4 bind to bacterial cell wall components LTA 
and LPS as previously discussed) and intracellular expression (e.g., TLRs 3 and 9 utilise viral 
nucleic acid double-stranded RNA (dsRNA) and DNA as receptors respectively 
(Alexopoulou et al., 2001, Hochrein et al., 2004, Tabeta et al., 2004)) modes (Akira et al., 
2006). Constant modulation of TLR expression is an essential governing factor of the innate 
immune response if the host is effectively able to counter-attack insults by PPMs and respond 
to environmental stresses such as allergens thus inducing an inflammatory cascade and the 
release of components that comprise the adaptive immune response such as cytokines and 
chemokines (Zass and Schwartz, 2005). Indeed, as has been previously elucidated, an 
inflammatory cascade in the LRT in response to tissue architecture insults can in fact be 
occasionally detrimental to the host as seen in asthma, COPD, nCFBR, and CF respiratory 
conditions in which the innate immune response plays a pivotal role in the governance of 
these disease phenotypes. 
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1.11 Aims and objectives of research undertaken 
The primary goal of the investigative work undertaken was to characterise the microbial 
communities in two chronic obstructive respiratory disease patient cohorts whilst also 
inferring the optimum DNA polymerase enzyme to perform the culture-independent analysis 
using an environmental matrix (sandy soil). Determination of a suitable DNA polymerase 
will aid in the subsequent investigation and characterisation of the polymicrobial 
communities of the lung microbiome. Using PCR-DGGE technique analysis both in cross-
sectional patient cohorts presenting with nCFBR and COPD we aim to examine the effects of 
bacterial and fungal communities in the LRT and their relation to intrinsic and extrinsic 
factors such as pulmonary function, patient gender, height, and antimicrobial therapy, etc. 
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Chapter Two: Materials & methods 
2.1 DNA polymerase enzymes and microbial diversity 
2.1.1 Sandy soil sampling strategy 
Soil samples were taken from dunes located on Longsands Beach, Tynemouth, North East 
England (55⁰ 1’ 8.66’’ N, 1⁰ 25’ 36.23’’ W) in October 2008. The sand dunes themselves had 
typical plant cover for the area, consisting mainly of Marram grass (Ammophila spp.). Five 
plots (1.5 m x 0.5 m) were created 1 m (± 0.25 m) up the dune. Within each of the five plots 
sandy soil was taken from five randomly placed sub plots at a depth of 20 cm. The sandy soil 
was then combined to create one sample per plot before being stored at -80 °C. 
2.1.2 DNA extraction from sandy soil 
Microbial genomic deoxyribonucleic acid (gDNA) extraction from sandy soil was 
performed using a MO BIO PowerSoil™ DNA Isolation Kit. To the PowerBead Tubes 
provided in the kit, 0.25 g of soil was added before being gently vortexed. Sixty µL of 
Solution C1 was then pipetted and mixed in the PowerBead tubes by inversion following 
addition of the lysis buffer. PowerBead Tubes were then vortexed (Vortex-Genie2™) at 
maximum speed for 10 min; these were secured horizontally to the vortexer using the MO 
BIO Vortex Adaptor tube holder. Following this, the PowerBead tubes were then centrifuged 
at room temperature for 1 min at 10 000   g in which the supernatant was then transferred to 
a clean sterile 2 mL microfuge tube. Two hundred and fifty µL of Solution C2 was then 
added to the supernatant. This supernatant was then vortexed for 5 s and incubated for 5 min 
at 4 °C before being centrifuged at 10 000   g at room temperature for 1 min to form a cell 
pellet. Avoiding the cell pellet, 600 µL of supernatant was transferred to a clean, sterile 2 mL 
collection tube in which 200 µL of Solution C3 was added and then vortexed briefly. An 
incubation time at 4 °C for 5 min followed before the collection tubes were centrifuged at 10 
000   g at room temperature for 1 min. 
Again, transfer of the supernatant (up to 750 µL in volume) to a clean 2 mL collection 
tube was performed before the addition of 1.2 mL Solution C4 to the transferred supernatant 
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(ensuring at the same time that the Solution C4 supernatant mix did not exceed the rim of the 
2 mL collection tube). Approximately 650 µL was then loaded onto a Spin Filter and 
centrifuged at 10 000   g for 1 min at room temperature after which any flow through liquid 
was discarded. This Spin Filter process was repeated twice more (i.e., a total of three loads 
was required to pass through the Spin Filter). Five hundred µL of Solution C5 (ethanol wash 
solution) was added before centrifugation at 10 000   g for 1 min at room temperature in 
which the flow through liquid was discarded from the 2 mL collection tube. Centrifugation at 
10 000   g was carried out again for 1 min at room temperature for effective removal of any 
residual ethanol wash solution (these trace amounts can interfere with many downstream 
DNA applications). After removal of Solution C5, the Spin Filter was placed into a clean 
sterile 2 mL collection tube and 100 µL of Solution C6, an elution buffer (10 mM Tris), was 
added to the centre of the white filter membrane releasing the previously bound gDNA from 
the silica Spin Filter membrane. The final step was to centrifuge the 2 mL collection tube at 
10 000   g for 1 min at room temperature after which the released gDNA (50 µL in volume) 
was collected. The Spin Filter was discarded and the extracted gDNA was stored at -80 °C. 
2.1.3 Bacterial community detection PCR 
Bacterial community detection by polymerase chain reaction (PCR) in all five soil samples 
was performed by amplification of the V3 hypervariable region within the bacterial 16S 
rRNA gene using extracted gDNA as template. Primers V3F-GC (5′-CGC CCG CCG CGC 
GCG GCG GGC GGG GCG GGG GCA CGG GGG GCC TAC GGG AGG CAG CAG-3′) 
and V3R (5′- ATT ACC GCG GCT GCT GG-3′) were used producing amplicons of 16S 
rDNA regions of different bacterial species in the soil community as previously shown 
(Muyzer et al., 1993). Amplification of the 16S rDNA V3 regions corresponded to positions 
341 to 534 in Escherichia coli. Forward primer V3F-GC has an additional 40-bp GC-rich 
nucleotide sequence (GC-clamp) attached to its 5′ end allowing for higher sensitivity in 
detection of bacterial genomic DNA sequence variation in denaturing gradient gel 
electrophoresis (DGGE) processing and greater PCR fragment stability (Sheffield et al., 
1989). Addition of bovine serum albumin (BSA) was also introduced into the PCR as this has 
been previously shown to relieve inhibitory substances such as humic acids which are present 
in soil and other environmental samples (Kreader, 1996). 
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Positive and negative controls were set up in all PCR experiments. Positive control 
bacterial gDNA was extracted from a pure culture of Haemophilus influenzae (NCTC 
(National Collection of Typed Cultures) no. 11931 (generously donated by Prof. J.D. Perry, 
Freeman Hospital, Microbiology Department, Newcastle upon Tyne, U.K.)) for confirmation 
of V3 region amplicons. A negative control set up was for the determination of any 
environmental contaminants that may be present during PCR. Five different DNA 
polymerases (pols) were implemented for enzymatic amplification of the V3 hypervariable 
region: Platinum® Pfx (Invitrogen
™
), TaKaRa Ex Taq™ Hot Start (TAKARA BIO INC.), 
AmpliTaq® (Applied Biosystems™), GoTaq® Hot Start (Promega), and Taq (New England 
BioLabs®, Inc.) respectively. All DNA polymerases used generated technical replicates for 
each sandy soil sample, 3  50 µL vials of amplicons per pol, eventually yielding 15 batches 
of amplicons altogether for each sandy soil sample analysed by DGGE. Common to the entire 
repertoire of Taq DNA pols executed here was a touchdown protocol (commonly referred to 
as touchdown PCR), and a manual and automatic hot start (HS). Touchdown PCR reduces the 
formation of spurious by-products, created in the amplification process, by increasing the 
expected initial annealing temperature by 10 °C (Don et al., 1991); i.e., 65 °C as opposed to 
55 °C in this instance and then reducing the annealing temperature by 0.5 °C per cycle in 
PCR. Automatic HS DNA pols such as Ex Taq™ HS employ an antibody bound enzyme in 
which the activation temperature (e.g., 97 °C) results in release of the previously bound pol 
inhibiting not only spurious PCR product formation before initiation, but also minimising 
non-specific annealing primers to non-target DNA regions. Manual HS protocols execute a 
pol not bound to an antibody, but instead involve manually pipetting the pol at a specific 
volume and temperature (i.e., 80 °C) into the incubated sample once initial DNA template 
denaturation has been completed (i.e., 97 °C for 5 min). Introduction of DNA pols as a 
manual HS into PCR mirrors the purposes of automatic HS DNA pols. In summary, all of the 
above enzymes required different PCR conditions for satisfactory amplification of the V3 
rDNA PCR fragments. These conditions were programmed into a thermocycler (Eppendorf 
Mastercycler gradient) according to the manufacturer’s recommendations for each DNA pol 
used in PCR. These conditions are described below. 
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2.1.3.1 V3 rDNA amplification using AmpliTaq™ DNA polymerase 
The PCR performed using AmpliTaq® (Applied Biosystems™) pol involved the use of a 
manual HS and a touchdown protocol on a Mastercycler gradient (Eppendorf). PCR reagents 
per reaction were added as follows: 0.5 µM primers (both forward (V3F-GC) and reverse 
(V3R)), 1  GeneAmp® Buffer (Applied Biosystems™), 0.3 mM each dNTP (New England 
BioLabs®, Inc.), 2 mM MgCl2 (SIGMA® Life Science), 10 µg/µL BSA (Promega), 1.25 U 
AmpliTaq® and 2 µL of DNA template made up to 50 µL with sterile 18.2 Ω H20 
(MILLIPORE, Direct-Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm filter). Samples 
were incubated for 5 min at 97 °C executing an initial denaturation step of template DNA 
before holding at 80 °C indefinitely to allow a manual HS via introduction of AmpliTaq® pol 
into the sample; then 96 °C for 1 min, 65 °C for 1 min, with a reduction of 0.5 °C per cycle 
until touchdown at 55 °C. Primer extension lasted for 30 s at 72 °C and this was repeated for 
20 cycles. An additional fifteen cycles was carried out at 94 °C for 1 min, 55 °C for 1 min, 72 
°C for 3 min and a final extension time of 72 °C for 30 min. This extended final DNA 
elongation step was implemented to reduce the formation of artifactual double bands which 
can be problematic in microbial community profiling techniques such as DGGE (Janse et al., 
2004). 
2.1.3.2 V3 rDNA amplification using Ex Taq™ Hot Start DNA polymerase 
Unlike the above conditions, PCR fragments amplified using Ex Taq™ HS (TAKARA 
BIO INC.) pol utilised an automatic HS and a touchdown protocol on a Mastercycler 
gradient (Eppendorf). PCR reagents per reaction were added as follows: 0.5 µM primers 
(both forward (V3F-GC) and reverse (V3R)), 1  Ex Taq Buffer (TAKARA BIO INC.), 0.2 
mM each dNTP (TAKARA BIO INC.), 1 mM MgCl2, 10 µg/µL BSA (Promega), 1.25 U Ex 
Taq™ HS and 2 µL of DNA template made up to a total volume of 50 µL with sterile 18.2 
MΩ H2O (MILLIPORE, Direct-Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm 
filter). Samples were incubated for 5 min at 97 °C releasing antibody bound polymerase Ex 
Taq™ HS, then at 96 °C for 1 min, 65 °C for 1 min, with a reduction of 0.5 °C per cycle until 
touchdown at 55 °C. Primer extension lasted for 30 s at 72 °C and this was repeated for 20 
cycles. An additional fifteen cycles was carried out at 94 °C for 1 min, 55 °C for 1 min, 72 °C 
for 3 min and a final extension time of 72 °C for 30 min. 
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2.1.3.3 V3 rDNA amplification using GoTaq® Hot Start DNA polymerase 
Amplification of V3 rDNA using GoTaq® HS (Promega) pol was carried out with both an 
automatic HS and touchdown conditions on an Eppendorf Mastercycler gradient. PCR 
reagents per reaction were added as follows: 0.5 µM primers (both forward (V3F-GC) and 
reverse (V3R)), 2  Colorless GoTaq® Buffer (Promega), 0.3 mM each dNTP (New England 
BioLabs®, Inc.), 1 mM MgCl2 (Promega), 10 µg/µL BSA (Promega), 1.25 U GoTaq® HS 
and 2 µL of DNA template made up to 50 µL with sterile 18.2 Ω H20 (MILLIPORE, Direct-
Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm filter). Samples were incubated for 5 
min at 97 °C, releasing antibody bound polymerase GoTaq® HS, then at 96 °C for 1 min, 65 
°C for 1 min, with a reduction of 0.5 °C per cycle until touchdown at 55 °C. Primer extension 
lasted for 30 s at 72 °C and this was repeated for 20 cycles. An additional fifteen cycles was 
carried out at 94 °C for 1 min, 55 °C for 1 min, 72 °C for 3 min and a final extension time of 
72 °C for 30 min. 
2.1.3.4 V3 rDNA amplification using Platinum® Pfx DNA polymerase 
Platinum® Pfx (Invitrogen™) pol conditions differed from the Taq DNA pol enzymes 
employed here as no touchdown PCR was carried out. However, an automatic HS was still 
performed. PCR reagents were added as follows: 0.5 µM primers (both forward (V3F-GC) 
and reverse (V3R)), 2  Pfx Amplification Buffer (Invitrogen™), 0.5  Pfx Enhancer Solution 
(Invitrogen™), 0.3 mM each dNTP (New England BioLabs®, Inc.), 1 mM MgSO4 
(Invitrogen™), 10 µg/µL BSA (Promega), 1.25 U Platinum® Pfx and 2 µL of DNA template 
made up to 50 µL with sterile 18.2 Ω H20 (MILLIPORE, Direct-Q™ Ultra Pure Water 
Systems, MILLIPAK® 0.22 µm filter). Samples were incubated at 94 °C for 4 min 
initialising DNA template denaturation and release of bound Platinum® Pfx pol. Following 
this, 35 cycles at 97 °C for 30 s, 65 °C for 30 s, and 68 °C for 30 s were performed with a 
final elongation step at 68 °C for 30 min. 
2.1.3.5 V3 rDNA amplification using Taq DNA polymerase 
New England BioLabs® Inc., Taq pol amplification of V3 rDNA amplicons was executed 
on a Mastercycler gradient (Eppendorf) using a manual HS and touchdown PCR. PCR 
reagents per reaction were added as follows: 0.5 µM primers (both forward (V3F-GC) and 
reverse (V3R)), 1  Standard Taq Reaction Buffer (New England BioLabs® Inc.), 0.3 mM 
each dNTP (New England BioLabs®, Inc.), 2 mM MgCl2 (SIGMA® Life Science), BSA 
 30 
 
(Promega), 5 U Taq pol and 2 µL of DNA template made up to 50 µL with sterile 18.2 MΩ 
H20 (MILLIPORE, Direct-Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm filter). 
Samples were incubated for 5 min at 97 °C executing an initial denaturation step of template 
DNA before holding at 80 °C indefinitely to allow a manual HS via introduction of Taq pol 
into the sample; then 96 °C for 1 min, 65.8 °C for 1 min, with a reduction of 0.5 °C per cycle 
until touchdown at 55.8 °C. Primer extension lasted for 30 s at 72 °C and this was repeated 
for 20 cycles. An additional fifteen cycles was carried out at 94 °C for 1 min, 55.8 °C for 1 
min, 72 °C for 3 min and a final extension time of 72 °C for 30 min. 
2.1.4 Agarose gel electrophoresis of V3 rDNA amplicons 
PCR fragments amplified by all five different polymerases were run out and validated 
using agarose gel electrophoresis (1 % (
w
/v) (App. 1) stained with SYBR® Safe DNA gel 
stain (10 000  concentrate in dimethyl sulphoxide (DMSO)) (Invitrogen™). Five µL of PCR 
product, 2 µL 6× bromophenol blue (BPB), and 5 µL 18.2 MΩ H2O (MILLIPORE, Direct-
Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm filter) were mixed by trituration 
before a final volume of 10 µL was loaded into the appropriate gel well, in addition to 5 µL 
of Hyperladder 1 (200-10 000 molecular bp size markers (BIOLINE)) (App. 2). PCR 
products were electrophoresed at 120 mA constant (BIO-RAD, Basic PowerPac™) for 20 
min in 1× TAE running buffer (tris-acetate-EDTA (ethylenediamine tetraacetic acid)). 
Visualisation of PCR products was done under ultra-violet (UV) light using a BIO-RAD Gel 
Doc 2000 system and Quantity One software (v. 4.6.6). Comparison of the molecular bp 
markers in Hyperladder I (BIOLINE) and the positive control confirmed the correct size of 
the amplicons for the V3 rDNA fragments produced by each DNA pol utilised, i.e., 233 bp. 
Hard copies of the electropherograms were generated using a Mitsubishi Video copy 
processor (model P91 attached to the Gel Doc 2000 system). 
2.1.5 Denaturing gradient gel electrophoresis of the bacterial community 
2.1.5.1 Assembly of parallel gradient gel sandwich 
Before DGGE analysis of PCR fragments, appropriate gel sandwich and casting was 
required (described below) for accurate determination of electrophoretic data. To ensure 
proper alignment of parallel gradient gel sandwich, all plates (16   16 cm) and spacers (1.0 
mm in width) were clean and dry before assembly and constructed on a clean laboratory 
bench surface. The large rectangular glass plate (termed long glass plate) was laid down first 
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before placement of the spacers in which a thin layer of silicone grease (glisseal® HV) was 
applied to the straight edge of the spacers facing inwards towards the large glass plate. 
Application of a thin layer of silicone grease prevents leaking of denaturing substances such 
as urea and formamide into the buffer reducing the formation of “down smiling” across the 
gel gradient in all lanes used, in particular the outermost lanes (Brinkhoff and van Hannen, 
2001). The smaller glass plate (termed short glass plate) was then placed on top of the 
spacers, but aligned so that it was flush with the bottom edge of the long glass plate. Each 
screw located at the top of the sandwich clamps was turned counter-clockwise (i.e., to loosen 
the screws) before placement at the appropriate side of the gel sandwich with the locating 
arrows facing up and towards the glass plates. Attachment of the sandwich clamps involved 
both the long and short plates fitting into the correct notches in the clamp (attached one at 
time) before tightening the screws (finger-tight) enough to hold both plates in position. 
Following this, a thin layer of silicone grease was applied to the entire bottom length of the 
assembled gel sandwich sealing the critical area (the attached spacers and glass plates) which 
prevents leakage of gel solution during the casting of gels (Brinkhoff and van Hannen, 2001). 
The gel sandwich assembly was then placed into the alignment slot of the casting stand 
with the short glass facing towards the author. Sandwich clamps were loosened to allow the 
insertion of the alignment card to keep spacers parallel to the clamps. Alignment of plates and 
spacers simultaneously was achieved by pushing inward on both clamps at the locating 
arrows whist at the same time pushing down on the spacers ensuring that the spacers and 
glass plates are flush against the sides of the clamps. Both clamps were tightened just enough 
to hold the sandwich assembly in place before removal of the alignment card. The sandwich 
assembly was then removed entirely from the casting stand to ensure that both the plates and 
spacers were flush at the bottom. Clamps were then tightened until finger-tight. 
2.1.5.2 Casting of parallel denaturing gradient gel 
Using the front casting slot the gel sandwich assembly was placed on top of a grey sponge 
with the short plate facing towards the author. Upon correct positioning, the handles of the 
camshafts were turned down to lock the sandwich assembly in place. This is in preparation 
for gel casting. Pieces of Tygon tubing cut into two lengths of 15 cm and an additional 
shorter piece cut at 9 cm was used to conduct the gel solution from the Y-fitting into the gel 
sandwich assembly. One end of the shorter 9 cm piece of Tygon tubing was attached to the 
 32 
 
Y-fitting, the other end a luer coupling with a 19 gauge needle (BD Microlance™ 3). This 
needle was then inserted in between the short and long glass plates of the sandwich assembly 
located in the centre before being taped (parcel tape providing the most stable attachment) to 
the forward facing side of the long glass plate Two other luer couplings were also connected 
to one end of both long Tygon 15 cm tubing pieces in addition to both 30 mL syringes (BD). 
Each syringe labelled either HI (for the high density solution) and LO (for the low density 
solution) had attached a plunger cap, positioned exactly onto each syringe plunger “head”. 
Both syringes were correctly positioned into a syringe sleeve (with volume gradations 
visible); lever attachment screw was in the same plane as the flat or back side of the sleeve. 
This alignment enabled effective and undisturbed delivery of the denaturing gradient gel 
solution from the Gradient Delivery System. The cam wheel on the Gradient Delivery System 
was rotated back to its starting position (i.e., clockwise) with the delivery volume set to 16 
mL. 
Two 50 mL centrifuge tubes (SARSTEDT) labelled either HI (for high density solutions) 
or LO (for low density solutions) were used for preparation of denaturing gel solutions in a 
fume hood (Morgan and Grundy (Unitform) Ltd.). One hundred µL of DCode™ dye (App. 1) 
was pipetted into the HI 50 mL centrifuge tube before the addition of (i), 20 mL of 55 % 
denaturing gradient solution (12 % acrylamide/bis-acrylamide of gel percentage) (App. 1), 
216 µL of 10 % (
w
/v) ammonium persulphate (APS (SIGMA-ALDRICH®)) (App. 1), and 
then 21.6 µL of N,N,N′,N′-tetramethylethylenediamine (TEMED (SIGMA-ALDRICH®)) 
before the 50 mL centrifuge tube was inverted several times to mix contents; and (ii), into the 
LO 50 mL centrifuge tube, 20 mL of 35 % denaturing gradient solution (12 % 
acrylamide/Bis-acrylamide of gel percentage) (App. 1) 216 µL of 10 % (
w
/v) ammonium 
persulphate (APS), and then 21.6 µL of TEMED before the centrifuge tube was inverted 
several times to mix contents. Using the 30 mL syringes, with 15 cm Tygon tubing attached, 
~ 18 mL of each denaturing gradient solution was withdrawn from both the HI and LO 
centrifuge tubes and into the appropriately labelled syringe vials. Any air bubbles present (in 
particular in the LO syringe) were removed at this time by turning the syringe upside down 
and gently tapping the syringe against a hard surface in addition to pushing these solutions to 
the end of the tubing to remove any further air bubbles. 
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The two syringes were then placed into the Gradient Delivery System syringe holder on 
each side, both designated LO and HI density side, by insertion of the lever attachment 
screws into the lever groove. Following this, the ‘free’ ends of the 15 cm Tygon tubing from 
the 30 mL syringes were then slid over and attached to both ‘free’ ends of the Y-fitting ready 
for denaturing gradient solution distribution. The cam wheel of the Gradient Delivery System 
was then rotated in a counter clockwise direction at a steady flowing pace with two hands in a 
constant motion for delivery of the denaturing gel solution from the attached syringes into the 
gel sandwich assembly. Once dispensed to the top of the short plate, the 19 gauge needle with 
Tygon tubing still attached was removed and placed into a 500 mL beaker of hot water before 
careful insertion of a 16-tooth comb. The gel was then left to polymerise for 1 h before use. 
Both HI and LO syringes were removed from the Gradient Delivery System with Tygon 
tubing still attached and then using the syringes themselves were thoroughly rinsed with hot 
water from the 500 mL beaker to remove any excess denaturing gel solution. This was 
repeated several times and performed quickly after gel casting to avoid premature gel 
polymerisation taking place inside the syringes, Tygon tubing and Y-fitting. After gel 
polymerisation (1 h from the initial gel casting procedure), the 16-tooth comb was removed 
by pulling it straight up and slowly as not to disturb the cast wells within the gel. Distilled 
water (dH2O) was finally dispensed across the top of the short plate to fill all of the wells 
ready for sample loading. 
2.1.5.3 Assembly of the upper buffer chamber before electrophoresis of 
amplicons 
After gel polymerisation, the gel sandwich was released from the casting stand by turning 
the camshafts 180° to the up position and pulling them both outward and placed to the side on 
the bench. Laying the inner core flat on a bench, the gel sandwich assembly was then placed 
into position so the locating pins on the core fitted into the grooves on the outside surface of 
the sandwich clamps at an approximate angle of 20 °. The gel sandwich was then locked into 
position against the inner core by pushing up against the locating pins with the end result 
being that the upper edge of the short inner glass plate was seated against the notches of the 
U-shaped gasket and the tabs of both sandwich clamps held securely against the latch 
assemblies on both sides of the inner core. These above steps were repeated once again in 
order to attach a second gel sandwich assembly on the reverse side of the inner core, except 
soil sample 5 replicates (SS5R), in which only one gel sandwich assembly was required for 
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DGGE analysis. In this instance a ‘balance’ DGGE plate was constructed using the same 
method as the gel sandwich assembly above, but without the addition of the 1 mm spacers. 
2.1.5.4 V3 rDNA amplicon preparation and loading on DGGE apparatus 
The electrophoresis reservoir tank was filled with ~ 7 L of 1  TAE running buffer (App. 
1) to the “fill” line and pre-heated up to 65 °C (this was carried out whilst performing the gel 
sandwich assembly and gel casting steps as reaching the desired running temperature can take 
1 to 1.5 h). A 5 °C increase than the actual DGGE running temperature allows for quicker 
DGGE experimental and sample loading running time. Following this, the DCode™ 
temperature control module was switched off, removed, and placed on the DCode™ lid 
stand. Five hundred mL of 1  TAE running buffer was then removed from the reservoir tank 
to allow filling of the upper buffer chamber of the inner core assembly using a plastic beaker. 
The inner core with attached gel assemblies was placed into the buffer chamber with the red 
button towards the right hand side and the black button along the left hand side of the system. 
Approximately 350 mL of 1  TAE running buffer from the plastic beaker was decanted into 
the upper buffer chamber of the inner core assembly whilst in the reservoir tank; any excess 
was then used to fill the reservoir tank running buffer to the “max” line indicated. 
All amplicons synthesised by AmpliTaq™, Ex Taq™ HS, Go Taq® HS, Platinum® Pfx, 
and Taq DNA polymerases respectively were prepared for loading onto the DCode™ system 
as follows; PCR products were thoroughly thawed, pulsed (MSE MicroCentaur (SANYO)) 
and 15 µL of amplicons was mixed with 15 µL of 2  gel loading dye by trituration before 
being pulsed again. Thirty µL of amplicons and 2  gel loading dye mixture was then loaded 
into the appropriate wells present in both gel sandwich assemblies attached to the inner core 
(except SS5R in which a balance plate was attached to the inner core). In terms of loading 
strategy, all 3 technical replicate amplicons synthesised by each DNA pol enzyme in sandy 
soil samples 1-5 was loaded as follows using SS1R as an example: replicates A-C synthesised 
by Taq, replicates A-C synthesised by Go Taq® HS, replicates A-C synthesised by 
AmpliTaq™, replicates A-C synthesised by Ex Taq™ HS, and finally replicates A-C 
synthesised by Platinum® Pfx (Fig. 3.2A-E). This loading pattern was repeated for the 
remaining four sandy soil samples analysed by DGGE. The DCode™ temperature control 
module from the DCode™ lid stand was placed back on top of the electrophoresis tank, 
ensuring that the stirring mechanism fitted neatly into the correct socket, locking the core in 
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place, and the power, pump, and heater were all switched back on with a final adjustment of 
the initial running temperature; i.e., 60 °C as opposed to 65 °C. 
2.1.5.5 DGGE of V3 rDNA amplicon technical replicates in sandy soil samples 
When a running temperature of 60 °C was finally obtained, technical replicates of V3 
rDNA GC-clamped PCR fragments, amplified by the five different DNA polymerase 
enzymes in each sandy soil sample, were analysed by DGGE using the DCode™ Universal 
Mutation Detection System (BIO-RAD) on a 35-55 % denaturing gradient for 4.5 h at a 
constant of 200 V (Basic PowerPac™, BIO-RAD). All gels were removed before staining 
with SYBR Green nucleic acid stain I (Invitrogen™) for 30 min on a shaking platform at 75 
rpm (Edmund Bühler, KM-2). The staining solution was then decanted and any excess 
present on the gel(s) was rinsed off with distilled dH20. Visualisation of denaturing gels was 
under UV light using a BIO-RAD Gel Doc 2000 system and Quantity One software (v. 
4.6.6). Hard copies of DGGE bacterial community profiles from each sandy soil sample and 
pol type were generated using a Mitsubishi Video copy processor (model P91 attached to the 
Gel Doc 2000 system). 
2.1.6 Statistical and ecological analyses of bacterial community profiling 
2.1.6.1 DGGE profile capture and analysis 
The BIO-RAD Gel Doc 2000 system was used to capture all of the DGGE profile images 
(i.e., a photograph taken where the gel is converted into a digital file (TDS 1-D scan file 
format) producing an electropherogram) produced from the assessment of the DNA pol 
enzymes and the analysis performed using the included Quantity One software (version 
4.6.6). Initial DGGE profiles captured were then converted to an inverted electropherogram 
(i.e., black bands set against a white background producing a clearer image for band 
discrimination). From here, a rolling ball algorithm was selected manually to subtract any 
background interference so peak detection performed represented actual bands and not 
artifacts. Lanes within the DGGE profile were created manually and subsequently framed to 
address DGGE experimental nuances such as ‘smiling’ and ‘leaning’ by the creation of lane 
anchors that could be manipulated to centralize all of the bands produced in each 
corresponding lane. Band detection itself was carried out using Quantity One’s auto-detect 
software algorithm with lane width set to 4.100 mm preventing lane overlap. Subsequently, 
detected bands in the DGGE profile were assessed by eye and either removed or added using 
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the Create/Remove bands tool. Bands generated across all lanes were then matched using the 
Match command in Quantity One in which unique bands identified in all five gels were 
matched across different lanes. A distinct band that appeared in a lane or across several lanes 
is identified via matching as a unique band type generating a band number. This was required 
to ascertain the normalised relative band intensities in the gel. Following band matching 
within the gel image produced, both qualitative and quantitative data arising from the DGGE 
profile was exported via the All Lanes Report command. Exportation of this data contained 
the relative quantity, lane and band number variables respectively. These three variables were 
then manually inputted into Microsoft® Excel™ where a DGGE band matrix was 
subsequently created. 
Using the DGGE band matrix, the total intensity of each lane was calculated by using the 
AutoSum formula in Microsoft® Excel™ in which the normalised band values per lane were 
derived by dividing the relative intensity of each band in a lane by the total intensity value 
yielding a value between 0-1. A value of 0 corresponded to no band being present, whereas a 
value of 1 indicated that particular band accounted for the total intensity derived in that 
respective lane (i.e., one band was present or observable from the initial gel analysis 
performed in Quantity One). 
2.1.6.2 Shannon diversity index derivation 
Detection of the bacterial community by the five DNA polymerase enzymes employed 
was also assessed by calculation of the Shannon diversity index (H′) in each sample type. The 
Shannon diversity index is a biodiversity quantitative measure which derives both the species 
richness (number of bacterial taxa present) and evenness (J′) (how equal the different taxa are 
numerically distributed) in a sample type. The H′ was calculated by using the formula: 
      ∑(    [  ]) 
Where pi is the normalised relative intensity of each band detected in the DGGE profile, 
calculated using Microsoft® Excel™ (see section 2.1.6.1), and ln the natural logarithmic 
number of the normalised relative intensity band value. The ln was firstly derived of all the 
normalised relative intensity band values in each lane before being multiplied by these same 
values. Secondly, the sum of all these values per lane was multiplied by -1 converting the 
negative numbers into a positive H′ score for each respective DNA pol technical replicate. 
 37 
 
Species richness (R) (i.e., the number of bacterial taxa present) was derived from the number 
of bands produced per lane per DNA pol technical replicate. 
2.1.6.3 Principal components analysis 
Once all normalised values were deduced in all five DGGE profiles generated, they were 
then copied and pasted into the PAST (v. 1.85) software program (Hammer and Harper, 
2001) and subjected to multivariate analysis using principal components analysis (PCA). All 
Eigenvalues (a measure of variation in each axis measured in PCA) were < 1 so the PCA 
scores generated were accepted. The PCA scores of the first two axes of variation, principal 
components 1 and 2 (PC1 is the x-axis whereas PC2 represents the y-axis) were then used to 
plot graphs for each sandy soil sample and DNA pol technical replicate represented. The PC1 
and PC2 percentage of variation were then added together to deduce the cumulative 
percentage of variation explained in the outputs. The variance between the DNA pol assessed 
and their detection of the bacterial diversity in each sample type was deduced by inputting 
both PC1 and PC2 scores into Minitab® 15 (v. 15.1.30.0). Variances along the x-axis and y-
axis corresponding to PC1 and PC2 were subjected to a one-way ANOVA (analysis of 
variance) (confidence level was set at 95 %) where a P-value was calculated indicating 
whether there was a significant difference or not between the five DNA pol employed in the 
diversity generated in all five sandy soil samples. Additionally, a Tukey’s test was performed, 
a post ad hoc ANOVA to determine if amplicons generated by the DNA pol enzymes 
differed. 
2.2 Bacterial and fungal standard organism ladders for semi-
quantitative DGGE analyses in patient cohorts 
2.2.1 Bacterial 16S standard ladder construction 
Nine bacterial species were selected for 16S standard ladder (SL) construction as these 
were all associated with microbial infection in both cystic fibrosis (CF) and non-CF 
bronchiectasis (nCFBR) individuals. These bacterial organisms (table 2.1) were comprised of 
reference strains from the NCTC, Laboratory of Microbiology, University of Ghent (LMG) 
and fully identified wild type strains from the Freeman Hospital, Microbiology Department, 
Newcastle upon Tyne. 
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Table 2.1 Bacterial species utilised in 16S standard ladder construction. 
Number Species Reference strain 
1 Haemophilus influenzae NCTC 11931 
2 Staphylococcus aureus NCTC 6571 
3 Ralstonia pickettii NCTC 11149 
4 Pseudomonas aeruginosa NCTC 10662 
5 Streptococcus oralis NCTC 11427 
6 Burkholderia cepacia complex LMG 17997 
7 Stenotrophomonas maltophilia NCTC 10257 
8 Pseudomonas fluorescens NCTC 10688 
9 Achromobacter xylosoxidans Wild strain FRH 604914 
 
The method of 16S SL construction has been previously demonstrated in both cross-
sectional and temporal patient cohorts in CF using PCR-DGGE technique (Nelson, 2011). 
Briefly, the above bacterial isolates, with the exception of H. influenzae, were all inoculated 
onto Luria-Bertani (LB) agar (App. 1) and incubated overnight at 37 °C under aerobic 
conditions excluding S. oralis (incubated anaerobically). H. influenzae was cultured on 
NADsens agar (App. 1) at 37 °C in a static incubator with 5 % CO2 saturation overnight. 
Subsequently, colony morphologies were validated by eye to ensure pure growth before a 
single colony (excluding H. influenzae) was utilised to inoculate 10 mL of sterile LB broth 
(incubated overnight at 37 °C). Colonies of H. influenzae were inoculated into 10 mL of 
sterile NADsens broth and subsequently incubated overnight in a microaerophilic 
environment. Examination of broth cultures for pure growth by inoculating fresh agar plates 
with 10 µL of culture and incubation overnight (as illustrated above) was performed as a 
quality control procedure. Once pure growth was validated, broth cultures were then 
subsequently utilised for gDNA extraction (UltraClean® Microbial Isolation Kit) (MO BIO 
Laboratories, Inc.)). 
Using the extracted gDNA as template from each pure bacterial isolate grown, the V3 
region of the 16S rRNA gene was targeted as previously demonstrated (Muyzer et al., 1993, 
Nelson et al., 2010) with the identical conditions described in section 2.3.4 performed on a 
Mastercycler gradient (Eppendorf) thermocycler. PCR amplification of V3 rDNA amplicons 
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was verified by agarose gel electrophoresis (as previously described in section 2.1.4) before 
being subsequently run out for DGGE analysis (DCode™ Universal Mutation Detection 
System (BIO-RAD)) on a 32.5-60 % denaturing gradient (12 % acrylamide/bis-acrylamide of 
gel percentage) (App. 1). Two µL of pure V3 rDNA amplicons mixed with 2 µL 2× loading 
dye was required before 4 µL was loaded into each well. The V3 rDNA amplicons from each 
bacterial species were also pooled and run out for DGGE analysis (36 µL in total (18 µL PCR 
products of 9 different bacterial species and 18 µL 2  gel loading dye)). Electrophoresis of 
bacterial isolate V3 rDNA amplicons was performed at 200 V constant (Basic PowerPac™, 
BIO-RAD) for 4.5 h, stained with SYBR Green nucleic acid stain I (Invitrogen™), incubated 
for 30 min (75 rpm on a shaking platform (Edmund Bühler, KM-2)), de-stained briefly with 
dH2O, before visualisation under UV light (BIO-RAD Gel Doc 2000 system and Quantity 
One software (v. 4.6.6)). Hard copies were generated as previously described. Pure V3 rDNA 
single bacterial strain PCR products amplified from the bacterial isolates listed above were to 
comprise the 16S SL. Execution of this 16S SL was essential for inter-comparison of the 
bacterial DGGE community profiles generated in all of the patient cohorts analysed enabling 
inter-gel alignment via these internal standards (Tourlomousis et al., 2010). 
2.2.2 Fungal 28S standard ladder construction 
2.2.2.1 Fungal isolates selection and collection 
Seven fungal species were selected and utilised for the construction of the 28S SL for 
fungal community studies in all patient cohorts enlisted. Selection of the following was based 
on the implication of all species being opportunistic invasive respiratory pathogens in CF 
patients. Fungal species chosen were comprised of one spore-forming species, Aspergillus 
fumigatus, and five yeast-forming species: Candida albicans, Candida dubliniensis, Candida 
glabrata, Candida parapsilosis, Exophiala dermatitidis, and Scedosporium apiospermum. All 
fungal collections prior to gDNA extraction were generously donated by Mrs. Claire 
Rennison at the Freeman Hospital, Microbiology Department, Newcastle upon Tyne. The 
fungal isolates themselves were from clinical samples, identified in the Microbiology 
Department laboratory according to standard operating procedure (SOP) affiliated with the 
Freeman Hospital. 
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2.2.2.2 Extraction of fungal gDNA from isolates 
Extraction of fungal gDNA was performed using an UltraClean® Microbial Isolation Kit 
(MO BIO Laboratories, Inc.) in a Class II safety airflow cabinet (envair Bio 2+) with 
amendments to the protocol. Fungal species were firstly inoculated in 100 mL of sterile 
Sabourad (OXOID) liquid broth (pH 7.0) (App. 1) before being incubated (SANYO) at 22 °C 
for 7 days. Following incubation, a tea spoonful of sterile glass beads (3 mm diameter) was 
dropped into each fungal culture species before being placed in an orbital shaker (New 
Brunswick Scientific Ltd.) for 10 min at 200 rpm, 37 °C. This step is critical as it aids in the 
rupture and softening of the previously hard mycelial wall (prominent in the spore-forming 
species A. fumigatus) seen after the first incubation step. 
From the yeast cultures grown, 1.8 mL of microbial culture (broth liquid medium) was 
pipetted into a clean, sterile 2 mL microfuge tube and centrifuged at 10 000   g for 1 min at 
room temperature before the supernatant was decanted. The tubes were then spun down again 
at 10 000   g at room temperature generating a cell pellet. Any supernatant still present was 
removed by a pipette tip. For A. fumigatus fungal culture: using a clean pair of forceps 
(washed down with 70 % 
v
/v ethanol), a small piece of softened mycelia present at the top of 
the Sabourad broth was transferred to a clean sterile 2 mL collection tube, centrifuged at 10 
000   g for 1 min at room temperature before the supernatant was discarded. Again, this was 
spun down once more at 10 000   g for 1 min at room temperature in which any supernatant 
still present was removed by pipette as in the yeast species above. Cell pellets were 
resuspended in 300 µL of MicroBead Solution then gently vortexed before transfer of 
resuspended cells to MicroBead Tubes. Fifty µL of MD1 Solution was then added to the 
Microbead Tubes. 
Fungal cell preps (in MicroBead Tubes) were then heated at 70 °C for 10 min as an 
additional aid in fungal cell lysis. Following this incubation step, fungal cell preps were then 
vortexed at maximum speed for 10 min using the Mo Bio Vortex Adapter tube holder. After 
bead beating step, the 2 mL MicroBead Tubes were then centrifuged at 10 000   g for 1 min 
at room temperature. The supernatant (~ 300-350 µL) was aliquoted into a clean sterile 2 mL 
collection tube in which 100 µL of Solution MD2 was then added. Microfuge tubes were 
gently vortexed for 5 s then incubated at 4 °C for 5 min. Following this incubation step, 
fungal cell preps were centrifuged at 10 000   g for 1 min at room temperature. The entire 
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volume of supernatant (~ 450 µL) was then transferred to a clean sterile 2 mL collection tube, 
whilst avoiding the cell debris pellet. Solution MD3 was briefly shaken and 900 µL was 
aliquoted to the recently transferred supernatant and then vortexed for 5 s. 
Seven hundred µL was then loaded into the Spin Filter and centrifuged at 10 000   g for 1 
min at room temperature twice. All flow through liquid following this centrifugation step was 
discarded. Three hundred µL of MD4 Solution was then added before centrifugation at room 
temperature for 1 min at 10 000   g. Flow through liquid from Spin Filter was again 
discarded before repeating the above centrifugation step (10 000   g at room temperature for 
1 min). Spin Filter basket was then removed and placed into a new clean sterile 2 mL 
collection tube in which 50 µL of Solution MD5 was pipetted to the centre of the white filter 
membrane. Microfuge tubes containing Spin Filter baskets were then finally centrifuged at 
room temperature for 1 min, 10 000   g to elute isolated fungal gDNA. The Spin Filter 
basket was discarded and fungal gDNA was stored at -80 °C. 
2.2.2.3 PCR amplification of 28S rDNA segments 
Amplification of all seven fungal isolates using extracted gDNA was used as template for 
PCR. Two conserved regions flanking a highly variable region within the 28S rRNA gene 
were selected as previously demonstrated for amplification of small segments of 28S rDNA 
(Sandhu et al., 1995). Universal fungal primers U1F (5′-GTG AAA TTG TTG AAA GGG 
AA-3′) and U2R-GC (5′-CGC CCG CCG CGC GCG GCG GGC GGG GCG GGG GCA 
CGG-3′) primer sets were executed, in addition to Ex Taq™ HS pol (TAKARA BIO INC.), 
to enzymatically amplify small segments of 28S rDNA (U1-U2 rDNA fragments). Both 
universal fungal primers both refer to co-ordinate numbers 403-422 (forward primer U1F) 
and 645-662 (reverse primer U2R) of the reference Saccharomyces cerevisiae 28S rRNA 
gene (Sandhu et al., 1995). As in the bacterial community detection PCR, addition of a GC-
clamp was executed, however, this was attached to the reverse fungal primer (U2R-GC) to 
aid in genomic sequence variation detection in DGGE (Sheffield; 1989). The PCR of the 
fungal isolates was performed on a Mastercycler gradient (Eppendorf). PCR reagents for this 
reaction were added as follows: 0.5 µM primers (both forward (U1F) and reverse (U2R-GC)), 
1  Ex Taq Buffer (TAKARA BIO INC.), 0.2 mM each dNTP (TAKARA BIO INC.), 1 mM 
MgCl2, 10 µg/µL BSA (Promega), 1.25 U Ex Taq™ HS and 1 µL of gDNA template made 
up to a total volume of 50 µL with sterile 18.2 MΩ H2O (MILLIPORE, Direct-Q™ Ultra 
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Pure Water Systems, MILLIPAK® 0.22 µm filter). An automatic HS and touchdown PCR 
protocol was utilised in which the conditions were an initial denaturation step of 97 °C for 5 
min, 94 °C for 1 min, 60 °C for 1 min with a reduction of 1.0 °C per cycle reaching 
touchdown at 50 °C and 72 °C for 1 min repeated for 10 cycles. An additional 25 cycles were 
performed at 94 °C for 3 min, 50 °C for 1 min, and 72 °C for 1 min. As previously 
introduced, a final extension time at 72 °C for 30 min was implemented in addition to the 
touchdown protocol (Don et al., 1991, Janse et al., 2004). 
2.2.2.4 Agarose gel electrophoresis of 28S rDNA segments 
The small pure 28S rDNA fragments from each fungal isolate were validated for 
amplification by running PCR products out on a 1 % (
w
/v) agarose gel stained with SYBR® 
Safe DNA gel stain (10 000  concentrate in (DMSO) (Invitrogen™). PCR fragments were 
then electrophoresed for 20 min at 120 mA constant (BIO-RAD, Basic PowerPac™) in 1  
TAE running buffer with 5 µL of PCR product, 2 µL 6  BPB, and 5 µL 18.2 MΩ H2O 
(MILLIPORE, Direct-Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm filter) mixed 
prior to 10 µL loaded into each well. Five µL of Hyperladder I (200-10 000 molecular bp-
size markers (BIOLINE)) was also added, in which after electrophoresis amplicons migrated 
between the 200 and 400-bp marker sizes (amplicon size was 300 bp in length, including the 
GC-clamp attached to U2R-GC reverse primer) confirmed under UV light (Gel Doc 2000 
system and Quantity One software (v. 4.6.6) (BIO-RAD). Hard copies of the 
electropherograms were generated using a Mitsubishi Video copy processor (model P91 
attached to the Gel Doc 2000 system). 
2.2.2.5 DGGE of U1-U2 rDNA PCR fragments 
The amplification of 28S rDNA segments (termed U1-U2 rDNA) using PCR from the 
fungal isolates selected for 28S standard ladder construction were subsequently analysed by 
DGGE to validate individual fungal strain migration position and pooled amplicon migration 
positions; a necessity when the fungal communities were amplified in patient cohorts 
investigated in thesis. Fungal species standard ladder analysis was performed using the 
DCode™ Universal Mutation Detection System (BIO-RAD) where U1-U2 rDNA fragments 
from each fungal isolate were run out on a 40-60 % denaturing gradient (12 % 
acrylamide/bis-acylamide of gel percentage) (App. 1) in addition to a balance plate attached 
to the inner core. Four µL of each fungal strain and its amplicons were loaded into the 
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appropriate gel wells (2 µL pure fungal strain U1-U2 rDNA and 2 µL 2× loading dye). 
Additionally, all fungal species amplicons were pooled together (28 µL (14 µL PCR products 
of 7 different fungal species and 14 µL 2× gel loading dye)) and loaded onto the DGGE 
apparatus. All PCR fragments were then electrophoresed at 70 V constant (Basic 
PowerPac™, BIO-RAD) for 17 h, stained with SYBR Green nucleic acid stain I 
(Invitrogen™), incubated for 30 min at 75 rpm, (Edmund Bühler, KM-2) and de-stained 
briefly with dH2O, before being finally visualised under UV light (BIO-RAD Gel Doc 2000 
system and Quantity One software (v. 4.6.6)). Hard copies of the fungal 28S standard ladder 
were generated by using a Mitsubishi Video copy processor (model P91 attached to the Gel 
Doc 2000 system). 
2.3 PCR-DGGE study of a cross-sectional cohort with non-CF 
bronchiectasis 
2.3.1 Patient cohort selection and ethical considerations 
Ethical approval was obtained from County Durham and Tees Valley research ethics 
committee. The inclusion criteria were adult out-patients attending a specialist bronchiectasis 
weekly clinic in North East England (Freeman Hospital, Newcastle upon Tyne) with a 
clinical diagnosis of non-cystic fibrosis bronchiectasis (nCFBR) diagnosed by high-resolution 
computed tomography (HRCT) scanning. Seventy patients (App. 3) were enrolled into the 
study in which all non-CF aetiologies were included with the related nCFBR condition. 
Information on bronchiectasis aetiology, patient sex, age, clinical status, forced expiratory 
volume in one second (FEV1) and one second predicted (FEV1% predicted) in addition to 
inhaled antibiotic therapy was collected. Patient cohort enrolled consisted both of clinically 
stable and exacerbated individuals. For clinical status an exacerbation was defined as per the 
British Thoracic Society 2010 Bronchiectasis guidelines in the presence of increased cough, 
malaise and increased sputum volume and purulence (Pasteur et al., 2010). Frequent 
exacerbators within cohort were defined as those patients who had greater than 3 episodes 
over this period (Pasteur et al., 2010). Aetiological designation was based upon the suggested 
protocols (Pasteur et al., 2001). Cystic fibrosis genotyping and/or sweat testing was 
undertaken as suggested by national guidelines. 
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2.3.2 Sputum sample collection and diagnostic microbiology 
Spontaneously expectorated sputum samples were collected from an outpatient cohort of 
an adult nCFBR population. Samples were divided with one half being used for genomic 
DNA extraction (below) whilst the remainder underwent routine microbial culture using 10 
µL aliquots of Sputasol (OXOID) treated and homogenised sputum according to the 
standardised Health Protection Agency methodology at the Department of Microbiology, 
Freeman Hospital, Newcastle-upon-Tyne (see App. 4 for standard operating procedure (SOP) 
regarding the selective media employed from this sample type). Information, from up to 10 
years previously, on patient sex, age, clinical and microbiological status, FEV1, and inhaled 
antibiotic therapy was collected. The definitions of Pasteur et al., (2001) were used to define 
persistent infection in study cohort. 
2.3.3 DNA extraction from sputum clinical samples 
All DNA extractions on sputum samples in patient cohort were performed using an 
UltraClean® Microbial DNA Isolation Kit (MO BIO Laboratories, Inc.) in a Microflow 
Peroxide Advanced Bio Safety Cabinet (Class I) at the Freeman Hospital, Microbiology 
Department. Before collection of extracted gDNA from sputum all samples were thawed 
thoroughly and then vortexed (Vortex-Genie2™) rigorously after addition of an approximate 
equal volume of sputolysin (if required as most sputum samples varied in their degree of 
purulence). The addition of sputolysin breaks down any mucus plugs that may be present in 
the sputum sample and aids in the creation of a more aqueous solution enabling the sample 
supernatant to pass through the 0.2 µm filter without obstruction. 
Once mucus plugs in sample were dissolved, 1.8 mL from aqueous solution (i.e., the 
sputum sample) was aliquoted into a sterile 2 mL collection tube before being spun down at 
10 000   g (SIGMA® 12094 rotor) at room temperature for 1 min in a microcentrifuge 
(SIGMA®). The supernatant was discarded leaving behind another mucus plug. At this stage 
all sputum samples extracted for gDNA left behind varying amounts of mucus plugs. As a 
precautionary step, any mucus plugs which exceeded > 200 µL needed be to be aliquoted off 
to approximately < 200 µL to ensure unobstructed flow through 0.22 µm filter at a later stage. 
Following this the sample was spun down again at 10 000   g to maximally concentrate and 
pellet microbial cells. Any supernatant present in sample was discarded. The cell pellet was 
re-suspended in 300 µL of MicroBead Solution containing salts and a buffer stabilising and 
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homogeneously dispersing the microbial cells present in the re-suspension solution prior to 
cellular lysis. After addition of MicroBead Solution re-suspended cells were gently vortexed 
to aid in microbial cell dispersion before being transferred to a MicroBead Tube. Fifty µL of 
MD1 solution (i.e., lysis buffer) was then added to re-suspended cells. The lysis buffer 
contains the anionic detergent sodium dodecyl sulphate (SDS) and other chaotropic salts 
(undisclosed in kit protocol, but these can be guanidine hydrochloric acid (HCl), guanidine 
thiocyanate, urea, and lithium perchlorate). Both chemical agents aid in cellular lysis, the 
former acting to breakdown fatty acids and cell membrane lipids via solubilisation; the latter, 
in addition to also breaking down the cellular membrane, plays an important role in the 
disruption of hydrogen bonds, van der Waals forces, and hydrophobic interactions. 
All MicroBead Tubes were then secured horizontally using the MO BIO Vortex Adapter 
tube holder and subsequently vortexed at maximum speed for 10 min to release ssDNA from 
lysed cells. Recovery of gDNA from cell debris was achieved by centrifuging at room 
temperature the 2 mL MicroBead Tubes at 10 000   g for 1 min in which the supernatant 
(now containing the gDNA) was transferred to a clean 2 mL microfuge tube. One hundred µL 
of MD2 Solution was added to the supernatant and then vortexed for 5 seconds before being 
incubated at 4 °C for 5 min. Solution MD2 precipitates both non-DNA and inorganic material 
present in proteins and cell debris. After incubation, the supernatant was then spun down at 
room temperature at 10 000   g for 1 min. 
Avoiding the pellet, as this contained non-DNA organic and inorganic materials (i.e., cell 
debris and proteins), the entire supernatant volume was transferred into an empty syringe vial 
(BD) with filter (PALL Gelman Laboratory, Acrodisc® Syringe Filter, 0.2 µm Supor® 
membrane, non-pyrogenic) attached before insertion of the syringe plunger. Once inserted, 
plunger was pushed down to filter sterilise the supernatant into an empty, clean 2 mL 
collection tube. Filter sterilisation of the supernatant ensured the removal of any tubercular 
agents that may be still present in the supernatant processed. Approximately 200-300 µL of 
supernatant volume was collected after this step. 
Solution MD3 was shaken before use and then 900 µL of this was added to the filter 
sterilised supernatant and subsequently vortexed for 5 s. Solution MD3 creates a high salt 
concentration which is necessary for the binding of the gDNA to the Spin Filter in the 
following step. Seven hundred µL of supernatant was loaded into the Spin Filter and 
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centrifuged (room temperature) at 10 000   g for 1 min before the flow through was 
discarded. The remaining supernatant was added to the Spin Filter and this process was 
repeated once more. Again, all flow through liquid was disposed of as the gDNA is 
selectively bound to the silica membrane in the Spin Filter device allowing impurities such as 
protein and polysaccharides to pass unobstructed in the flow through liquid. Three hundred 
µL of Solution MD4 (an ethanol based wash solution) was then added to further clean the 
gDNA bound to the silica membrane removing residues of salt and other impurities that may 
be still present in the previous step. All flow through liquid containing ethanol wash solution 
waste and contaminants was discarded as before. The Spin Filter was then spun down at 10 
000   g for 1 min at room temperature to remove any residual ethanol wash solution present 
(essential for a clean eluant). The Spin Filter basket was then placed in a new clean 2 mL 
collection tube before addition of 50 µL Solution MD5 (an elution buffer containing 10 mM 
Tris, pH 8) to the centre of the white membrane. The collection tube containing the Spin 
Filter was centrifuged at 10 000   g at room temperature for 1 min eluting the gDNA bound 
to the filter membrane. The elution buffer solution MD5 allows this, as release of the bound 
DNA is permitted only in the presence of this elution buffer as it contains no salt (previously, 
DNA was bound to the silica Spin Filter membrane only in the presence of salt). Following 
elution of the gDNA (50 µL in volume) the Spin Filter was discarded and the gDNA was 
stored at -80 °C. 
2.3.4 Bacterial community detection PCR 
As previously described, the V3 hypervariable region of the 16S rRNA gene was targeted 
for enzymatic amplification using gDNA as template. Primer sets V3F-GC (5′-CGC CCG 
CCG CGC GCG GCG GGC GGG GCG GGG GCA CGG GGG GCC TAC GGG AGG CAG 
CAG-3′) and V3R (5′- ATT ACC GCG GCT GCT GG-3′) as previously shown (Muyzer et 
al., 1993, Nelson et al., 2010) were utilised to produce different V3 rDNA fragments 
amplified from multiple species of bacteria present in the clinical sputum samples. As before, 
a 40-bp GC-rich nucleotide sequence was attached to the 5′ end of the forward primer V3F-
GC (Sheffield et al., 1989). 
An automatic HS and touchdown PCR protocol (Don et al., 1991) was performed on a 
Mastercycler gradient (Eppendorf) with the PCR reagents per reaction added as follows: 0.5 
µM primers (both forward (V3F-GC) and reverse (V3R)), 1  Ex Taq Buffer (TAKARA BIO 
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INC.), 0.2 mM each dNTP (TAKARA BIO INC.), 1 mM MgCl2, 10 µg/µL BSA (Promega), 
1.25 U Ex Taq™ HS pol and 1 µL of gDNA template made up to a total volume of 50 µL 
with sterile 18.2 MΩ H2O (MILLIPORE, Direct-Q™ Ultra Pure Water Systems, 
MILLIPAK® 0.22 µm filter). Positive (extracted gDNA from a pure culture of H. influenzae, 
NCTC no. 11931) and negative controls were also set up to determine the correct size of the 
V3 rDNA fragments and to rule out any environmental DNA contamination. Samples were 
incubated for 5 min at 97 °C releasing antibody bound polymerase Ex Taq™ HS, then at 96 
°C for 1 min, 65 °C for 1 min, with a reduction of 0.5 °C per cycle until touchdown at 55 °C. 
Primer extension lasted for 30 s at 72 °C and this was repeated for 20 cycles. An additional 
15 cycles was carried out at 94 °C for 1 min, 55 °C for 1 min, 72 °C for 3 min and a final 
extension time of 72 °C for 30 min as previously described (Janse et al., 2004). 
2.3.5 Fungal community detection PCR 
As previously described in the 28S standard ladder construction sections, in addition to the 
bacterial community, we also investigated the fungal community in the cross-sectional 
cohort. Using primer sets U1F (5′-GTG AAA TTG TTG AAA GGG AA-3′) and U2R-GC 
(5′-CGC CCG CCG CGC GCG GCG GGC GGG GCG GGG GCA CGG-3′) to target 
conserved regions containing hyper-variable regions within the 28S rRNA gene, small 
fragments of 28S rDNA were generated using gDNA as template (Sandhu et al., 1995, 
Nelson, 2011). 
An automatic HS and touchdown PCR protocol was performed on an Eppendorf 
Mastercycler gradient apparatus. Reagents for this reaction were added as follows: 0.5 µM 
primers (both forward (U1F) and reverse (U2R-GC)), 1  Ex Taq Buffer (TAKARA BIO 
INC.), 0.2 mM each dNTP (TAKARA BIO INC.), 1 mM MgCl2, 10 µg/µL BSA (Promega), 
1.25 U Ex Taq™ HS (TAKARA BIO INC.) and 1 µL of gDNA template made up to a total 
volume of 50 µL with sterile 18.2 MΩ H2O (MILLIPORE, Direct-Q™ Ultra Pure Water 
Systems, MILLIPAK® 0.22 µm filter). Conditions for the PCR were as follows: an initial 
denaturation step of 97 °C for 5 min, 94 °C for 1 min, 60 °C for 1 min with a reduction of 1.0 
°C per cycle reaching touchdown at 50 °C and 72 °C for 1 min repeated for 10 cycles. An 
additional 25 cycles were performed at 94 °C for 3 min, 50 °C for 1 min, and 72 °C for 1 
min, with a final extension time at 72 °C for 30 min implemented as previously described in 
addition to the touchdown protocol (Don et al., 1991, Janse et al., 2004). Positive and 
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negative controls were also conducted confirming the correct size of the fungal U1-U2 rDNA 
amplicons (using extracted gDNA from a pure culture of A. fumigatus) and validation of any 
environmental sources of contamination. 
2.3.6 Agarose gel electrophoresis of both V3 and U1-U2 rDNA amplicons 
Regions amplified from both the 16S and 28S rRNA genes in extracted gDNA, i.e., V3 
and U1-U2 rDNA fragments, were confirmed by running PCR products on a 1 % (
w
/v) 
agarose gel stained with SYBR® Safe DNA gel stain (10 000  concentrate in (DMSO) 
(Invitrogen™). PCR fragments were electrophoresed for 20 min at 120 mA constant (BIO-
RAD, Basic PowerPac™) in 1  TAE running buffer with 5 µL of PCR product, 2 µL 6  
BPB, and 5 µL 18.2 MΩ H2O (MILLIPORE, Direct-Q™ Ultra Pure Water Systems, 
MILLIPAK® 0.22 µm filter) mixed prior to 10 µL loaded into each well. Five µL of 
Hyperladder I (200-10 000 molecular bp-size markers (BIOLINE)) was also added, in which 
after electrophoresis, positive confirmation of both the V3 and U1-U2 rDNA fragments was 
validated (233 and 300 bp in size respectively) under UV light (Gel Doc 2000 system and 
Quantity One software (v. 4.6.6) (BIO-RAD). Hard copies of the electropherograms were 
generated using a Mitsubishi Video copy processor (model P91 attached to the Gel Doc 2000 
system). 
2.3.7 Molecular fingerprinting of bacterial and fungal communities in 
patient cohort 
2.3.7.1 DGGE of V3 rDNA amplicons 
Molecular fingerprinting of V3 rDNA amplicons in cross-sectional patient cohort was 
carried out using a DCode™ Universal Mutation Detection System (BIO-RAD) run out on a 
32.5-60 % denaturing gradient (12 % acrylamide/bis-acrylamide of gel percentage) (App. 1) 
with a balance plate attached to the inner core of the DCode™ system apparatus. PCR 
fragments generated from each clinical sample (30 µL (15 µL PCR product and 15 µL 2  gel 
loading dye) were loaded onto wells in the denaturing gel in addition to a 16S standard ladder 
(36 µL (18 µL PCR products of 9 different bacterial species and 18 µL 2  gel loading dye)). 
Electrophoresis of V3 rDNA amplicons was performed at 200 V constant (Basic 
PowerPac™, BIO-RAD) for 4.5 h, stained with SYBR Green nucleic acid stain I 
(Invitrogen™), incubated for 30 min (75 rpm on a shaking platform (Edmund Bühler, KM-
2)), de-stained briefly with dH2O, before visualisation under UV light (BIO-RAD Gel Doc 
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2000 system and Quantity One software (v. 4.6.6)). Hard copies of the bacterial community 
DGGE profiles in cross-sectional patient cohort were generated (Mitsubishi Video copy 
processor (model P91) attached to the Gel Doc 2000 system). 
2.3.7.2 DGGE of U1-U2 rDNA amplicons 
Fungal community analysis of nCFBR cohort was performed using the DCode™ 
Universal Mutation Detection System (BIO-RAD) on a 40-60 % denaturing gradient (12 % 
acrylamide/bis-acylamide of gel percentage) in addition to a balance plate attached to the 
inner core. Amplicons consisting of U1-U2 rDNA fragments from each patient sample, (30 
µL (15 µL PCR product and 15 µL 2  gel loading dye)) were loaded appropriately, in 
addition to a 28S standard ladder (28 µL (14 µL PCR products of 7 different fungal species 
and 14 µL 2  gel loading dye)) were electrophoresed at 70 V constant (Basic PowerPac™, 
BIO-RAD) for 17 h, stained with SYBR Green nucleic acid stain I (Invitrogen™), incubated 
for 30 min at 75 rpm, (Edmund Bühler, KM-2) and de-stained briefly with dH2O, before 
being finally visualised under UV light (BIO-RAD Gel Doc 2000 system and Quantity One 
software (v. 4.6.6)). Hard copies of the fungal community DGGE profiles in the cross-
sectional patient cohort were generated as previously described. 
2.3.8 Bacterial and fungal DGGE profile capture and analysis 
Both bacterial and fungal DGGE profiles generated were first captured in the Quantity 
One software (v. 4.6.6) program, cropped appropriately and then copied. These copied 
DGGE profiles were then exported as TIFF (tagged image file format) picture files at 276 
dots per inch (DPI) resolution and subsequently imported into TotalLab’s Phoretix 1D 
(TotalLab Ltd.) via a new experimentation file being created. All DGGE profiles imported 
were subsequently converted into the inverted version of the DGGE profiles, thus 
measurements were all subsequently inverted. Processing of both the bacterial and fungal 
DGGE community profiles firstly involved the creation of lanes and appropriate framing 
before suitable adjustment to compensate for inter-gel variance effects such as lane bending. 
Once these changes were implemented and accepted, background detection was removed 
from the DGGE profiles using the rolling ball software algorithm (100 pixel radius) in 
Phoretix 1D. Detection of bands in gels was performed using the automatic detection 
algorithm, before bands and gel artefacts were either removed or added manually by eye; 
band width was also assessed and adjusted manually by eye. 
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Inter-gel alignment was achieved by executing both 16S and 28S SLs for bacterial and 
fungal community detection, important in relative front (Rf) calibration function 
(Tourlomousis et al., 2010). Comprising of 16S and 28S rRNA gene amplicons derived from 
pure cultures of selected relevant species, these served as internal markers in which all lanes 
were aligned relative to. Lane alignment was manually created and adjusted by the 
assignment of standard Rf values for the most reproducible bands (in particular the 16S SL) 
present in the standard ladders based upon migration distance through gel as these were 
approximately the same between gels analysed. Both 16S and 28S standard ladders contained 
> 5 reference bands throughout entire patient cohort analysis and for inter-gel alignment this 
has been suggested for accurate interpolation of multiple gels (Tourlomousis et al., 2010). 
The Rf lines created were then manipulated to correct for common inter-gel effects such as 
‘smiling’ and ‘leaning’. Once accomplished, the current Phoretix 1D experiment was saved 
and closed. 
Using TotalLab’s Phoretix 1D Pro program, a database was created in which all of the 
previously analysed DGGE profiles in Phoretix 1D were subsequently added to this database. 
Alignment of all gels was first validated by eye and then using the compare lanes software 
algorithm tool. Once alignment of gels was visually accepted, all gels and their respective 
standard ladders were matched using the match gel function in Phoretix 1D Pro. Following 
this, an automatic DGGE band matrix was then created using the Rf values and relative 
intensities of all detected bands in the experimental file. Both band presence and relative 
intensities were exported to Microsoft® Excel™ for further statistical and ecological 
analysis. The exported band presence matrix was directly utilised for the species richness in 
patient cohort (see below). The relative band intensities were normalised as previously 
described in section 2.1.6.1 (DGGE profile capture and analysis). 
2.3.9 Ecological analysis inferred from DGGE profiling 
Examination of the structure of the bacterial communities present in the sputum samples 
analysed by DGGE was performed. Biodiversity measures such as species richness (R) (the 
number of taxa present), evenness (J′) (the proportion contributed to the community by each 
taxa), and Shannon diversity (H′) (a diversity index giving a measure of both species numbers 
and the evenness of their abundance), were calculated using the exported DGGE band matrix 
in Microsoft® Excel™. Note that fungal biodiversity measures could not be carried out due 
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to scarce detection in patient cohort (only three fungal taxa in whole cohort). The H′ derived 
from the normalised band values in Excel™ has been previously described in section 2.1.6.2 
(Shannon diversity index derivation). This was conducted for the entire patient cohort 
analysed by DGGE and the bacterial community profiles generated. The J′ was also derived 
once the H′ was calculated, executed by the following formula: 
   
  
   (  )
 
Where J′ is the species evenness derived from the natural logarithm (ln) of the sum of the 
species richness (R) value per lane divided by the H′ of that particular lane. 
2.3.9.1 Raup-Crick similarity index 
The Raup-Crick similarity index was used to assess if the bacterial communities present in 
each patient were non-randomly (P = 0.05 ≤ or ≥ 0.95) or stochastically (P = > 0.05 and < 
0.95) assembled using the PAST software program in which the probabilities were calculated 
by 200 pair-wise Monte Carlo simulations (Hammer and Harper, 2001). 
2.3.10 Ordination analyses by Canoco 
Matrices derived from the normalisation of the band relative intensities were subjected to 
ordination analyses by using the Canoco (v. 4.5.1) software package with ordination plots 
being generated by CanoDraw (v. 4.14). In Microsoft® Excel™, normalised band matrices 
were copied onto the clipboard before being transposed into a data file format suitable for 
Canoco using the WCanoImp (v. 4.5.2.0) plug-in. Environmental variables such as patient 
phenotypic data (age, gender, current colomycin and azithromycin therapy, etc.) were 
assigned either contiguous values (e.g., age, FEV1% predicted) or a binary system to denote 
indiscreet variables (positive values = 1; negative values = 0). 
Band matrices were firstly analysed by detrended correspondence analysis (DCA) in 
Canoco to determine 1° axis length, used to ascertain what appropriate ordination analysis to 
use. If 1° axis length was < 3 SD (standard deviation units of species turnover) a redundancy 
analysis (RDA; a constrained linear ordination method) was executed as opposed to > 3 SD 
in which canonical correspondence analysis (CCA (a constrained unimodel ordination 
method)) was chosen instead. Statistical analysis of both the bacterial community, discreet 
and indiscreet variables was performed using full model Monte Carlo testing (499 
 52 
 
permutations) with significant factors identified if P-values were < 0.05 and not significant if 
P = > 0.05. Following analysis, analysed data was then imported into CanoDraw for 
generation of ordination plots containing samples (patient subject number) and environmental 
factors. Ambiguity between discreet and indiscreet variables was solved by assigning discreet 
factors with centroids whereas contiguous variables were represented by an arrow. Patient 
samples analysed by DGGE, i.e, the normalised band matrices plotted, could be denoted by 
different shapes and colours in CanoDraw for clarity if deemed necessary. Ordination 
analyses of the bacterial profiles, derived from the initial DGGE analysis seek to represent 
the similarity between the bacterial communities from each sample. Profiles that have a 
similar community structure and composition group more closely together. Constrained 
unimodel (canonical) analyses show variation between the sample profiles that can be 
explained by the measured categorical and continuous environmental variables (ter Braak and 
Šmilauer, 2002). 
2.4 Molecular fingerprinting and metagenomic analysis in a chronic 
obstructive pulmonary disease cohort 
2.4.1 Sampling methodology and ethical considerations within patient 
cohort 
Eleven clinically stable patients (App. 5), comprised of smokers and ex-smokers with 
GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages II and III of chronic 
obstructive pulmonary disease (COPD) attended a routine clinic at the Freeman Hospital, 
Newcastle upon Tyne, to undergo bronchoscopy, in which a bronchoalveloar lavage (BAL) 
fluid was produced (except in one patient, where bronchial secretion (BS) fluids were 
obtained instead due to difficulty of BAL fluid extraction). The BAL and BS fluids were then 
processed for conventional microbiology testing in the Microbiology Department at the 
Freeman Hospital, Newcastle upon Tyne, under Health Protection Agency protocols (SOP in 
App. 4), where the remaining aliquots of clinical specimen fluids were stored at -80 °C prior 
to microbial gDNA extraction. Ethical approval for this study was granted by Northumbria 
University’s School of Life Sciences Research Ethics Committee and Newcastle upon Tyne 
Hospitals NHS Foundation Trust. 
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2.4.2 DNA extraction from bronchoalveolar lavage and bronchial 
secretion fluid clinical samples 
Microbial gDNA extraction from BAL and BS fluid samples was achieved using an 
UltraClean® Microbial DNA Isolation Kit (MO BIO Laboratories, Inc.) in a Microflow 
Peroxide Advanced Bio Safety Cabinet (Class I) at the Freeman Hospital, Microbiology 
Department, Newcastle upon Tyne with amendments to the kit protocol. All fluid samples (< 
5 mL in volume) contained in a 25 mL plastic universal were thawed thoroughly and then 
vortexed (Vortex-Genie2™) rigorously with addition of an equal volume of sputolysin 
(added only to slightly purulent fluid samples to aid in breakage of any mucus plugs present 
and enabling passage of the supernatant through the 0.22 µm filter (in later stages of this 
procedure)). Both the BAL and BS fluid samples were then centrifuged at 3000   g for 10 
min at room temperature (CENTAUR, P20075 rota) before the supernatant was decanted 
carefully and the cellular pellet resuspended in 300 µL of MicroBead Solution within the 25 
mL universal tube. This was gently vortexed and 500 µL of this mix was then transferred to a 
MicroBead Tube in which 50 µL of MD1 solution was added. 
The MicroBead Tubes were then secured horizontally using the MO BIO Vortex Adaptor 
tube holder and vortexed at maximum speed for 10 min before being spun down at 10 000   
g (SIGMA® 12094 rotor) at room temperature for 1 min in a microcentrifuge (SIGMA®). 
The supernatant was then transferred to a clean, sterile 2 mL Collection Tube with ~ 300-350 
µL of supernatant present. One hundred µL of Solution MD2 was then added to the 
supernatant and vortexed for 5 s and then incubated at 4 °C for 5 min. Following this 
incubation step, the 2 mL Collection Tubes were then centrifuged at 10 000   g for 1 min at 
room temperature. A 2 mL syringe (BD) was attached to a filter (PALL Gelman Laboratory, 
Acrodisc® Syringe Filter, 0.2 µm Supor® membrane, non-pyrogenic) and the syringe 
plunger removed and placed to one side. The entire supernatant medium from the 2 mL 
Collection Tube was then transferred to the empty syringe vial and filter-sterilised, via re-
attachment of the syringe plunger into the syringe vial, by pushing the supernatant through 
the 0.2 µm filter into another clean, sterile 2 mL Collection Tube. As previously described, 
this filter-sterilisation process was an extra step introduced into the gDNA extraction 
procedure to circumvent possible exposure to any tubercular agents that may have been 
present in the clinical sample. Less than 300 µL of supernatant volume should have been 
dispensed from the filter, although this varied due to the amount of BAL and BS fluids 
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originating from the 25 mL universal tube. Syringe and filter apparatus were discarded after 
use and only used once. 
Nine hundred µL of shaken and mixed Solution MD3 was then added to the filtered 
supernatant, vortexed for 5 s, before 750 µL of this mixture was added to a Spin Filter before 
being initially centrifuged at 10 000   g for 1 min at room temperature. Any flow through 
liquid was discarded and the remaining supernatant was added to the Spin Filter and 
centrifuged again at 10 000   g for 1 min at room temperature. All flow through liquid was 
discarded. Three hundred µL of Solution MD4 was then added to the Spin Filter before being 
centrifuged at 10 000   g for 1 min at room temperature. Again, any flow through liquid was 
discarded and the Spin Filter was centrifuged at 10 000   g for 1 min at room temperature. 
The spin filter basket was removed and the Spin Filter was placed into a new 2 mL Collection 
Tube in which 50 µL of Solution MD5 was pipetted directly into the centre of the white filter 
membrane. A final centrifugation at 10 000   g at room temperature for 1 min was required 
to release the gDNA (50 µL in volume) from the filter membrane. Following this, the Spin 
Filter itself was discarded and the eluted gDNA from the BAL and BS samples was stored at 
-80 °C prior to downstream processing. 
2.4.3 ‘Semi-nested’ bacterial community detection PCR in BAL and BS 
fluid samples 
As previously described in the nCFBR materials and methods sections, the bacterial 
community in the eleven COPD patients enrolled was amplified using Ex Taq™ HS pol 
(TAKARA BIO INC.). Primers V3F-GC (5′-CGC CCG CCG CGC GCG GCG GGC GGG 
GCG GGG GCA CGG GGG GCC TAC GGG AGG CAG CAG-3′) and V3R (5′- ATT ACC 
GCG GCT GCT GG-3′) targeted the V3 hypervariable region of the 16S rRNA gene resulting 
in the enzymatic amplification of V3 rDNA amplicons using extracted gDNA as template as 
previously shown (Muyzer et al., 1993). As before, the forward primer V3F-GC had a 40-bp 
GC-rich nucleotide sequence attached to its 5′ end enabling greater detection of variances in 
bacterial gDNA within the V3 rDNA amplicons and PCR fragment stability when analysed 
by DGGE (Sheffield et al., 1989). 
An automatic HS and touchdown PCR protocol was performed on a Mastercycler 
gradient (Eppendorf) with the PCR reagents per reaction added as follows: 0.5 µM primers 
(both forward (V3F-GC) and reverse (V3R)), 1  Ex Taq Buffer (TAKARA BIO INC.), 0.2 
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mM each dNTP (TAKARA BIO INC.), 1 mM MgCl2, 10 µg/µL BSA (Promega), 1.25 U Ex 
Taq™ HS pol and 1 µL of gDNA template made up to a total volume of 50 µL with sterile 
18.2 MΩ H2O (MILLIPORE, Direct-Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm 
filter). Positive (extracted gDNA from a pure culture of H. influenzae, NCTC no. 11931) and 
negative controls were also set up to determine the correct size of the V3 rDNA fragments 
and to rule out any environmental DNA contamination. Samples were incubated for 5 min at 
97 °C releasing antibody bound polymerase Ex Taq™ HS, then at 96 °C for 1 min, 65 °C for 
1 min, with a reduction of 0.5 °C per cycle until touchdown at 55 °C. Primer extension lasted 
for 30 s at 72 °C and this was repeated for 20 cycles. An additional fifteen cycles was carried 
out at 94 °C for 1 min, 55 °C for 1 min, 72 °C for 3 min and a final extension time of 72 °C 
for 30 min. Following this completed reaction, the V3 rDNA amplicons were then used as 
DNA template for a second round of bacterial community amplification with exactly the 
same concentrations and conditions outlined above (a ‘semi-nested’ approach). As previously 
described, implementation of both a touchdown protocol and a longer final extension time 
was executed to circumvent spurious PCR product and double band formation bias on DGGE 
analyses (Don et al., 1991, Janse et al., 2004). These implementations were also executed on 
the consecutive round of PCR when the V3 rDNA fragments were utilised as template. 
2.4.4 ‘Semi-nested’ fungal community detection PCR in BAL and BS fluid 
samples 
As in the cross-sectional nCFBR patient cohorts, community fungal PCR on a 
Mastercycler gradient (Eppendorf) was also performed in addition to universal bacterial 
community detection. PCR primers specific for the amplification of variable regions within 
the 28S rRNA gene ubiquitous in the fungal genome were utilized as shown previously 
(Sandhu et al., 1995). PCR using the U1F (5′-GTG AAA TTG TTG AAA GGG AA-3′) and 
U2R-GC (5′-CGC CCG CCG CGC GCG GCG GGC GGG GCG GGG GCA CGG-3′) primer 
sets were executed, in addition to Ex Taq™ HS pol (TAKARA BIO INC.) to enzymatically 
amplify small segments of 28S rDNA (U1-U2 rDNA fragments). 
PCR reagents for this reaction were added as follows: 0.5 µM primers (both forward 
(U1F) and reverse (U2R-GC)), 1  Ex Taq Buffer (TAKARA BIO INC.), 0.2 mM each dNTP 
(TAKARA BIO INC.), 1 mM MgCl2, 10 µg/µL BSA (Promega), 1.25 U Ex Taq™ HS and 1 
µL of gDNA template made up to a total volume of 50 µL with sterile 18.2 MΩ H2O 
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(MILLIPORE, Direct-Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm filter). An 
automatic HS and touchdown PCR protocol was utilised in which the conditions were an 
initial denaturation step of 97 °C for 5 min, 94 °C for 1 min, 60 °C for 1 min with a reduction 
of 1.0 °C per cycle reaching touchdown at 50 °C and 72 °C for 1 min repeated for 10 cycles. 
An additional 25 cycles were performed at 94 °C for 3 min, 50 °C for 1 min, and 72 °C for 1 
min. As previously introduced, a final extension time at 72 °C for 30 min was implemented 
in addition to the touchdown protocol ((Don et al., 1991, Janse et al., 2004). Following this 
completed reaction, the U1-U2 rDNA amplicons were then used as DNA template for a 
second round of fungal community amplification with exactly the same concentrations and 
conditions outlined above (a ‘semi-nested’ approach). Both positive and negative controls 
were executed for confirmation of the correct size of the fungal U1-U2 rDNA amplicons 
(using extracted gDNA from a pure culture of A. fumigatus) and to rule out any 
environmental sources of contamination. 
2.4.5 Agarose gel electrophoresis of both V3 and U1-U2 rDNA amplicons 
from BAL and BS fluid samples 
Amplicons generated from bacterial and fungal community PCR from BAL and BS fluid 
samples were validated for positive amplification of their respective 16S and 28S rRNA gene 
segments by running out PCR fragments on an agarose gel (1 % (
w
/v) and electrophoresing at 
120 mA constant for 20 min (BIO-RAD, Basic PowerPac™). The agarose gel was stained 
with SYBR® Safe DNA gel stain (10 000  concentrate in DMSO) (Invitrogen™) prior to 
use for visualisation under UV light. Five µL of PCR product, 2 µL 6× BPB, and 5 µL 18.2 
MΩ H2O (MILLIPORE, Direct-Q™ Ultra Pure Water Systems, MILLIPAK® 0.22 µm filter) 
were mixed by trituration before a final volume of 10 µL was loaded into the appropriate gel 
well, in addition to 5 µL of Hyperladder 1 (BIOLINE). Using a BIO-RAD Gel Doc 2000 
system and Quantity One software (v. 4.6.6) comparison of the molecular base pair markers 
in Hyperladder I (BIOLINE), in addition to the positive control, confirmed the correct sizes 
of both types of amplicons; i.e., V3 and U1-U2 rDNA fragments (233 bp and 300 bp in size 
respectively). Hard copies of the electropherograms were generated using a Mitsubishi Video 
copy processor (model P91 attached to the Gel Doc 2000 system). 
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2.4.6 Molecular fingerprinting of the bacterial and fungal community 
within BAL and BS fluid samples 
2.4.6.1 DGGE of V3 rDNA amplicons from BAL and BS fluid samples 
Bacterial molecular fingerprinting within the BAL and BS clinical samples was carried out 
using DGGE as previously described on a DCode™ Universal Mutation Detection System 
(BIO-RAD) on a 32.5-60 % denaturing gradient (12 % acrylamide/bis-acrylamide of gel 
percentage). Amplicons from all 11 patients in addition to a 16S SL consisting both of V3 
rDNA fragments were loaded appropriately into wells; 30 µL (15 µL PCR product and 15 µL 
2  gel loading dye) and 36 µL (18 µL PCR products of 9 different bacterial species (see 
above) and 18 µL 2  gel loading dye) respectively. PCR fragments were electrophoresed for 
4.5 h at 200 V constant (Basic PowerPac™, BIO-RAD), stained with SYBR Green nucleic 
acid stain I (Invitrogen™) and incubated for 30 min at 75 rpm (Edmund Bühler, KM-2), de-
stained briefly with dH2O, before being finally visualised under UV light (BIO-RAD Gel Doc 
2000 system and Quantity One software (v. 4.6.6)). A hard copy of the bacterial community 
DGGE profile in this particular patient cohort was also generated (Mitsubishi Video copy 
processor (model P91) attached to the Gel Doc 2000 system). 
2.4.6.2 DGGE of U1-U2 rDNA amplicons from BAL and BS fluid samples 
Fungal community analysis of COPD cohort was performed using the DCode™ Universal 
Mutation Detection System (BIO-RAD) on a 40-60 % denaturing gradient (12 % 
acrylamide/bis-acylamide of gel percentage). As before, all eleven patient amplicons (30 µL 
(15 µL PCR product and 15 µL 2  gel loading dye)) were loaded appropriately, in addition 
to a 28S SL (28 µL (14 µL PCR products of 7 different fungal species (see above) and 14 µL 
2  gel loading dye)). Electrophoresis of U1-U2 rDNA amplicons was executed at 70 V 
constant (Basic PowerPac™, BIO-RAD) for 17 h, stained with SYBR Green nucleic acid 
stain I (Invitrogen™) and incubated for 30 min at 75 rpm, (Edmund Bühler, KM-2) de-
stained briefly with dH2O, before being finally visualised under UV light (BIO-RAD Gel Doc 
2000 system and Quantity One software (v. 4.6.6)). A hard copy of the fungal community 
DGGE profile in the COPD patient cohort was also generated (Mitsubishi Video copy 
processor (model P91) attached to the Gel Doc 2000 system). 
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2.4.7 Metagenomic analysis of BAL and BS fluid samples 
Extraction of gDNA from both BAL and BS fluid samples yielded 50 µL of eluted gDNA, 
20 µL of which was sent to Research and Testing Laboratories (RTL) LLC. (Lubbock, Texas, 
U.S.) for 454-pyrosequencing generating the metagenomic data within patient cohort. The 
bacterial tag-encoded FLX-Titanium amplicon pyrosequencing (bTEFAP) method targeted 
the V3-V5 hypervariable regions of the 16S rRNA gene creating amplicon libraries (Dowd et 
al., 2008). Primer sets corresponded to 341F (5′-CC TAC GGG AGG CAG CAG-3′) and 
907R (5′-CC GTC AAT TCC TTT GAG TTT-3′) co-ordinates of the reference E. coli 16S 
rRNA gene in addition to sample nucleotide bar codes. Roche A & B primers were then 
implemented to perform pyrosequencing by established methods (Dowd et al., 2008). 
Resulting 16S pyroamplicon sequences were then pre-processed and aligned using the 
SILVA reference alignment database, before being trimmed and eliminated for chimeras as 
previously described (Costello et al., 2009) in the open-source, platform-independent, 
community-supported software program mother (http://www.mothur.org) (Schloss et al., 
2009). The processed 16S pyroamplicon reads were then subsequently analysed and assigned 
OTUs with a 3 % cutoff with further analysis of the metagenomic data following the Costello 
Stool Analysis example (http://www.mothur.org/wiki/Costello_stool_analysis). 
2.4.8 Statistical and ecological analysis of COPD patient cohort 
From both the PCR-DGGE and metagenomic profiles generated, these were analysed 
using Canoco for Windows (v.4.5.1) with the ordination plots displayed in CanoDraw (v. 
4.14). Band and metagenomic matrices data was transposed into a suitable format for Canoco 
for Windows using WCanoImp (v. 4.5.2.0) plug-in and ordination plots and subsequent 
analysis was performed as previously described in section 2.3.10 (Ordination analyses by 
Canoco). 
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Chapter Three: DNA polymerase 
enzymes and microbial diversity 
3.1 Abstract 
Molecular fingerprinting techniques such as denaturing gradient gel electrophoresis 
(DGGE) enable the analysis of microbial communities in a variety of environments. 
However, a ‘gold standard’ DNA polymerase (pol) enzyme used to determine the microbial 
diversity in any given sample type is yet to be established. Reviewing the current literature, 
five DNA polymerase enzymes, Platinum® Pfx (Invitrogen
™
), TaKaRa Ex Taq™ Hot Start 
(TAKARA BIO INC.), AmpliTaq® (Applied Biosystems™), GoTaq® Hot Start Polymerase 
(Promega), and Taq (New England BioLabs®, Inc.) have all been widely utilised to study 
microbial diversity from a variety of different environments. These five DNA pol enzymes 
were assessed to determine the microbial diversity generated in sandy soil taken from dunes 
on Longsands Beach, Tynemouth, North East England. Using DNA extraction to obtain 
genomic DNA (gDNA) from sandy soil, the variable V3 region of the 16S rRNA gene was 
amplified with the five DNA pol using PCR conditions set out by the manufacturer’s 
recommendations for each enzyme. The PCR products from all five DNA pol reactions were 
compared by DGGE and multivariate analysis to determine the similarity of the profiles. Data 
strongly suggests that Platinum® Pfx and TaKaRa Ex Taq™ Hot Start detected greater 
microbial diversity present within sandy soil than the other DNA pol enzymes employed. 
3.2 Background 
Since the origins of life on Earth, polynucleotide pols exhibited the first signs of 
enzymatic activity early in the course of evolution; if absent, accurate and efficient genome 
replication would not have occurred, thus preventing the pre-requisites of evolution itself 
(Steitz, 1999). Evidently, accurate processing of genetic information in all organisms from 
parent to offspring is an absolutely essential process if the preservation and survival of all 
species is to continue; however, a critical step in species continuity is the tolerances in base-
pair mutation rates occurring over time, but providing life with an evolutionary selective 
advantage over other species (Perler et al., 1996). This preservation of the Watson-Crick 
structure in DNA during replication and repair is performed by DNA pol enzymes (Beard and 
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Wilson, 2003), a ubiquitous family of enzymes that are composed of functionally distinct 
domains and subdomains (Steitz, 1999). Characteristics of the DNA pol enzymes are often 
described as having a broad structural homology to that of the right hand, with “thumb”, 
“palm” and “fingers” sub-domains, all a common structural theme (Kohlstaedt et al., 1992). 
These enzymes can be further divided into several distinct families deduced from the 
structural homologies displayed from crystallographic studies and amino acid sequences in 
which the DNA pol families A, B, C, D, X and Y have all been characterised (Bebenek and 
Kunkel, 2004, Delarue et al., 1990, Joyce and Steitz, 1994). The best known and the most 
intensively studied is the DNA pols from the A family which include DNA pol I and Klenow 
fragments (a truncated version of this enzyme, which includes the C-terminal portion, 
containing the 3′ → 5′-exonuclease and pol domains) isolated from Escherichia coli and 
Bacillus DNA pol I in which the crystal structures of the above have been previously 
published (Ollis et al., 1985, Beese et al., 1993, Kiefer et al., 1998). Different DNA pol 
families exhibit general functions: (i), families B, C, and D and their respective DNA pols 
appear to be involved in chromosomal replication, (ii), A and B families exclusively promote 
the replication of DNA in viruses and bacteriophages, and (iii), DNA repair mechanisms are 
incorporated in all six families (Pavlov et al., 2004). 
Structurally homologous to all DNA pol families is the palm sub-domain ― the X family 
is unusual in that the DNA pol enzymes are described as being “left handed” and thus not 
homologous with the other families above (Steitz et al., 1994, Beard and Wilson, 2000) ― 
whereas across all DNA pol families, the finger and thumb domains differ in structure 
(Brautigam and Steitz, 1998). The palm sub-domain provides the catalytic action necessary 
for the addition of nucleotides via three catalytic residues that co-ordinate with two essential 
divalent metal ions that assist in the nucleotidyl transferase reaction (Steitz et al., 1994). The 
acquisition of two magnesium (Mg
2+
) cations is critical in the accurate synthesis of DNA, 
however, manganese (Mn
2+
) cations can be implemented as opposed to Mg
2+
 ions resulting in 
an increase in synthesising error rate during DNA replication but enabling numerous DNA 
pols to use RNA template as an alternative to DNA (Pavlov et al., 2004). Despite all of these 
differences in their tertiary structures, DNA pols all operate and synthesise new nucleotides 
via a standard catalysed reaction in which the addition of a nucleotide is added to the 3′-end 
of a DNA primer. 
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In the polymerase chain reaction (PCR) thermostable DNA pols are a necessity if one is to 
effectively select for and produce many copies of the gene of interest in addition to the 
subsequent isolation, characterisation and DNA template required for sequencing. In a 
sequence of events that led to the development of the polymerase chain reaction (PCR) (Saiki 
et al., 1985), the discovery of the thermophile (a micro-organism which proliferates optimally 
at < 80 °C) Thermus aquaticus and the isolation of its respective DNA pol I enzyme (Chien et 
al., 1976, Kaledin et al., 1980) has revolutionised thermocycling by enabling automation via 
the facilitation of thermostable Taq pol in PCR. Since the 1980s, the number of commercially 
available thermostable enzymes for automated thermocycling has risen rapidly, leading 
investigators to address specific questions such as which DNA pol is suitable for the 
investigation to be performed and will a ‘gold standard’ of DNA pol ever come into 
commercial viability? 
Thermostable DNA pols are derived from both thermophilic and hyperthermophilic 
eubacterial species; prior to this, many of the inherent properties of DNA pol enzymes were 
studied from the isolation and characterisation of said enzymes from mesophiles such as E. 
coli (Perler et al., 1996). In addition to exhibiting common structural themes derived from 
crystallographic studies, DNA pol enzymes also exhibit variances in their thermostability, 
extension rate, processivity and fidelity; all essential properties of thermostable DNA 
polymerases. Efficient replication of DNA in automated thermocycling must utilise 
thermostable DNA pol enzymes. Indeed, thermostability of all DNA pols is a critical property 
as free template DNA must be liberated during the DNA melting step, each cycle involving 
temperatures at ~ 95 °C, a necessity if new strands of double-stranded DNA (dsDNA) are to 
be synthesised in amplification procedures. The specific extension rate of a DNA pol is 
expressed as the number of dNTPs (deoxyribonucleoside triphosphates) polymerised per 
second per molecule of DNA polymerase, whereas processivity is characterised by the mean 
number of bases affixed by a DNA pol in a single binding episode during DNA synthesis 
(Pavlov et al., 2004). As in the other essential preceding properties, DNA pol enzymes also 
display an intrinsic property termed fidelity, defined as the comparison of the ability of a pol 
enzyme to insert a correct nucleotide versus an incorrect base (Beard and Wilson, 2003), this 
efficiency can vary 10
7
-fold (Beard et al., 2002, Kunkel, 2004). Inefficient DNA polymerases 
are naturally occurring enzymes that generally display poor correct nucleotide insertion 
efficiency, i.e., low fidelity, whereas more efficient DNA pols exhibit a higher fidelity, an 
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increased capacity for correct base insertion during DNA replication and other mechanisms 
(Beard and Wilson, 2003). 
As previously stated, the inherent microbial diversity within Earth’s biosphere is vast. Due 
to the limitations in using culture-dependent techniques and the ‘great plate count anomaly’ a 
paradigm was created in that an incomprehensible amount of bacteria are uncultivable and 
are therefore alluded to us (Amman et al., 1995, Rappé and Giovannoni, 2003, Staley and 
Konopka, 1985). However, in the last two decades culture-independent methodologies 
encompassing molecular fingerprinting techniques such as DGGE have emerged to provide 
investigators with powerful tools for discerning the many microbial communities that 
comprise the biosphere. Microbial communities have been identified and characterised from 
an extensive number of dissimilar natural habitats, not only around us, but also within us 
(Postec et al., 2005, Fujimoto et al., 2003, Vitali et al., 2007, Brakstad et al., 2008, Edenborn 
and Sexstone, 2007, van de Wiele et al., 2004). 
In terms of the other molecular fingerprinting methods briefly elaborated on, DGGE is one 
of the most established culture-independent techniques used in molecular microbial ecology 
studies (Muyzer and Smalla, 1998) as for most laboratories the initial implementation and 
cost-effectiveness of next generation sequencing (NGS) platforms is too high. Operating on 
principles and modifications since 1983 when it was first introduced (Fischer and Lerman, 
1983); small PCR fragments (~ 200-700 base pairs (bp)) are amplified from variable regions 
within the 16S rRNA gene representing members from the bacterial community. 
Amplification of these variable regions (e.g., the V3 region yielding V3 rDNA fragments) is 
usually performed by universal PCR primers resulting in amplicons of approximately the 
same length, thus, PCR products analysed by DGGE cannot be separated on traditional 
agarose or non-denaturing acrylamide gels. The bacterial community produced from the pool 
of V3 rDNA amplicons from extracted total gDNA in either environmental or clinical 
samples are separated out on a linear chemical denaturing gradient (urea and formamide) 
embedded within an acrylamide gel matrix according to genome fragment base-composition, 
i.e., guanine (G) and cytosine (C) content (Hovig et al., 1991) and a decrease in the 
electrophoretic mobility of the partially melted dsDNA molecules (Muyzer, 1999). 
Differential migration of these heterogeneous PCR amplicons containing gDNA sequence 
variation is achieved by the amount of denaturant in the gradient and the dissociation of the 
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two DNA strands containing differences in the number of hydrogen (H) bonds between the 
complementary nucleotides binding the DNA strands together; i.e., three H bonds bind G and 
C, as opposed to adenine (A) and thymine (T) which only contain two H bonds (Nakatsu, 
2007). Thus, PCR fragments containing a greater amount of GC-rich amplicons will take 
longer to denature and dissociate migrating towards the bottom of the gradient in which the 
partial melting point of these GC-rich DNA fragments is reached, whereas AT-rich DNA 
sequences will migrate towards the top of the denaturant gradient. Once this partial melting 
temperature has been achieved, the DNA fragments can no longer migrate through the 
denaturing gradient and are immobilised because of the transition of the DNA macromolecule 
from a helical to partially melted structure, thus dsDNA sequence variation is not only 
separated out by GC-content, but also variations in the partial melting temperatures thus 
affecting dissimilar immobilisation points within the linear denaturing gradient of the PCR 
amplicons analysed (Muyzer and Smalla, 1998). Further to this, the attachment of a GC-
clamp (a GC-rich nucleotide sequence) to the 5′-end of one of the universal primers can 
facilitate greater detection of sequence variants within the community being analysed as this 
increases PCR fragment stability as it migrates through the denaturing gradient, increasing 
the melting temperature, thus preventing complete dissociation of the dsDNA into single-
stranded DNA (ssDNA) (Muyzer and Smalla, 1998). Attachment of a GC-clamp in PCR-
DGGE mediated studies in microbial ecology studies under optimum running conditions in 
DGGE can result in the detection of ~ 100 % of sequence variants within the microbial 
community in DNA fragments ≤ 500 bp in size (Sheffield et al., 1989, Myers et al., 1985). 
Thus DGGE can represent a global ‘snapshot’ of the microbial population structure and 
diversity analysed by said technique (Nakatsu, 2007) from when it was first introduced to 
study bacterial communities in soil (Muyzer et al., 1993). 
In PCR-DGGE mediated studies of environmental samples and indeed human clinical 
samples, a variety of thermostable DNA polymerases are utilised in order to ascertain the 
microbial communities present. In this study, five DNA pols were assessed to analyse the 
bacterial communities in sandy soil obtained from dunes on Longsands Beach, Tynemouth, 
North East England. These were, AmpliTaq® (Applied Biosystems™), GoTaq® Hot Start 
Polymerase (Promega), Platinum® Pfx (Invitrogen
™
), TaKaRa Ex Taq™ Hot Start 
(TAKARA BIO INC.), and Taq (New England BioLabs®, Inc.). All of the thermostable 
DNA polymerases used in this study were originally isolated from strains of T. aquaticus 
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expressing modified versions of the DNA polymerase gene which were then inserted and 
expressed in strains of E. coli (Lawyer et al., 1989) thus belonging to the A polymerase 
family (Kim; Eom refs.). The exception being Platinum® Pfx ― cloned and purified from the 
archaeon Pyrococcus spp. strain KOD1 a member of the B polymerase family (Westfall et 
al., 1999, Takagi et al., 1997, Nishioka et al., 2001). Comparison of the DNA polymerase 
enzymes assessed in this study are summarised below in table 3.1. 
Table 3.1: Comparison of DNA pols utilised to determine microbial diversity in sandy soil 
samples. 
DNA 
polymerase 
DNA polymerase 
family group 
Supplier Average error rate 
reported‡ 
Taq A New England BioLabs® 
Inc. 
285 × 10-6 bp 
GoTaq® Hot 
Start 
A Promega ~ 8.0 × 10
-6 bp† 
AmpliTaq® A Applied Biosystems™ Not available 
Ex Taq™ Hot 
Start 
A TAKARA BIO INC. 8.7 × 10
-6 bp 
Platinum® Pfx B Invitrogen™ 1.58 × 10-6 bp 
‡ Determined by the Cline method (Cline et al., 1996). 
† Was not determined, error rate is based on older versions of Taq DNA pol that Promega 
used to distribute. 
Different DNA pols from the above were assessed in order to select the most appropriate 
DNA polymerase enzyme prior to study of clinical samples involving sputum and 
bronchoalveolar lavage fluid from multiple patient cohorts with chronic respiratory tract 
diseases. Sandy soil obtained from dunes was utilised in this assessment for several reasons: 
(i), no ethical approval was needed prior to initial sample excavation, (ii), the microbial 
communities inhabiting the soil microenvironment are genetically diverse, with estimates 
ranging from 467 to 500,000 species of bacteria present (Curtis et al., 2002, Hughes et al., 
2001, Torvisk et al., 1998, Dykhuizen, 1998) ― thus if the DNA pol enzymes assessed were 
to effectively amplify DNA template producing V3 rDNA amplicons this would be detected 
by DGGE strongly indicating the dominant microbial taxa present in sandy soil ― and (iii), 
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humic acids consisting of complex polyphenolic compounds produced from the 
decomposition of organic matter within soil sediments can strongly inhibit PCR (Tsai and 
Olsen, 1992b, Tsai and Olsen, 1992a), sandy soil contains less of these interfering humic 
substances due to a relative lack of organic matter content as opposed to agricultural soils. 
From here, once the appropriate DGGE profiles were generated, statistical methods were 
executed to ascertain if there was a difference within the community generated from the 
pooled V3 rDNA fragments amplified in each sandy soil sample analysed by each DNA pol 
enzyme employed. 
3.3 Results 
3.3.1 Optimisation of PCR amplifications 
As previously described in Chapter Two, steps were taken to minimise artefacts, spurious 
and heteroduplex PCR products (Don et al., 1991, Janse et al., 2004); relief of sample 
inhibitors was also implemented (Kreader, 1996). In terms of optimisation of each DNA pol 
assessed, both Ex Taq™ HS and GoTaq® HS followed the protocol closely outlined as 
previously described (Muyzer et al., 1993) producing the amplifications in figure 3.1A and B. 
The only differences between the Ex Taq™ HS and GoTaq® HS PCR experiments were 
buffer, dNTP, and MgCl2 concentrations per reaction. Applied Biosystems™ AmpliTaq® 
was optimised using an MgCl2 concentration gradient set-up experiment (0.5-2 mM MgCl2), 
optimum MgCl2 concentration was 1 mM. However, despite repeated attempts at adjustment 
of GeneAmp® Buffer and AmpliTaq® DNA pol volumes in multiple reactions, V3 rDNA 
amplification was still poor (figure 3.1C). Taq (New England BioLabs® Inc.) DNA pol was 
optimised by slight adjustment to the annealing temperature using a temperature gradient 
(ranging from 53-63 °C, optimum annealing temperature was at 55.8 °C) and addition of 5 U 
Taq pol instead of 2.5 U. Pfx DNA pol was optimised by the addition of Pfx Enhancer 
Solution (Invitrogen™) at 0.5   concentration as opposed to 1   concentration. Final 
amplification of V3 rDNA fragments using both Taq and Pfx are shown in figures 3.1D and E 
respectively. 
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Fig. 3.1A-E: Gel images showing final PCR amplifications of V3 rDNA fragments by each DNA pol 
technical replicate in sandy soil samples 1-5. A, Ex Taq™ HS amplification; B, GoTaq® HS 
amplification; C, AmpliTaq® amplification; D, Taq amplification; E, Pfx amplification. HL, 
Hyperladder I (10 000-200 bp) in which four molecular markers are annotated for clarity. Lane 
numbers: 1-3, SS1R V3 rDNA amplicons; 4-6, SS2R V3 rDNA amplicons; 7-9, SS3R V3 rDNA 
amplicons; 10-12, SS4R V3 rDNA amplicons; 13-15, SS5R V3 rDNA amplicons. 
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3.3.2 Ecological analysis from DGGE profiles generated 
Each commercially available DNA polymerase enzyme was assessed in all five sandy soil 
samples by employment of technical replicates to ensure PCR bias was countered for (within 
a certain degree) when the appropriate statistical analysis was performed (below). Ecological 
analysis of the bacterial community generated in each DGGE profile varied. Isolated distinct 
bands migrating through the denaturing gradient were treated as a single bacterial taxon from 
which the mean species richness and diversity indices (i.e., Shannon diversity index scores 
(H′)) was calculated from the technical replicates of the five different DNA pol enzymes in 
addition to the average number of bands detected (summarised in table 3.2). 
Across sample numbers 1-5, both high-fidelity enzymes Ex Taq™ HS and Pfx generated 
the greatest mean number of bands in each DGGE profile analysed and highest mean H′ 
scores (the only exception being in SS3R where the mean H′ score (2.30) of Ex Taq™ HS 
was equivalent to GoTaq® HS). Applied Biosystems™ AmpliTaq® detected the lowest 
number of bands (only 1 in SS5R as opposed to Platinum® Pfx in which 20.7 bands were 
detected on average) across all five samples in addition to the lowest mean H′ scores, again, 
taking into consideration that no H′ indices could be calculated for SS5R (each AmpliTaq® 
replicate only detected one bacterial taxa) and in SS4R as previously mentioned above. 
Overall bacterial diversity in the five sandy soil sample types is summarised in table 3.3. 
SS3R yielded the highest detection of bacterial diversity (H′ range 0.66-3.16 (mean = 2.31)) 
in addition to also showing the highest band range (2-25 (mean = 13.5)) whereas SS4R 
displayed the lowest (H′ range 0.61-3.03 (mean = 1.95)). Both SS3R and SS4R produced a 
wide range in their H′ scores, it should be noted however that in two of the AmpliTaq® 
technical replicates SS4R and SS5R (i.e., all AmpliTaq® replicates) Shannon diversity 
indices could not be derived as only one bacterial taxa each was detected. 
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Table 3.2: Comparison of mean number of bands detected and H′ scores calculated using 
technical replicates of the five DNA polymerase enzymes assessed. 
Sample 
replicate 
number 
DNA pol 
enzyme§ 
Mean number of bands 
detected by each DNA 
pol 
Mean H′ score generated 
by each DNA pol (n = 5) 
SS1R Taq 7.7 1.94 
GoTaq® HS 12 2.29 
AmpliTaq® 4 1.29 
Ex Taq™ HS 18.3 2.83 
Pfx 16 2.65 
SS2R Taq 7 1.84 
GoTaq® HS 10.7 2.30 
AmpliTaq® 3.7 1.27 
Ex Taq™ HS 11.7 2.30 
Pfx 12 2.42 
SS3R Taq 9.3 2.16 
GoTaq® HS 11.7 2.37 
AmpliTaq® 3.7 1.06 
Ex Taq™ HS 18 2.80 
Pfx 25 3.16 
SS4R Taq 8 1.94 
GoTaq® HS 10 2.20 
AmpliTaq® 1.3 0.20 
Ex Taq™ HS 21 3.02 
Pfx 14 2.39 
SS5R Taq 11.3 2.36 
GoTaq® HS 9.7 2.16 
AmpliTaq® 1 0
† 
Ex Taq™ HS 17.7 2.76 
Pfx 20.7 2.87 
§ In order of loading on DGGE profile generated. 
† Average H′ score cannot be derived if only one bacterial taxon is detected across all three 
AmpliTaq® technical replicates. 
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Table 3.3: Comparison of bacterial diversity in the five sandy soil samples analysed by 
DGGE. 
Sample 
replicate 
number 
Band range 
per lane 
Mean number of 
bands per lane 
H′ range 
across sample 
Mean H′ 
across sample 
SS1R 4-19 11.6 1.23-2.88 2.20 
SS2R 4-13 9 1.10-2.52 2.03 
SS3R 2-25 13.5 0.66-3.16 2.31 
SS4R 1-21 10.9 0.61-3.03 1.95 
SS5R 1-21 12.1 2.01-2.95 2.03 
 
Qualitatively, each DGGE profile generated (i.e., SS1R to SS5R) yielded similar banding 
patterns from bacterial taxa detected by the five individual DNA pols assessed, including the 
technical replicates (Fig. 3.2A-E). Applied Biosytems™ AmpliTaq® performance was very 
poor in comparison to the other DNA pol assessed due to the distinct lack of bands 
throughout the denaturing gradient, in particular, the bands that were detected are faint (white 
arrows, Fig. 3.2C). New England BioLabs® Inc. Taq and Promega’s GoTaq® HS both 
produced approximate equivalent banding patterns from their technical replicates in all 
DGGE profiles (Fig. 3.2A-E). Both high-fidelity DNA pol enzymes Ex Taq™ HS and 
Platinum® Pfx detected the most abundant bacterial taxa from the dominant members of the 
community as seen in all gels below resulting in a greater mean band range across all five 
sample types. Amplification of the V3 rDNA regions performed with Pfx did result in more 
bacterial taxa being detected in SS2R, SS3R, and SS5R. Interestingly, bands were notably 
absent in the upper 25 % of the denaturing gradient (i.e., near the top of the gel in Fig. 3.2A-
E, circled) in almost all Pfx technical replicates and thus consequently not detected. 
TAKARAS BIO INC. Ex Taq™ HS in SS1R-SS5R in this regard produced a more 
widespread detection of bacterial taxa throughout the 35-55 % denaturing gradient utilised 
(and indeed more numerous specifically in SS1R and SS4R), in addition to taxa that migrated 
towards the top of the gradient. A global factor in all of the DNA pol enzymes assessed is 
that band detection in the lower part of the denaturing gradient seemed to be more abundant 
in the derived Thermus aquaticus DNA pol types despite the band number, whereas in Pfx, 
derived from Pyrococcus spp. strain KOD1, detected a greater number of bands in the middle 
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of the gradient. All DGGE profiles generated showed heteroduplex artefacts (i.e., double 
band formations that migrate through the denaturing gradient very close together) and these 
have been putatively identified with examples shown in Fig. 3.2A, B, and D. These double 
bands were common in all Taq, GoTaq® HS, and Ex Taq™ HS technical replicates across all 
five sample types. 
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A 
B 
                Taq               GT                 AB                 ET                 Pfx 
Fig. 3.2A-E: DGGE profiles (35-55 % denaturing gradient) of SS1R-SS5R showing V3 rDNA 
fragments from all DNA pol technical replicates assessed. SS1R = A; SS2R = B; SS3R = C; SS4R 
= D, and SS5R = E. Top of the denaturing gradient is shown (35 %) along with the bottom (55 %). 
Migration direction of the amplicons and denaturing gradient is indicated on the left in gels A-E 
(arrow). Technical replicates of each DNA pol enzyme are indicated above each DGGE profile (A-E) 
respectively. Non-detection of bands by Pfx in all technical replicates across SS1R-SS5R is circled. 
Examples of putative artefacts in DGGE profiles are shown (black arrows) whereas detection of 
taxa by AmpliTaq® is indicated because of faint bands produced in gel profiles (white arrows). AB, 
AmpliTaq®; ET, Ex Taq™ HS; GT, GoTaq® HS. 
55% 
35% 
55% 
35% 
                    Taq               GT                AB                 ET                  Pfx 
 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35% C 
55% 
55% 
35% D 
                      Taq                GT                AB                 ET                 Pfx 
                       Taq                GT                  AB                ET                 Pfx 
 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35% 
55% 
E
                     Taq                 GT                 AB                 ET                  Pfx 
 75 
 
3.3.2 Statistical analysis from DGGE profiles generated 
All DGGE profiles generated and the number of taxa detected by each DNA pol enzyme 
was then subjected to principal components analysis (PCA) to see if there were any 
differences between enzyme and sandy soil sample. The first two components were displayed 
in the outputs (x- and y-axis) accounting for the cumulative percentage variance explained 
with SS5R showing the highest percentage variation at 84 %, followed by 80 % (SS4R), 61 
% (SS3R), 44 % (SS2R), and finally 59 % (SS1R). All P-values derived from the first 
principal component output by one-way ANOVA (analysis of variation) were significant 
indicating that there was differences in the number of bacterial taxa detected between the 
disparate DNA pol enzymes assessed in each DGGE profile (SS1R, P = < 0.001, SS2R, P = 
0.001, SS4R, P = < 0.001, and SS5R, P = < 0.001) with the exception of SS3R (P = 0.118). 
Furthermore, from the PCA outputs a difference can be clearly seen in the clustering between 
the disparate types of thermostable polymerases assessed and their technical replicates. Both 
high-fidelity pols Ex Taq™ and Pfx exclusively cluster together in all of the DGGE profiles 
(Fig. 3.3A-E). This strongly suggests that though they detected the most number of bacterial 
taxa in comparison to the other enzymes, there was still a difference between these two 
enzyme’s performances in some of the soil samples analysed due to spatial distribution. All 
second principal components analysed were not significant indicating that there was no inter-
sample variance between the DGGE profiles SS1R-SS5R examined. 
We next wanted to investigate whether there was a difference in bacterial taxa detected by 
the technical replicates analysed in SS1R-SS5R. Shannon diversity index scores generated by 
each thermostable DNA pol enzyme technical replicate were calculated and then a one-way 
ANOVA was performed using Tukey’s test to determine which thermostable enzymes were 
significantly different from each other in terms of their microbial diversity detected. All P-
values were significant (SS1R-SS5R, P = < 0.001) between the H′ scores obtained by each 
DNA pol in each soil sample showing differences in the microbial diversity detected using 
the five different thermostable enzymes (tables 3.4-3.8). In all five samples analysed, 
AmpliTaq® thermostable DNA pol was significantly different from the other DNA 
polymerases assessed (tables 3.4-3.8 (P = < 0.001)). However in SS1R, (GoTaq® HS and 
Taq; table 3.4 (P = < 0.001)), SS2R (Taq; table 3.5 (P = < 0.001)) and SS4R (Ex Taq™ HS; 
table 3.7 (P = < 0.001)) DNA pol enzymes indicated in brackets were also significantly 
different to the other in addition to AmpliTaq® based on their H′ scores. In SS5R all DNA 
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pol were significantly different from each other in the bacterial taxa detected (table 3.8 P = < 
0.001). 
Table 3.4: Comparison of H′ scores generated by each DNA pol replicate and significant 
differences in diversities detected in SS1R. 
DNA pol replicate H′ score Tukey’s test grouping from ANOVA‡ 
Taq 1.86 A 
Taq 1.93 
Taq 2.02 
GoTaq® HS 2.15 B 
GoTaq® HS 2.42 
GoTaq® HS 2.30 
AmpliTaq® 1.31 C 
AmpliTaq® 1.33 
AmpliTaq® 1.23 
Ex Taq™ HS 2.81 D 
Ex Taq™ HS 2.79 
Ex Taq™ HS 2.89 
Pfx 2.65 D 
Pfx 2.59 
Pfx 2.72 
‡ Tukey’s test: DNA pols that do not share a letter are significantly different from each other 
(P = < 0.001) 
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Table 3.5: Comparison of H′ scores generated by each DNA pol replicate and significant 
differences in diversities detected in SS2R. 
DNA pol replicate H′ score Tukey’s test grouping from ANOVA 
Taq 2.17 A 
Taq 1.78 
Taq 1.56 
GoTaq® HS 2.33 B 
GoTaq® HS 2.34 
GoTaq® HS 2.24 
AmpliTaq® 1.34 C 
AmpliTaq® 1.38 
AmpliTaq® 1.10 
Ex Taq™ HS 2.44 B 
Ex Taq™ HS 2.35 
Ex Taq™ HS 2.10 
Pfx 2.39 B 
Pfx 2.52 
Pfx 2.34 
 
Table 3.6: Comparison of H′ scores generated by each DNA pol replicate and significant 
differences in diversities detected in SS3R. 
DNA pol replicate H′ score Tukey’s test grouping from ANOVA 
Taq 2.34 A 
Taq 2.13 
Taq 1.99 
GoTaq® HS 2.38 A 
GoTaq® HS 2.39 
GoTaq® HS 2.33 
AmpliTaq® 1.83 B 
AmpliTaq® 0.69 
AmpliTaq® 0.66 
Ex Taq™ HS 2.83 A 
Ex Taq™ HS 2.79 
Ex Taq™ HS 2.79 
Pfx 3.16 A 
Pfx 3.16 
Pfx 3.15 
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Table 3.7: Comparison of H′ scores generated by each DNA pol replicate and significant 
differences in diversities detected in SS4R. 
DNA pol replicate H′ score Tukey’s test grouping from ANOVA 
Taq 2.25 A 
Taq 1.77 
Taq 1.79 
GoTaq® HS 2.28 A 
GoTaq® HS 2.16 
GoTaq® HS 2.17 
AmpliTaq® 0 B 
AmpliTaq® 0.60 
AmpliTaq® 0 
Ex Taq™ HS 3.0 C 
Ex Taq™ HS 3.0 
Ex Taq™ HS 3.0 
Pfx 2.43 A 
Pfx 2.24 
Pfx 2.51 
 
Table 3.8: Comparison of H′ scores generated by each DNA pol replicate and significant 
differences in diversities detected in SS5R. 
DNA pol replicate H′ score Tukey’s test grouping from ANOVA 
Taq 2.60 A 
Taq 2.29 
Taq 2.18 
GoTaq® HS 2.21 B 
GoTaq® HS 2.01 
GoTaq® HS 2.25 
AmpliTaq® 0 C 
AmpliTaq® 0 
AmpliTaq® 0 
Ex Taq™ HS 2.78 D 
Ex Taq™ HS 2.94 
Ex Taq™ HS 2.54 
Pfx 2.84 E 
Pfx 2.84 
Pfx 2.95 
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PC1: 46% of variation explained 
A: PCA of SS1R DNA polymerase technical replicates Fig. 3.3A-E: PCA of SS1R-SS5R 
from each of the DGGE profiles 
generated and DNA pol technical 
replicates assessed. SS1R = A; 
SS2R = B; SS3R = C; SS4R = D; 
SS5R = E. Each DNA pol 
technical replicate is indicated in 
the PCA ouput (AB, AmpliTaq®; 
ET, Ex Taq™ HS; GT, GoTaq® 
HS; Pfx, Platinum® Pfx; Taq, New 
England BioLabs® Inc. Taq). The 
x-axis (PC1) explains the most 
variation followed by the y-axis 
(PC2) explaining the second most 
variation in the PCA output. This 
variation is shown as two 
percentages indicated on both the 
x- and y-axes respectively. 
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PC1: 24% of variation explained 
B: PCA of SS2R DNA polymerase technical replicates 
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PC1: 40% of variation explained 
C: PCA of SS3R DNA polymerase technical replicates 
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PC1: 70% of variation explained 
D: PCA of SS4R DNA technical polymerase replicates 
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PC1: 79% of variation explained 
E: PCA of SS5R DNA polymerase technical replicates 
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3.4 Discussion 
In this study we have demonstrated that five available commercial thermostable DNA pol 
enzymes amplifying the V3 region within the bacterial 16S rRNA gene can produce DGGE 
profiles across five sandy soil samples excavated from Longsands Beach, Tynemouth, North 
East England. However, within the DGGE profiles generated and between the technical 
replicates of the five DNA pol enzymes assessed significant dissimilarity was exhibited in the 
detection of the dominant members of the bacterial community in four out of the five sample 
types. Further, high fidelity DNA polymerases (Ex Taq HS™ and Pfx) enabled detection of 
abundant bacterial taxa that eluded detection by the low-fidelity DNA pols, i.e., AmpliTaq®, 
GoTaq® HS and Taq. In all five samples analysed by DGGE, AmpliTaq™ DNA pol 
performance was significantly different (P = < 0.001) in detection of bacterial taxa in sandy 
soil (tables 3.4-3.8). 
From the results presented above, a discussion of the data and each respective DNA pol 
performance must be approached with caution in respect to other PCR-DGGE mediated 
studies and the inherent bacterial community because of several underlying potential biasing 
factors: (i), PCR amplification can be inhibited by co-extracted contaminants from the sample 
type (i.e., humic substances in soil) (ii), differential amplification ― does the amplification of 
16S rDNA produce a pool of either homologous or heterogeneous template molecules? (iii), 
PCR fragment artefactual formation (iv), contaminating DNA, and (v), rRNA gene region 
(rrn operon) variability within the community amplified (von Wintzingerode et al., 1997). 
The high-fidelity polymerases, (Ex Taq™ HS and Platinum® Pfx) gave significantly (P = < 
0.001) higher bacterial taxa detection than the lower fidelity alternatives used in this study. In 
particular is the amplification of the V3 region by both Ex Taq™ HS and Pfx which resulted 
in a higher proportion of GC-rich bacterial taxa detected (Fig. 3.2A-E) such as the 
Actinobacteria. Conversely where one expects to find bands with a low GC-ratio typical of 
the Proteobacteria it was possible to differentiate between Pfx and Ex Taq™ HS PCR 
products. The latter appeared much more effective in amplifying low GC-ratio 16S rRNA 
genes as seen in all of the gels produced (Fig. 3.2A-E; circled). In three soils (SS2R, SS3R, 
SS5R) the diversity of bacteria detected by Pfx was greater than that detected by Ex Taq™ 
HS (tables 3.5, 3.6, and 3.8) Whereas in SS1R and SS4R bacterial diversity detected using Ex 
Taq™ HS was higher than that of Pfx (tables 3.4 and 3.7). However, in comparing Ex Taq™ 
 85 
 
HS and Pfx high-fidelity pols only significant differences between the two were observed in 
SS4R and SS5R (P = < 0.001). In SS1R, SS2R, and SS3R there was no significant difference. 
Production of PCR artefacts and chimeras is a confounding factor that may lead to an 
over-estimation of the microbial diversity present in the sample analysed, however, the 
formation of these anomalies is not uncommon in DGGE (Muyzer, 1999). Chimera formation 
is generated by incompletely synthesised extended DNA fragments annealing together 
producing closely related sequences generating recombinants between starting templates 
(Judo et al., 1998, Bradley and Hillis, 1997). Differentiation between original haplotypes and 
chimeras generated can be problematic resulting in occasionally an overestimation of the 
community diversity in microbial ecology studies (von Wintzingerode et al., 1997, 
Hugenholtz and Huber, 2003, Berney et al., 2004). A study reported several years ago has 
tried to circumvent this problem by introducing an additional extension time of 30 min 
reducing the formation of double bands in PCR-DGGE analysis in environmental microbial 
diversity PCR (Janse et al., 2004). This longer extension time was implemented here in all 
DNA pol technical replicates carried out at the end of each PCR cycle. GC-clamp attachment 
to the forward primer, although designed to improve sequence heterogeneity from the pool of 
amplicons in analysis by DGGE, can induce effects such as G quartet or four-stranded 
tetraplex formation caused by multiple adjacent G residues (Poon and Macgregor, 1998, Poon 
and Macgregor, 2000). Further, a recently published study suggested the procurement of 
enough oligonucleotides incorporating a GC-clamp in a single batch for a project to avoid the 
GC-clamp sequence itself actually affecting DGGE profiles due to differences in 
performance between repeat syntheses of GC-clamp oligonucleotide primers from disparate 
batches (Rettedal et al., 2010). 
Duplex banding patterns seen in the DGGE profiles (Fig. 3.2A, B, and D) could also be 
attributed to the formation of spurious PCR products after the addition of the DNA pol to the 
reagent master mix (MM). This can be circumvented by the induction of either a manual or 
automatic HS; with the exception of Ex Taq™ HS, GoTaq® HS and Platinum® Pfx, (all 
bound to a proprietary antibody) both AmpliTaq® and Taq were introduced into the master-
mix via a manual HS procedure, but despite this process, poor AmpliTaq® performance was 
unequivocal in bacterial taxa detection unlike that of its counterpart Taq. A previous study 
assessed the impact of DNA polymerase bound to a proprietary antibody on the resulting 
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PCR products synthesised. This demonstrated an increased specificity, sensitivity, and yield, 
in addition to reducing the formation of spurious PCR products before the PCR was actually 
initialised (Sharkey et al., 1994). 
Assessment of the microbial diversity in sandy soil samples using the T. aquaticus derived 
DNA pol enzymes (i.e., Taq, GoTaq® HS, and AmpliTaq®) produced similar banding 
patterns in most replicates across SS1R-SS5R. However, AmpliTaq® amplification of pooled 
V3 rDNA amplicons produced very faint bands in the denaturing gradient (Fig. 3.2C; white 
arrows). It is questionable if this is a true reflection of AmpliTaq®’s capability in comparison 
to the other DNA pols. Further optimisation of AmpliTaq® is probably required to draw 
satisfactory results and conclusions. Detection of hypothetical GC-rich bacterial taxa was 
noticeable in both GoTaq® HS and Taq, although less so than in Ex Taq™ HS and Pfx. 
Another mitigating factor in the variances of DGGE profiles generated from the 
commercially available thermostable enzymes assessed here, concerns the DNA pol property 
of fidelity. The DNA pols Taq, GoTaq®, and AmpliTaq® carry out DNA replication and 
repair with a low degree of fidelity and have a low proofreading capacity in comparison to Ex 
Taq™ and Pfx. In relation to this, it can be suggested that the formation of PCR-mediated 
recombination or chimeras, giving rise to heteroduplex PCR products, would increase when 
using Taq, GoTaq® HS, or AmpliTaq® when assessing the microbial diversity in any given 
environmental type in PCR-DGGE studies. It is worth noting that despite the higher mean 
band ranges and H′ scores produced by both Ex Taq™ HS and Pfx, the risk of artefactual 
PCR products is decreased compared to their lower-fidelity counterparts. Surprisingly, it has 
been previously shown that even high-fidelity DNA pols insert incorrect nucleotides with 
similar efficiencies to that of naturally occurring low-fidelity polymerases (Beard and 
Wilson, 2003). This finding concludes that right from selection of DNA pol in PCR-DGGE 
mediated investigations, there will always be an inherent bias, and as thus, this must be taken 
into account from the data presented. 
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3.5 Conclusions 
In summary, all DNA pol enzymes employed in this study could have been optimised 
further, in particular AmpliTaq®, raising concerns over its true performance in the microbial 
community detection from the sample types collected herein. What is apparent, and 
significant in four out of the five samples analysed (P = < 0.001), is that from the DNA pol 
technical replicates assessed is that PCA shows that the higher-fidelity pols Ex Taq™ HS and 
Platinum® Pfx cluster together explaining some of the variance observed. This variance can 
be attributed between the other DNA pols assessed, in addition to greater bacterial taxa 
detection and H′ scores generated. From the data presented, comprising both the multivariate 
analysis and DGGE profiles generated, Ex Taq™ HS DNA pol proved the most effective in 
best representing the microbial communities present in the samples analysed by DGGE 
despite the inherent limitations of this approach outlined above. Thus Ex Taq™ HS will be 
implemented in the PCR-DGGE mediated studies in two chronic respiratory tract disorders 
presented further in this body of work. 
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Chapter Four: PCR-DGGE study of a 
cross-sectional cohort with non-cystic 
fibrosis bronchiectasis 
4.1 Abstract 
The aim was to investigate the polymicrobial communities in sputum samples derived from 
an adult non-cystic fibrosis bronchiectasis cohort that consisted of 70 individuals (25 males 
and 45 females). Twenty patients had symptoms consistent with an exacerbation, the 
remainder were clinically stable. DNA was extracted from sputum samples of all patients. 
Universal primers were used to amplify fragments both within the 16S and 28S rRNA genes. 
Amplicons were analysed by denaturing gradient gel electrophoresis. Demographic and 
culture data were used in constrained ordination analyses to identify any significant 
associations between these data and changes in the sputum microbiota. Standard culture 
indicated that 19 (27 %) sputum samples were negative for recognised pathogens. Molecular 
analyses demonstrated these samples contained a bacterial diversity (mean = 7 taxa) not 
significantly different to culture positive sputum. There was a significant difference between 
the bacterial community structure in the sputum samples of exacerbated patients compared to 
those that were clinically stable (P = 0.002). Antibiotic administration within 1 month of 
sampling caused no significant changes to the microbial community investigated. 
Haemophilus influenzae carriage is identified as a significant driver (P = 0.006) of change in 
the microbial community structure. Further, H. influenzae was not identified in samples (n = 
12) that harboured Pseudomonas aeruginosa. Consistent with earlier studies, the persistent 
presence of P. aeruginosa (n = 23) determined by culture was significantly correlated with 
reduced lung function (P = < 0.001). In adult non-CF bronchiectasis patients bacterial lung 
communities show significant differences between exacerbation and clinically stable states 
and also when H. influenzae is present. Antibiotic administration does not significantly alter 
these microbial communities. Persistent colonisation by P. aeruginosa is significantly 
associated with reduced lung function, and is negatively correlated with H. influenzae 
carriage. 
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4.2 Background 
Bronchiectasis is a highly debilitating disease causing severe pulmonary infections and 
lung function decline resulting in chronic morbidity, and in some cases, premature mortality 
(King et al., 2005). The disease itself was initially characterised in 1819 by René Théophile 
Hyacinthe Laënnec in which from his writings, he described that “This affection of the 
bronchioles is always produced by chronic catarrh, or by some other disease attended by 
long, violent, and often repeated fits of coughing” (Laënnec, 1962). Presently, bronchiectasis 
is defined by irreversible abnormal dilatation of one or more bronchi, with chronic airway 
inflammation, associated with chronic cough and sputum production, recurrent chest 
infections, and airflow obstruction (Barker, 2002, Cohen and Sahn, 1999, Wilson and 
Boyton, 2006). In terms of a primary phenotype, bronchiectasis exists in two forms; (i) cystic 
fibrosis (a genetically inherited disease resulting in a severe form of bronchiectasis 
(Strausbaugh and Davis, 2007)), and (ii), non-cystic fibrosis bronchiectasis (nCFBR). 
Contributing factors that induce nCFBR can be physical obstruction or post infectious 
damage, genetic defects (as observed in cystic fibrosis (CF)), abnormal host defence 
mechanisms or autoimmune disease, in many cases nCFBR is idiopathic (Pasteur et al., 
2001). 
Diagnosis of nCFBR using high-resolution computed  tomography (HRCT) reveals 
varying structural and anatomic phenotypes within either one lobe or both lobes of the lung, 
pending local or more commonly general distribution of the disease in the lower lobes (King 
et al., 2006). These characteristic phenotypes defined by Reid described three main subtypes 
of bronchiectasis; (i), smooth dilation of the bronchi giving rise to the tubular form (ii), 
dilated bronchi populated with multiple indentations ― varicose phenotype and (iii), cystic, 
dilated bronchi terminating in blind sacs (Reid, 1950). As opposed to HRCT, pathology of 
bronchiectasis lung tissue specimens by Whitwell resulted in the addition of three sub-types 
of the bronchiectasis phenotype: (i), follicular (ii), saccular and (iii), atelectatic. From his 
findings, infiltration of the bronchial wall with inflammatory cells in conjunction with the 
loss of elastin, and in more severe cases, muscle and cartilage injury was associated with 
bronchial dilatation (Whitwell, 1952). In conjunction with HRCT and Whitwell’s description, 
the dominant form of bronchiectasis disease today is the follicular sub-type corresponding to 
the tubular phenotype. In this form, as Whitwell had previously shown earlier; in the small 
airways lymphoid follicle formation by the infiltration of inflammatory cells in the bronchial 
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walls is extensive, causing obstruction of the small airways. Conversely, in the larger 
airways, dilation is followed by the loss of elastin, cartilage and muscle (King, 2011b). 
Paradoxically, studies have shown that in bronchiectasis individuals, lung function decline 
occurs gradually with loss of forced expiratory volume in one second (FEV1), despite the 
characteristic dilatation of the airways (King et al., 2005, Martínez-García et al., 2007, Twiss 
et al., 2006). Explanation of this paradox is demonstrated by Whitwell’s original pathology 
findings demonstrating that during large airway dilation, the small airways were obstructed; 
net effect of the pulmonary tree is airflow obstruction as composition of this is in the small 
airways (King, 2011a). Pulmonary airflow obstruction in bronchiectasis caused by structural 
anatomic changes is critical as they adversely affect normal airway clearance and impede 
innate immunity mechanisms (Morrisey, 2007). Indeed, bronchiectasis pathophysiology 
defines the impairment, control, prevention, and resolution of respiratory tract diseases. 
Cole’s original paradigm in bronchiectasis disease states that a vicious circle of recurrent or 
persistent airway infection and inflammation promotes additional lung tissue structural insults 
predisposing bronchiectasis individuals to prolonged infection ― a self-promoting cycle 
(Cole, 1986). 
Chronic airway infection is strongly associated with bronchiectasis disease and this 
appears to contribute to the underlying pathogenesis of the disease, with progressive lung 
damage resulting from recurrent bacterial infections and inflammatory responses (Wilson and 
Boyton, 2006). Previous studies investigating the bacteriology of nCFBR from several types 
of clinical samples have identified common lower respiratory tract pathogens including 
Haemophilus influenzae, Pseudomonas aeruginosa, Streptococcus pneumoniae, and 
Moraxella catarrhalis; other less frequently encountered isolates are Staphylococcus aureus 
and non-tuberculosis mycobacterial (NTM) species (Angrill et al., 2002, King et al., 2007, 
Pasteur et al., 2001, Nicotra et al., 1995). S. aureus involvement in nCFBR is uncommon and 
repeated culture isolation from sputa is suggestive of cystic fibrosis, particularly in younger 
patients (King, 2011a). When using sputa to investigate the aetiology of nCFBR infection, 
both H. influenzae and P. aeruginosa are the most commonly cultured pathogens with many 
isolated strains showing significant antibiotic resistance (King, 2011a, Angrill et al., 2002). 
Infection with H. influenzae in the lower airways in nCFBR is almost always associated with 
the non-typeable strain of this species. A normal resident of the upper respiratory tract (URT) 
in most persons, non-typeable strains lack a polysaccharide capsule where recurrent or 
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chronic lower airway infection with non-typeable H. influenzae (NTHI) in nCFBR is 
common place (Grimwood, 2011). Persistence of NTHI in the lower airways is due to several 
mechanisms such as antigenic drift, protease secretion, expression of multiple adhesion 
molecules, and intracellular survival in either host lung macrophages or epithelial cells 
(Murphy et al., 2009). Indeed, infection with NTHI is a dynamic process as different strains 
of this organism can infect bronchiectasis patients sequentially as previously shown in CF 
(Román et al., 2004). Furthermore the lung bronchi have been shown to exhibit a dynamic 
turnover of lower respiratory tract (LRT) pathogens; the acquisition of new bacterial strains 
in bronchiectasis has been investigated in which patients were continually colonised with 
Moraxella catarrhalis, but strains of this bacterium were shown to have a continuous 
turnover every 2-3 months (Klingman et al., 1995). 
As opposed to H. influenzae, and the other bacterial isolates above, P. aeruginosa 
colonisation of the URT is infrequent in healthy individuals as it is rapidly cleared from the 
lower airways (Garau and Gomez, 2003). Indeed, P. aeruginosa infection with nCFBR in 
children is rare; however, in older individuals presenting with bronchiectasis, infection with 
P. aeruginosa is much more common. Individuals with nCFBR harbouring no pathogens 
showed the mildest disease whereas isolation of P. aeruginosa had the most severe 
bronchiectasis (King et al., 2007). Concurrently, isolation of H. influenzae tended to be from 
patients with moderately impaired pulmonary function (King et al., 2007). P. aeruginosa is 
widely dispersed throughout the environment and is a superb opportunistic respiratory 
pathogen able to acclimatise to the niche micro-environment of the lung as it is particularly 
adapted to binding to the damaged epithelial lining of the pulmonary tree in chronic 
respiratory diseases (de Bentzmann et al., 1996), but more specifically in CF. Most of our 
understanding of P. aeruginosa and its mechanisms of infection in individuals presenting 
with nCFBR is through extensive work carried out in CF where it is the most important 
pathogenic isolate (de Vrankrijker et al., 2010). Infection with P. aeruginosa in CF is 
comprised of three phases: no infection, intermittent infection, followed eventually by 
chronic infection, in which the pathogen undergoes gradual mutational changes in its 
bacterial genome in response to the micro-environmental challenges in the CF lung (Li et al., 
2005). One of the major mutational changes in P. aeruginosa in the CF lung is the 
development from a non-mucoid to mucoid phenotype commonly isolated by culture in 
chronically infected patients (Foweraker, 2009). Establishment of this mucoid phenotype 
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plays a major role in phagocytic evasion, increased tolerance to toxic oxygen free radicals 
mediated by neutrophils and resistance to antibiotics (Murray et al., 2007). The production of 
biofilms by P. aeruginosa is a critical factor in the treatment of CF patients, as the bacteria 
within them are inherently difficult to eradicate as antibiotics bind to the extracellular matrix 
as opposed to penetrating the inner matrix in addition to exhibiting increased resistance to the 
host immune system (Foweraker, 2009) (Davies and Bilton, 2009). Biofilm formation 
subsequently leads to persistent infection thus resulting in severe damage to the lung tissue 
architecture. 
Chronic infection in nCFBR with P. aeruginosa is associated with an increase in airflow 
obstruction, sputum production, hospitalisations, in addition to extensive lung disease and 
worsening in quality of life in patients’ afflicted (King, 2011b, Martínez-García et al., 2007, 
Wells et al., 1993). As a result of this, the presence and persistence of P. aeruginosa has been 
identified as a marker of bronchiectasis severity, although it remains unclear whether this is 
linked to accelerated lung function decline (Davis et al., 2006). Frequent exacerbations 
experienced by bronchiectasis patients may contribute to the progressive decline of lung 
function (Martínez-García et al., 2007) though the cause of these remains poorly understood. 
Exacerbations are frequently managed with antibiotics, however, viral infections may also be 
significant in many cases but their role requires clarification (King, 2011a). In CF 
bronchiectasis, there is a significant contribution to exacerbations by fungal pathogens 
(Bouchara et al., 2009). However, their role, if any, in nCFBR remains to be elucidated. 
In this study our aim was to undertake a community level investigation of the microbiome 
associated with the nCFBR lung, to characterise their diversity and structure, and to 
determine whether differences in the communities reflect the clinical status of the patient, the 
presence or absence of culturable pathogens or show significant changes in response to the 
interventions used in the clinic to manage patient outcomes. 
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4.3 Results 
4.3.1 Patient cohort analysis 
Seventy patients (25 male, 45 female) were enrolled in this study (App. 3), both consisting 
of clinically stable and exacerbating outpatients currently diagnosed with nCFBR at time of 
sampling. The mean FEV1 derived was 1.47 L (± 0.78 L) with a mean age of 61.6 ± 12.9 
years across cohort. Between the males and females comprising cohort, the absolute FEV1 
values were significantly higher in males 1.84 vs. 1.26 litre (P = 0.002). However, there was 
no significant difference in the age (P = 0.492) or the FEV1% predicted between the sexes (P 
= 0.785). Similarly, the distribution of genders between the culture-negative, exacerbated, 
non-exacerbated, H. influenzae and P. aeruginosa colonisation states were not significantly 
different to the overall sex ration of the cohort. For 61 of the 70 patients, data on the number 
of exacerbations reported in the preceding 12 months was available. Frequent exacerbators 
were defined as those patients who had greater than 3 episodes over this period, 38 patients in 
the cohort satisfied this criterion. At the time of sample collection 20 patients reported 
symptoms consistent with an exacerbation defined as per the British Thoracic Society (BTS) 
2010 bronchiectasis guidelines by the presence of increased cough, malaise, increased 
sputum volume and purulence (Pasteur et al., 2010). A summary of the patient demographic 
data is shown in table 4.1. 
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Table 4.1: Summary of patient demographic data. 
 All patients (n = 
70) 
Non-
exacerbated 
sub-cohort (n 
= 50) 
Exacerbated 
sub-cohort (n = 
20) 
Demographic data:    
Age (years) 61.6 ± 12.9 61.2 ± 12.9 62.5 ± 13.4 
Female population in cohorts (%) 45 (64.3) 30 (60) 15 (75) 
FEV1 (L) in both genders: 
Male population 
Female population 
1.47 
1.84a† 
1.26b 
1.46 
1.86a 
1.17b 
1.50 
1.77a 
1.41b 
FEV1% predicted 58.3 % 56.3 % 64.9 % 
Frequent exacerbators (%) (n = 61§) 38 (54) 26 (52) 12 (60) 
Culture-negative (%) 19 (27) 11 (22) 8 (40) 
H. influenzae colonisation (%) 12 (17.1) 7 (14) 5 (25) 
P. aeruginosa colonisation (%) 
Never isolated 
Intermittently isolated 
Persistent isolation 
 
28 (40) 
17 (24) 
25 (36) 
 
17 (34) 
12 (24) 
21 (42) 
 
11 (55) 
5 (25) 
4 (20) 
Recent Abx¿ 16 (23) 10 (20) 6 (30) 
§ Frequent exacerbation data was only available for 61 patients in total cohort. 
¿ Antibiotic treatment within the last month other than colomycin or azithromycin. 
† FEV1 (L) values in male and female populations followed by different letters are 
significantly different (P = <0.05). 
4.3.2 Microbial culture analysis 
In whole cohort, 51 patients (73%) from the sputa examined were culture-positive for 
pathogenic microorganisms; the remainder being classified as either no growth or culture 
identified mouth flora only (additionally defined as culture-negative because of non-isolation 
of associated respiratory pathogens). The most common pathogenic organisms isolated from 
sputa were P. aeruginosa (PA) found in 39 % and H. influenzae (HI) in 17 % of patients 
respectively, however, there were no instances of both these taxa being found within a single 
sputum sample. Only three clinical samples were culture positive for fungal species: 
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Aspergillus fumigatus was isolated from patient 32 and Candida spp. both from patients 8 
and 44 respectively. 
Assessment of lung function showed that patient’s culture negative for pathogens, or those 
harbouring HI, had similar values. But these were significantly higher (P = 0.0001 and P = 
0.0002 respectively) than individuals whose sputum was positive for PA isolation. From the 
medical records examined, 25 individuals were culture-positive for PA isolation from all 
previous sputum samples submitted for microbiological testing; these patients were defined 
as persistently colonised. A further 18 individuals were intermittently colonised and 28 were 
culture-negative for PA isolated from all previously submitted sputum samples. Following 
these criteria, we next examined the relationship between the presence and persistence of PA 
infection and forced expiratory volume in one second predicted (FEV1% predicted). This 
demonstrated a significant reduction in FEV1% predicted (P = < 0.001) between those ever 
and those never colonised by PA sub-groups. Further, FEV1% predicted lung function was 
significantly reduced in persistently versus intermittently colonised (P = 0.004) and 
persistently versus never colonised patients (P = < 0.001). However, FEV1% predicted was 
not significantly different between those with intermittent PA carriage and those where PA 
had not been isolated (P = 0.1). In patients culture-positive for HI the FEV1% predicted was 
significantly higher than the FEV1% predicted of individual’s chronically infected with P. 
aeruginosa (P = < 0.001). Patients experiencing frequent exacerbations (i.e., > 3 
exacerbations per annum; n = 38) were predominantly culture-positive for the presence of 
known lung pathogens (71 %). Within this sub-group of exacerbating individuals, 50 % were 
colonised with PA and 10.5 % with HI but co-isolation of these two respiratory pathogens 
was never observed. Pulmonary function (FEV1% predicted) was not significantly different 
between patients who frequently exacerbated and the remaining individuals that did not. 
4.3.3 Ecological analysis of bacterial community 
The bacterial community profiles generated from the PCR-DGGE analysis produced 45 
distinct band classes with a mean of 8.4 bands per lane (band range 1-18 per lane) (Fig. 4.1A-
G). Each individual DGGE band was presumed to be a single bacterial taxon and was used as 
a measure of species richness. The mean bacterial Shannon diversity (H′) was 1.53 (range 0-
2.55) and the mean species evenness (J′) of the bacterial communities was 0.78 (range 0.197-
0.992). Species evenness is a biodiversity measure used to ascertain how equal the bacterial 
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community is in this instance via quantification; whereas the H′ is a measure of both species 
richness and evenness in the community analysed. Analysis of variance on the entire cohort’s 
community profiles showed that there was no significant difference associated with the 
number of taxa, community diversity or evenness between those sputum samples where there 
was a self- reported exacerbation. Similarly, there were no significant differences between 
taxa or community diversity indices in patients who were never, intermittently or persistently 
colonised with P. aeruginosa or where H. influenzae could be isolated from sputa samples. 
  
SL     1      2     3      4     5     SL    6     7      8      9    10    11   SL 
A 
Fig. 4.1A-G: DGGE profiles of whole nCFBR cohort investigated using a 16S rRNA PCR-DGGE 
culture-independent approach. Amplicons were run out on a 32.5-60 % denaturing gradient 
(shown by arrow). Each band migrated was treated as a single bacterial taxon for the purposes of 
community profiling and multivariate statistical analysis subsequently carried out. Patient numbers 
are represented by a sequential series of numbers above each lane. Those lanes denoted with an 
X (and a red line) represent those individuals removed from the study. Patients indicated with 
blue, green and red arrows represent patients that are culture-negative and culture-positive for 
only H. influenzae or P. aeruginosa respectively. The 16S standard ladder (SL) comprised of V3 
rDNA fragments derived from pure bacterial cultivars is also shown. Because of the inter-gel 
variation in the 16S SL reproducibility, the Rf values (in parentheses) derived for each bacterial 
species are only indicated in DGGE profile D for clarification purposes. AX, Achromobacter 
xylosoxidans; BCC, Burkholderia cepacia complex; HI, Haemophilus influenzae; PA, 
Pseudomonas aeruginosa; RP, Ralstonia pickettii; SA, Staphylococcus aureus and SM, 
Stenotrophomonas maltophilia. Co-migration of bands against the HI and PA 16S SL markers are 
indicated in green and red rectangles respectively. 
32.5% 
60% 
PA (Rf: 0.200) 
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SL    12    13   14    15   16    SL   17   18    19   20     X     X    SL 
 SL    21   22    23    24   25    SL   26     X    27   28    29    30    SL 
B 
C 
32.5% 
60% 
32.5% 
60% 
HI (Rf: 0.075) 
PA (Rf: 0.200) 
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 SL   31   32     33    34   35    SL   36    37    38    39   40    41    SL 
  SL    42   43    44   45    46   SL   47    48   49    50   51    52   SL 
D 
E 32.5% 
60% 
32.5% 
60% 
HI (Rf: 0.075) 
SA (Rf: 0.100) 
RP (Rf: 0.140) 
PA (Rf: 0.200) 
BCC/SM     
(Rf: 0.400) 
AX (Rf: 0.560) 
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 SL   53    54   55    56   57   SL   58   59   60    61   62   63    SL 
  SL    64    65   66    67   68   SL    69   70                                 SL 
F 
G 32.5% 
60% 
32.5% 
60% 
HI (Rf: 0.075) 
PA (Rf: 0.200) 
HI (Rf: 0.075) 
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In the DGGE profiles shown in Fig. 4.1A-G, co-migration of bands against the 16S 
standard ladder (SL) annotated strongly suggest the presence of bacterial communities in our 
nCFBR cohort. However, the 16S SL across the DGGE profiles is not strictly reproducible 
(compare Fig. 4.1D with Fig. 4.1E); therefore any observations noted here are postulated. 
Culture-negative patients (App. 3) defined by conventional microbiology also included those 
patients for whom culture of mouth flora was identified (n = 19 (27 %)). Multiple bacterial 
taxa were detected by PCR-DGGE technique across this sub-cohort of patients; these are 
indicated (Fig. 4.1A-G (blue arrows)). Patient number 21 was reported as culturing for no 
growth, but detection of bands is present, although these are very faint (Fig. 4.1C, blue arrow 
and circle). 
Culture-positive individuals harbouring P. aeruginosa and H. influenzae without co-
isolation of mouth flora and any other bacterial species numbered eight (11.4 %) and four 
(5.7 %) patients respectively (App. 3). The co-migration of bands against the annotated HI 
(Rf 0.075) and PA (Rf 0.200) 16S SL markers are shown in these patients (Fig. 4.1A, B, D, E, 
and F (green arrows and red arrows indicate exclusively HI and PA culture-positive 
individuals respectively)). In all of the exclusively culture-positive HI individuals’ (n = 4) co-
migration against the HI (Rf 0.075) 16S SL marker is confirmed (Fig. 4.1B, D, F, and G 
(green rectangles)), in addition to other multiple bands being detected. Co-migration of bands 
against the PA 16S SL marker in the exclusively culture-positive PA patients (n = 8) is 
identified (Fig. 4.1A, B, D, and F (red rectangles)) in all but one patient (number 47 (Fig. 
4.1E red circle)). As before, detection of numerous bacterial taxa in addition to P. aeruginosa 
is also shown across the DGGE profiles in Fig. 4.1A, B, D, and F. Interestingly, patient 
numbers 36, 38, 41, and 63 show co-migration of bands against the HI 16S SL marker (Rf 
0.075). In the culture-based data that was reported co-isolation of P. aeruginosa and H. 
influenzae did not occur in the above patients. 
Using phenotypic data supplied from the complied cohort’s medical database we next 
investigated the bacterial community profiles generated from DGGE using the Canoco for 
Windows (v. 4.5.1) and CanoDraw (v. 4.14) software. Analysis of this data was then used to 
perform an initial detrended correspondence analysis (DCA) giving a 1° axis length of 5.171 
(i.e., > 3 SD (standard deviation units of species turnover). Therefore canonical 
correspondence analysis (CCA (a constrained unimodel ordination method)) was chosen 
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subjecting the entire cohort (n = 70) with permutation testing under full model (499 
permutations) constraining the bacterial community profile variance with 14 measured 
variables: presence of an exacerbation at sampling (P = 0.002); culture-positive for 
pathogenic micro-organisms (P = 0.01); isolation of HI and PA from sputum (P = 0.006 and 
0.06 respectively); persistent isolation of PA (P = 0.06); intermittent isolation of PA (P = 
0.003); no isolation of PA (P = ND (not determined); antibiotic treatment within 1 month of 
sample submission (P = 0.2); both current colomycin and azithromycin treatment (P = 0.8 
and 0.6 respectively) gender (P = 0.2); FEV1% predicted (P = 0.7); frequent exacerbation (P 
= 0.9) and finally age (P = 0.6). From the CCA three of the above variables tested for were 
significant: current exacerbation at time of sampling (P = 0.002), culture-positive isolation of 
H. influenzae (P = 0.006), and intermittent isolation of P. aeruginosa (P = 0.003). These 
variables were significantly associated with the variance of the community structure (Fig. 
4.2). Culture-positive identification of P. aeruginosa from sputum almost approached 
significance (P = 0.062). 
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Fig. 4.2: Canonical correspondence analysis of whole patient nCFBR cohort. The ordination plot 
shows within cohort that the presence of an exacerbation in an individual (P = 0.002) and H. 
influenzae colonisation (P = 0.006) affects the bacterial community assembly. The first (x-axis) and 
second (y-axis) axes explain 18.8 % and 14.9 % of the variance respectively. From the 14 patient 
phenotypes in the analysis only five are shown for clarity. Symbols represented are: ○, exacerbated 
bacterial profile individual; ●, stable bacterial profile individual. Discreet variables are indicated by ▲: 
Ex, exacerbation present; HI +ve, isolation of H. influenzae from sputum culture; PA +ve, isolation of 
P. aeruginosa from sputum culture (blue arrow indicates discreet variable). Continuous variables 
indicated by arrows are FEV1% predicted and age. 
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In addition to the whole cohort and the ordination analysis we also investigated a sub-
cohort of nCFBR patients who presented with an exacerbation at time of sampling (n = 20). 
As before, an initial DCA was executed to ascertain the appropriate method of analysing the 
bacterial community. The primary axis length gradient was 5.918, thus CCA was chosen to 
perform constrained ordination analyses (Fig. 4.3). From the 13 variables analysed [gender (P 
= 0.5); age (P = 0.5); FEV1% predicted (P = 0.6); recent antibiotic treatment within one 
month (P = 0.2); both current colomycin and azithromycin treatment (P = 0.6 and 0.09 
respectively); isolation of PA and HI from sputum (P = 0.7 and 0.6 respectively); no isolation 
of PA (P = 0.1); intermittent isolation of PA (P = 0.5) and frequent exacerbators within sub-
cohort (P = 0.5)] none exerted a significant effect (P   ≤ 0.05) on the variance explaining the 
community structure with the exception of those individuals within sub-cohort who were 
chronically infected with P. aeruginosa which approached significance (P = 0.058). As a 
comparison to the exacerbated individuals, we next examined the stable sub-cohort. As 
before, an initial DCA was performed (1° axis length gradient = 4.966) followed by a CCA 
(Fig. 4.4) of the stable sub-cohort resulting in three factors that significantly influenced the 
bacterial community structure: recent antibiotic treatment (excluding maintenance inhaled 
colomycin or oral azithromycin administration) (P = 0.04), culture positive detection of PA 
(P = 0.038), and intermittent colonisation of PA (P = 0.004). Culturable H. influenzae was 
notable (P = 0.08), although within this particular sub-cohort, the isolation from the 
individuals analysed was small (n = 7). A final constrained ordination analyses was 
performed on the subset of patients for whom data on exacerbation frequency for the 
preceding 12 months was available (61 individuals). Although within this sub-cohort of 
frequently exacerbating patients (n = 38) they did not exhibit a community structure that was 
significantly different to non-frequently exacerbating patients (data not shown). 
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Fig. 4.3: Canonical correspondence analysis of exacerbated nCFBR sub-cohort. Within this sub-
cohort only chronic infection with P. aeruginosa (PA) approached significance (P = 0.058). The first (x-
axis) and second (y-axis) axes explain 16.1 % and 12.8 % of the variance respectively. From the 14 
patient phenotypes in the analysis only three are shown for clarity. Symbols represented are: □, 
individuals with chronic PA infection bacterial profile; ●, individuals with non-chronic PA infection 
bacterial profile. Discreet variables are indicated by ▲: chronic PA infection (blue arrow indicates 
discreet variable). Continuous variables indicated by arrows are FEV1% predicted and age. 
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Fig. 4.4: Canonical correspondence analysis of stable nCFBR sub-cohort. Discreet variables indicated 
by ▲ (blue arrows for clear indication) such as recent antibiotic treatment (RAbx) (P = 0.036), isolation 
of P. aeruginosa (PA) from sputum (P = 0.0038), and intermittent colonisation with P. aeruginosa (PAi) 
(P = 0.004) exerted an effect on the bacterial community structure in sub-cohort. Both gender and 
isolation of H. influenzae (HI) are shown in the CCA output as they were notable from the analysis 
performed (P = 0.06 and P = 0.08 respectively). The first (x-axis) and second (y-axis) axes explain 
19.4 % and 15.8 % of the variance respectively. Symbols represented are: □, individuals with recent 
antibiotic treatment bacterial profile; ●, non-treatment of antibiotics in patient bacterial profile. 
Continuous variables indicated by arrows are FEV1% predicted and age. 
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4.3.4 Fungal DGGE analysis 
From the DGGE analysis performed on whole cohort of the fungal community 1 distinct 
band position was produced in two sputum samples, one each in patients 50 and 65. The band 
was compared with a standard ladder of pure fungal isolates and co-migrated with the band 
corresponding to Candida glabrata. 
4.3.5 Bacterial community assembly 
A total of 2,450 Raup-Crick pair-wise comparisons were carried out and the analysis 
found that 71 (3 %) of pair-wise comparisons yielded statistically different (P   ≤ 0.05) 
communities than would be expected by chance; 225 (9 %) of pair-wise comparisons were 
statistically similar (P   ≥ 0.95) and the remaining 2,154 (88 %) had no statistical 
significance (P   0.05 ≥ ≤ 0.95). 
4.4 Discussion 
We have demonstrated three substantive findings from the data presented. Firstly, that the 
bacterial community profiles from exacerbating individuals were significantly different from 
those of stable patients (Fig 4.1). From the twenty individuals recruited into the study that 
were exacerbating when sputum was collected, fourteen individuals had not yet been 
prescribed antibiotics for their symptoms suggesting that the data was not confounded by 
therapeutic intervention. The remaining six patients were administered recent antibiotics. The 
impact of exacerbation in nCFBR is in contrast to studies on the lower airway bacterial 
community in the CF lung which significantly resulted in no change in community 
composition as a result of these exacerbations (Tunney et al., 2011, Sibley et al., 2008). Both 
culture-dependent and culture-independent studies in chronic obstructive pulmonary disease 
(COPD) suggest that acquisition of new strains is highly associated with a risk of a COPD 
exacerbation (Murphy et al., 2008, Sethi et al., 2002). Further studies are, therefore, needed to 
define if nCFBR exacerbations are more analogous to COPD exacerbations rather than CF 
exacerbations. 
Secondly, as in previous studies (Angrill et al., 2002) we found 27 % of samples were 
culture-negative for recognised pathogens. Molecular analyses demonstrated that these 
samples did contain a bacterial community with on average 7 taxa which was not 
significantly different from the culture-positive sputum. Measures of community diversity, 
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species richness and evenness did not indicate that these indices were significantly different 
between the communities from culture-positive and culture-negative sputum. Moreover, the 
community structure was also not significantly different between sputum samples that were 
culture-positive or -negative. The significance of those taxa that are not routinely identified 
by culture is unknown. Under some circumstances they may be pathogenic (Tunney et al., 
2008), or the increased bacterial load they represent may be associated with airway 
inflammation and decline in lung function (Weinrich and Korsgaard, 2008). These data are 
important when considering the management of a patient who fails to respond to antibiotic 
regimens based on sensitivity results of the predominant species with culture data. 
Finally, we have also shown that the presence of H. influenzae is significantly associated 
with a distinct microbial community structure (Fig 4.2). In other studies, it is the most 
common pathogen isolated from the nCFBR lung (Angrill et al., 2002, King et al., 2007, 
Pasteur et al., 2001) and is particularly prevalent in paediatric patients. However, in our study 
the most prevalent organism isolated from sputum was P. aeruginosa, which is in agreement 
with a much earlier study (Nicotra et al., 1995), followed by H. influenzae. Infection with H. 
influenzae typically follows a pattern of sequential colonisation by different strains of the 
bacteria (Grimwood, 2011). H. influenzae stimulates mucous production and adheres to and 
damages epithelial cells, there may also be a role for biofilm formation in resisting host 
clearance from the lung (King, 2011a). A previous study on a cohort of paediatric CF 
bronchiectasis patients identified that there was an inverse relationship between P. 
aeruginosa and H. influenzae in both culture and metagenomic analyses of the microbial 
communities (Klepac-Ceraj et al., 2010). However, it was unclear whether the inhibition of 
H. influenzae was due to repeated antibiotic exposure, the arrival of P. aeruginosa, or indeed 
both factors. It is striking in our study that H. influenzae was never co-isolated from sputum 
with P. aeruginosa, which supports the observations of Klepac-Ceraj et al. (2010). Moreover, 
H. influenzae was present in patients who had been subjected to long term and repeated 
antibiotic therapy. This suggests a potentially significant relationship between P. aeruginosa 
colonisation and the loss of H. influenzae from the LRT. P. aeruginosa has been shown to 
inhibit the growth of H. influenzae in vitro (Riley and Hoffman, 1986) and the interaction 
between these two major pathogens deserves further study. 
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There has been some evidence to suggest the stratification of patients with nCFBR based 
on colonisation with P. aeruginosa, with those chronically infected showing significantly 
lower lung function than intermittently or never colonised patients (Davis et al., 2006, King 
et al., 2007, Martínez-García et al., 2007). Our data supports these finding with a significant 
reduction in FEV1 % predicted (P = < 0.001) between those persistently versus intermittently 
colonised (P = 0.002) and persistently versus never colonised patients (P = < 0.001). The 
presence of P. aeruginosa has been previously linked to reduced diversity in the bacterial 
communities in the CF lung (Klepac-Ceraj et al., 2010). Bacterial communities isolated from 
older CF patients are less diverse, more phylogenetically similar and increasingly dominated 
by Pseudomonas than those of younger CF patients (Cox et al., 2010). Within the total 
nCFBR cohort there was not a significant association between a patient ever having been 
colonised by P. aeruginosa and the bacterial community structure. In the stable cohort (n = 
50) the bacterial communities which are intermittently colonised with P. aeruginosa are 
significantly different from those never or persistently colonised (Fig. 4.3). In CF, persistent 
colonisation is associated with mucoid strains of P. aeruginosa and those that have acquired 
mutations enhance their adaptation to the CF lung (Grimwood, 2011). In contrast, these 
adaptations are not observed in COPD strains with P. aeruginosa infections being more 
intermittent and sporadic (Rakhimova et al., 2009). Currently, the persistence of P. 
aeruginosa infection and its impact on the overall bacterial community in nCFBR is not 
known. Our data suggests that P. aeruginosa infections are less likely to persist than those 
seen in CF as only 23 of 70 patients showed persistent P. aeruginosa infection. It has also 
been shown that measures of quality of life are significantly lower in patients colonised by P. 
aeruginosa compared to those that were culture-negative or where H. influenzae was the 
predominant pathogen (Wilson et al., 1997). The factors determining persistence require 
further study as they may allow new therapeutic interventions and a reduction in the 
morbidity associated with persistent P. aeruginosa infection. 
In this study, the patient cohort was recruited from an nCFBR out-patients clinic and as a 
result the administration of different antibiotics to individuals within the cohort may be a 
confounding factor to these analyses. We identified 25 patients that were not receiving any 
antibiotics for one month prior to the collection of samples. Ordination analyses showed that 
these individuals did not have a significantly different bacterial community to those who 
were receiving antibiotic therapy. Clinical observations show that antibiotics suppress the 
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symptoms of exacerbations but have limited effects on chronic symptoms (Anwar et al., 
2008). This may be because the non-CF community as in the CF lung are spatially 
heterogeneous. As a result antibiotic treatment may be ineffective against infections in some 
areas of the lung (Willner et al., 2012). Our data suggests that antibiotics do not cause a 
significant perturbation of the bacterial community in the lower airway as determined by 
analysis of expectorated sputum. 
The assembly of the bacterial community in the nCFBR lung does not follow strictly niche 
or neutral processes, Whereas, the Raup-Crick similarity index of the cohort profiles showed 
that the majority (88 %) of pair wise comparisons between bacterial profiles indicated neutral 
(random) community assembly as is observed in the CF lung (van der Gast et al., 2011). 
Ordination analyses demonstrated a significant role of exacerbation and, colonisation by H. 
influenzae on the community structure suggesting that these factors were drivers for a 
specific niche community to develop. Similar observations have been reported in other 
microbial systems (Dumbrell et al., 2010) where initial community assembly is by random 
immigration of taxa. However, as a community structure develops and interacts with the host 
lung, environmental niches develop that are occupied by species best adapted to them, 
resulting in highly adaptable species such as P. aeruginosa being common components of the 
lung microbiome. There appears little consistent colonisation by fungal pathogens within this 
patient cohort, which is in contrast to the CF airway where fungi have been implicated with 
lung function decline and increased exacerbations (Bouchara et al., 2009, Chotirmall et al., 
2010). 
Although we have demonstrated that the lower airways of nCFBR patients are dominated 
by numerous bacterial taxa by a 16S rRNA PCR-DGGE strategy, there are still limitations in 
using this approach. Firstly, the reproducibility of the 16S SL across the DGGE profiles 
generated and their inherent variance (Fig. 4.1A-G) between these profiles means that the 
assignment of any bacterial taxa must be postulated. This is additionally confounded by the 
lack of sequencing data to support our claims when comparing the co-migration of bands in 
individual patients against the 16S SL markers. Indeed, it has been previously demonstrated 
that PCR fragments from different bacterial species can also migrate at the same rate 
confounding bacterial species identification even further (Jackson et al., 2000). Other caveats 
in using 16S rRNA PCR-DGGE technique to analyse microbial communities also include 
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heterogeneity in the 16S rRNA gene itself which can often lead to an overestimation of the 
bacterial community being investigated (Dahllöf et al., 2000, Nübel et al., 1996). Another 
problem is that the microbial population in using PCR-DGGE is misrepresented or biased 
because of the detection limits in using the technique, i.e., the rDNA amplicons generated 
only represent the dominant members present in the community (Muyzer and Smalla, 1998). 
Analysis of sputa using conventional microbiology resulted in either H. influenzae or P. 
aeruginosa being isolated; none were co-isolated in our whole patient cohort. However, using 
PCR-DGGE we have revealed that in four patients (Fig. 4.1D and F (numbers 36, 38, 41, and 
63)) who were exclusively culture-positive for P. aeruginosa, co-migration of bands 
corresponding to the HI 16S SL marker were identified. This identification of H. influenzae is 
postulated as comparing bands against a 16S SL is limited by several factors, such as the 
above. Additionally, the identification of these co-migrated bands could also be assigned 
either Haemophilus parainfluenzae or Haemophilus haemolyticus. However, without any 
sequencing data available from the multitude of bands in each patient presented here, the 
identification of H. influenzae and indeed any other bacterial taxon is presumptive at best. 
Previous studies have demonstrated that even with molecular phylotyping techniques, the 
assignment of species within the Haemophilus genus itself is difficult (Hedegaard et al., 
2001, Nørskov-Lauritsen et al., 2009). An additional culture-independent approach which 
would have supplemented the data from our PCR-DGGE analysis would have been to 
employ a deep sequencing strategy via 454-pyrosequencing. 
Using conventional microbiology resulted in the detection of 14 bacterial taxa (12 taxa 
were identified to species level, the two remaining taxa identified to genus level) across our 
patient cohort. However, in each patient the maximum number of bacterial taxa identified 
was only two species. Selective media in diagnostic microbiology laboratories is a mitigating 
factor in this. The use of artificial media is limited in that only 1 % of bacteria can be cultured 
in vitro (Amman et al., 1995, Rappé and Giovannoni, 2003, Staley and Konopka, 1985) this 
is in addition that several human diseases are now being increasingly recognised as being 
polymicrobial in nature. Nevertheless, the employment of selective media is still very useful 
for the determination of bacterial species morphotypes such as the mucoid phenotype in P. 
aeruginosa which is frequently observed in chronically infected CF patients (Foweraker, 
2009). 
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In the past decade it has been previously shown that using culture-independent techniques 
to investigate other chronic pulmonary diseases that LRT infections could be polymicrobial 
in nature, as seen in CF (Bittar et al., 2008, Harris et al., 2007, Rogers et al., 2005a, Rogers et 
al., 2004, Rogers et al., 2003) and increasingly in (COPD) (Cabrera-Rubio et al., 2012, Erb-
Downward et al., 2011, Hilty et al., 2010, Huang et al., 2010, Pragman et al., 2012, Sze et al., 
2012). Clinical microbiology studies in nCFBR executed a conventional microbiological 
approach using sputum as a diagnostic marker of bacterial infection. Presently, no studies 
exist that have investigated the lung microbiome of non-cystic fibrosis patients employing 
metagenomic culture-independent techniques Recently, a study by Maughan et al., (2012) 
profiled lung tissue samples in both nCFBR (n = 10) and CF (n = 21) patients by a 16S rRNA 
clone library approach. They demonstrated a significant bacterial diversity in the 
bronchiectasis patients analysed, 955 16S rRNA gene sequences were obtained respectively, 
pertaining to 20 genera being identified in the bronchiectasis sub-cohort alone. Additionally, 
the most prevalent genus was that of Pseudomonas which was present in all ten 
bronchiectasis patients profiled. Interestingly, H. influenzae was detected in only one nCFBR 
individual. Maughan, et al., (2012) suggest that this could be attributable to the sample type 
analysed; tissue sections from end-stage lung disease as opposed to sputum in earlier nCFBR 
studies in which the isolation of H. influenzae is highly prevalent (Angrill et al., 2002, King 
et al., 2007, Nicotra et al., 1995, Pasteur et al., 2001). The authors also concluded that no 
significant differences in the community structure between the nCFBR and CF patients were 
observed (Maughan et al., 2012). 
The recent study by Maughan, et al., (2012) partly corroborates our culture-independent 
data, in particular the finding of significant bacterial diversity in their cross-sectional cohort 
against our conventional microbiology data. However, in the 16S rRNA PCR-DGGE 
methodology we carried out, expectorated sputum was profiled for bacterial community 
analysis not lung tissue sections. Additionally, a comparison of the bacterial genera that was 
identified in the above study from our own data cannot be drawn as no sequencing data was 
available from our own DGGE profiles that were generated in our nCFBR cohort. 
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4.5 Conclusions 
We have demonstrated that the microbial community of the lower airway in nCFBR is 
dominated by bacterial taxa. Using a 16S rRNA PCR-DGGE approach has revealed several 
putative bacterial taxa in patients who were initially diagnosed as being culture-negative by 
using conventional microbiology, although these additional bands could represent the 
microbial flora in the URT. Furthermore, application of this culture-independent technique 
has enabled us to discern both H. influenzae and P. aeruginosa taxa identification in four 
patients who were all exclusively culture-positive for P. aeruginosa. This assignment of the 
above taxa in these patients is postulated as no sequencing data was obtainable from any of 
the PCR-DGGE profiles generated in conjunction to the limitations of the technique 
employed. 
Patient exacerbations appear to be associated with a significant shift in the bacterial 
community therefore, identifying the taxa responsible for these changes are a priority as they 
may help explain the cause of exacerbation events. H. influenzae, when present in the lower 
airway, is associated with a distinct community profile. However, there appears to be a 
negative correlation between the presence of P. aeruginosa and the persistence of H. 
influenzae. Understanding the nature of this interaction is of interest as it may cast light on 
the persistence of H. influenzae in the lower airway and the dynamics of the microbial 
community as a whole. In agreement with other studies we have demonstrated that P. 
aeruginosa is a significant pathogen in nCFBR. Patient cohorts do appear to be stratifiable on 
the basis of the presence and persistence of infection by this bacterium which may be relevant 
to the design of future intervention trials. 
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Chapter Five: Molecular fingerprinting 
and metagenomic analysis in a 
chronic obstructive pulmonary 
disease cohort 
5.1 Abstract 
Culture-independent studies of chronic obstructive pulmonary disease (COPD) are only 
recently coming to light. Little is known about the role of bacterial colonisation in stable 
COPD populations. Earlier studies used sputum and classical conventional microbiological 
techniques to characterise infection in COPD patients. Bronchoalveolar lavage (BAL) fluid 
was taken from the right lower lobe (RLL) from which genomic DNA (gDNA) was 
extracted. This was then used as template for amplification of 16S rRNA and 28S rRNA 
genes. Amplicons were then run out for molecular fingerprinting by denaturing gradient gel 
electrophoresis (DGGE). Metagenomic analysis of the 16S rRNA gene using 454-
pyrosequencing was also performed. Both culture-independent techniques and the bacterial 
taxa identified were then subjected to multivariate statistical analysis. Culture-based detection 
resulted in four species. The DGGE profiles produced a distinct number of bands in each 
sample. The co-migration of bands in each BAL sample was compared against a 16S and 28S 
standard ladder enabling putative assessment of which taxa were present. Metagenomic 
analysis generated 1799 unique OTUs (operational taxonomic units) with the dominant 
genera identified being Streptococcus, Arthrobacter, and Staphylococcus species respectively 
across patient cohort. Bacterial OTUs resolved to class-level were found to be significantly 
associated with lung function (P = 0.002), moderate and severe COPD (P = 0.04), and 
smoking status (P = 0.05) of patient phenotypes in cohort. Using two culture-independent 
approaches we have characterised a polymicrobial community in eleven clinically stable 
COPD patients. Against conventional microbial culture, we have demonstrated the detection 
of a greater number of bacterial taxa and identified potential drivers of community structure 
within the COPD lung microbiome. 
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5.2 Background 
Chronic obstructive pulmonary disease is a serious and highly debilitating condition which 
is an increasing global health problem, ranked the sixth most common cause of mortality 
worldwide in 1990 (Barnes, 2007), by the year 2020 it is predicted to become the third most 
common cause of death worldwide and fifth in the cause of disability (Lopez and Murray, 
1998). COPD is defined as “a disease state characterised by airflow limitation that is not fully 
reversible. The airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lungs to noxious particles and gases” (Pauwels et al., 2001). 
Overall, the most determining factor in the cause of COPD is cigarette smoking (> 95 % of 
cases in developed countries); however, several other risk factors have been proposed: 
genetic disposition, poor diet, occupational exposure, and air pollution (Barnes et al., 2003). 
COPD patients commonly exhibit a disparate, overlapping, multi-factorial pathology of the 
lower respiratory tract (LRT); including chronic bronchitis, emphysema, mucus plugging, 
asthma, bronchiectasis, and bronchiolitis (Stockley et al., 2009). Chronic illnesses such as 
cardiovascular disease, depression, osteoporosis, and lung cancer have also been shown to be 
adjunct risk factors in patients with COPD (Decramer et al., 2008). Lung pathology in COPD 
patients leads to episodes of acute exacerbations, i.e., increased dyspnoea, cough, sputum 
volume and purulence. Over time as COPD progresses, these exacerbations both increase in 
frequency and severity leading to higher rates of morbidity and mortality in patients 
(Wedzicha and Wilkinson, 2006). 
Historically, the cause of exacerbations was hypothesised to be predominantly by tobacco 
smoke. However, in the past two decades the cellular and pathological mechanisms that occur 
during bacterial and viral infections in the respiratory tract has been defined more clearly. In 
light of this knowledge, there is considerable evidence that infection in COPD patients is now 
the predominant cause of exacerbations (Sethi et al., 2002, Papi et al., 2006, Murphy et al., 
2008, Murphy et al., 2005), although the roles that bacterial and viral agents predispose 
COPD patients to colonisation or infection with initial development of this disease is less 
clear and still controversial (Huang and Lynch, 2011). Lung structural damage caused by 
COPD gives rise to disruption of the innate respiratory tract defences causing mucus gland 
hypertrophy, hypersecretion, mucocilliary escalator disruption, airway antimicrobial peptide 
down regulation, and impaired alveolar macrophage function, facilitating the adherence of 
bacteria when they come into contact with the lower epithelial airways (Bourke, 2002, Sethi 
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et al., 2009). Colonisation of bacteria in the lower airways induces not only chronic infection 
in some cases, but also elicits an inflammatory response in COPD patients; both of these 
factors mitigate disease progression. This phenomenon is known as the vicious circle 
hypothesis proposed several years ago (Murphy and Sethi, 1992). 
The role of bacteria in exacerbations has been primarily investigated in COPD using 
culture-dependent approaches. These methods have led to the routine isolation of four 
bacterial pathogens, non-typeable Haemophilus influenzae (NTHI), Moraxella catarrhalis, 
Streptococcus pneumoniae, and Pseudomonas aeruginosa (Sethi and Murphy, 2001); 
acquisition of new bacterial strains relating to these four species isolates has been previously 
shown to induce exacerbations in COPD patients resulting in notably increased airway 
inflammation in contrast to those COPD patients whose exacerbations were not associated 
with a new strain (Sethi et al., 2007). Indeed, bacterial infection in COPD is associated with ~ 
50 % of exacerbations with isolation of H. influenzae species accounting for 20-30 % of 
known bacterial isolates in COPD patients (Huang and Lynch, 2011). Other bacterial isolates 
such as Staphylococcus aureus, Haemophilus parainfluenzae, Haemophilus haemolyticus, 
and members from the Enterobacteriaceae family have also been detected in COPD but their 
role in exacerbating the condition of the disease, particularly in stable COPD patients is 
unlikely (Sethi and Murphy, 2008). The use of culture-independent techniques exploiting the 
bacterial 16S rRNA gene for metagenomic analysis has only recently come to light in COPD 
(Erb-Downward et al., 2011, Hilty et al., 2010, Huang et al., 2010), unlike that of CF disease 
where several studies have been previously published (Bittar et al., 2008, Harris et al., 2007, 
Rogers et al., 2005a, Rogers et al., 2004, Rogers et al., 2003). Publications in COPD using 
these culture-independent techniques have successfully demonstrated that the lower airways 
of COPD subjects are composed of a resident microbial community (termed the lung 
microbiome), critically, said studies have also elucidated that the LRT in healthy individuals 
is also colonised with bacteria thus challenging the notion that the lower airways are a 
completely sterile environment. Definitively speaking, the presence of a lung microbiome in 
healthy individuals must be approached with caution as they are practical challenges in 
sampling the lower airways in human subjects such as oropharyngeal contamination in 
addition to the establishment of what actually constitutes a “healthy” individual in terms of 
pulmonary disease, as some conditions can be sub-clinical in their presentation. These 
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measures must also be expressed when assessing the lung microbiome in other chronic 
pulmonary diseases previously mentioned. 
As well as bacterial, viral infection is hypothesised to be a major determinant in inducing 
acute exacerbations in COPD patients especially during the winter season (Wedzicha, 2004). 
Viruses such as influenza A and B, rhinovirus, and adenovirus are highly prevalent in the 
community during these months and could be triggers of acute exacerbations in COPD 
patients. Pulmonary function decline and increases in clinical symptom severity in viral and 
bacterial co-infection in COPD patients has also been shown in exacerbations thus 
lengthening hospital bed stay (Papi et al., 2006, Wilkinson et al., 2006). Fungal infection 
induced acute exacerbation in COPD is currently undefined and their pathogenesis is not yet 
known, however, associations between the eukaryotic fungal pathogen Pneumocystis jiroveci 
and lower airway colonisation in COPD has been demonstrated (Morris et al., 2004). 
This chapter describes a comparison between traditional culture-based detection versus 
both molecular fingerprinting and a metagenomic approach via DGGE and next generation 
sequencing provided by 454-pyrosequencing from the eleven clinical samples analysed. 
Colonisation of bacteria in the lower airways due to the impairment of the innate immune 
system in the respiratory tract in COPD patients is hypothesised to be major contributing 
factor for the induction of acute exacerbations. This constant microbe-host agonist 
autoimmune response plays a major role in the damage of the lung tissue architecture as in 
the vicious circle hypothesis. The investigation of these colonising bacteria, and indeed viral 
infection, in COPD is critical for effective prophylactic and antibiotic administration regimen 
development to treat this increasingly significant disease. 
5.3 Results 
5.3.1 Patient cohort analysis 
From the 11 patients within the cohort (App. 5), they were two females (CS#9 and CS#12) 
and nine males, of which 3 were current smokes (CS#5, CS#9, and CS#10) the rest ex-
smokers (n = 8). Patient CS#11 was unable to submit a BAL sample so bronchial secretions 
(BS) were produced instead. Mean age (65), height (1.65 m), forced expiratory volume in one 
second (FEV1) (1.40), and FEV1% predicted (50 %) of cohort were also calculated 
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respectively. The FEV1% predicted was also used to ascertain how severe the COPD was in 
each patient according to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) 
stages of COPD. Patients at time of sampling presented with either GOLD stage II (i.e., 
moderate COPD clinical diagnosis; FEV1/FVC (forced vital capacity) < 0.7 L or 50 % ≤ 
FEV1 < 80 % predicted (CS#4, CS#7, CS#9, and CS#12)) or GOLD stage III (i.e., severe 
COPD; FEV1/FVC < 0.7 L or 30 % ≤ FEV1 < 50 % predicted (CS#1, CS#3, CS#5, CS#6, 
CS#8, CS#10, and CS#11)). Two patients were not receiving treatment for their COPD at the 
time of sampling (CS#4 and CS#9); only one patient (CS#4) had a previous high-resolution 
computed tomography (HRCT) scan resulting in a diagnosis of emphysema in addition to 
their COPD condition. 
5.3.2 Culture-dependent analysis of clinical samples 
All eleven patients enrolled in the study had routine culture and sensitivity testing 
performed in the Microbiology Department, Freeman Hospital, Newcastle upon Tyne, by 
Health & Care Professions Council (HCPC) registered Biomedical Scientists on the clinical 
samples submitted, i.e., 10 BALFs and 1 BS sample. Note that sample numbers do not follow 
consecutively as COPD subject 2 (CS#2) was later found not to be diagnosed with COPD and 
was subsequently removed from this study. From the eleven COPD subjects, five were 
positive for isolation of potentially pathogenic bacterial species, in which four COPD 
subjects’ yielded typical bacterial species associated with COPD exacerbations (CS#1, S. 
pneumoniae; CS#3, H. influenzae; CS#8, M. catarrhalis, H. influenzae; and CS#10, M. 
catarrhalis). Detection of an atypical pathogen in COPD was observed in CS#6 in which 
growth for Chryseobacterium indologenes was positive. The remaining six other COPD 
subjects yielded culture-negative growth; CS#4, CS#5, CS#7, CS#9, CS#11, and CS#12. Out 
of the 11 COPD patients, only CS#3 was positive for the growth of the yeast forming 
Candida spp. (species name was undetermined form the culture-based data provided). 
5.3.3 Ecological analysis of bacterial and fungal communities by DGGE 
Molecular fingerprinting analysis by DGGE of the 11 COPD subjects yielded 23 and 18 
distinct bands for the bacterial and fungal community analysed respectively. From the 
bacterial DGGE profile generated (Fig. 5.1) a mean of 8 bands per lane was deduced (2-17 
bands present per lane), whereas in the fungal DGGE profile (Fig. 5.2), band range was less, 
2-10 bands per lane, with a mean value of 5 bands per lane. Each individual band from the 
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DGGE profiles produced was thus assumed to be a single taxon or operational taxonomic unit 
(OTU) from which measurements of species richness and evenness could be derived. 
Shannon diversity (H′) indices were calculated and gave a mean of 1.39 (range, 0.423-2.28) 
for bacterial and 1.24 (range, 0.553-2.02) for fungal diversity present across cohort. 
Qualitatively, from the bacterial DGGE profile (Fig. 5.1), there is a strong band presence 
across the cohort towards the top of the gradient (upper 25 % of gel image shown (Fig. 5.1)), 
in which the bands present correspond to the bacterial organisms H. influzenae (Rf 0.075), S. 
aureus (Rf 0.100), Ralstonia pickettii (Rf 0.140), and P. aeruginosa. Although, these four 
bands migrated very closely together, the most prominent bands of the four reference 
organisms is that of P. aeruginosa and H. influenzae. Co-migration of bands matching that of 
P. aeruginosa was in all COPD subjects with the exception of CS#6. Samples containing 
bands that co-migrated with H. influenzae were present in CS#5, CS#7, CS#8, CS#10, 
CS#11, and CS#12. Bands that migrated further down the denaturing gradient, i.e., in the 
middle, are present, although across cohort these tend to be fainter than those produced in the 
upper 25 % of the denaturant gel. Migration of bacterial taxa at the bottom of the denaturing 
gradient is shown in only two patients (CS#11 and CS#12). Three COPD subjects (CS#6, 
CS#11, and CS#12) showed possible co-migration of bacterial taxa corresponding to the 
atypical cystic fibrosis pathogen Achromobacter xylosoxidans (Rf 0.560). 
From the fungal DGGE profile (Fig. 5.2), Aspergillus fumigatus, Exophiala dermatitidis, 
and Scedosporium apiospermum organisms whose bands all co-migrated very closely 
together (Rf values 0.660, 0.700, and 0.770 respectively), only samples CS#6 (Rf 0.740), 
CS#8 (Rf 0.700), and CS#12 (Rf 0.740) produced possible bands corresponding to these three 
fungal organisms. In contrast, four COPD patients, CS#1, CS#6, CS#7, and CS#9 revealed 
fungal taxa that co-migrated with the yeast-forming species Candida glabrata (Rf 0.340). 
However, in CS#7 a band was identified that co--migrated with Candida albicans (Rf 0.420). 
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Fig. 5.1: DGGE profile (32.5-60 % denaturing gradient) showing 
amplified V3 rDNA fragments in COPD cohort. Direction of 
denaturing gradient and migration of bands during electrophoresis is 
shown (arrow). Lane numbers: 1, 16S standard ladder (SL); 2, CS#1; 
3, CS#3; 4, CS#4; 5, CS#5; 6, CS#6; 7, 16S SL; 8, CS#7; 9, CS#8; 
10, CS#9; 11, CS#10; 12, CS#11; 13, CS#12; 14, 16S SL. Rf values 
of reference organisms in 16S SL are also shown indicating migration 
distances of bands in comparison to distinct bands seen in COPD 
subjects. AX, Achromobacter xylosoxidans; BCC, Burkholderia 
cepacia complex; HI, Haemophilus influenzae; PA, Pseudomonas 
aeruginosa; RP, Ralstonia pickettii; SA, Staphylococcus aureus and 
SM, Stenotrophomonas maltophilia. 
 1      2       3     4     5      6      7     8      9    10    11    12   13    14 
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 120 
 
  
Fig. 5.2: DGGE profile (40-60 % denaturing gradient) showing 
amplified U1-U2 rDNA amplicons in COPD cohort. Direction of 
denaturing gradient and migration of bands during electrophoresis is 
shown (arrow). Lane numbers: 1, 28S standard ladder (SL); 2, CS#1; 
3, CS#3; 4, CS#4; 5, CS#5; 6, CS#6; 7, 28S SL; 8, CS#7; 9, CS#8; 
10, CS#9; 11, CS#10; 12, CS#11; 13, CS#12; 14, 28S SL. Rf values 
of reference organisms in 28S SL are also shown indicating migration 
distances of bands in comparison to distinct bands seen in COPD 
subjects. AF, Aspergillus fumigatus; CA, Candida albicans; CD, 
Candida dubliniensis; CG, Candida glabrata; CP, Candida 
parapsilosis; ED, Exophiala dermatitidis and SAP, Scedosporium 
apiospermum. 
     1      2      3     4       5     6      7     8      9     10    11   12    13    14 
CP (Rf: 0.160) 
CD (Rf: 0.210) 
  
CG (Rf: 0.340) 
  
CA (Rf: 0.420) 
 
AF (Rf: 0.660) 
ED (Rf: 0.700) 
SAP (Rf: 0.740) 
40% 
60% 
 121 
 
Ordination plots using Canoco for Windows (v. 4.5.1) of both the bacterial and fungal 
communities in the COPD cohort analysed were produced. The bacterial community from the 
DGGE profile generated was analysed by detrended correspondence analysis (DCA) 
producing a 1° axis length of 2.336 (i.e., < 3 SD (standard deviation units of species turnover) 
so a redundancy analysis (RDA; a constrained linear ordination method) was executed to 
analyse the relationship between the bacterial taxa present and environmental variables 
within cohort at time of sampling. Using Monte Carlo full model permutation testing (499 
permutations), analysis of both the contiguous and discreet variables (seven in total 
including: age (P = 0.612); FEV1% predicted (P = 0.488); gender (P = 0.374); GOLD COPD 
stage (P = 0.662); height (P = 0.444) and smoking status (P = 0.274)) against the bacterial 
community resulted in no significant association between these variables and the variance 
seen in the community profile. GOLD COPD stages II and III discreet variables were 
removed from the RDA ordination plot for clarity (Fig. 5.3). The two axes explained 61.5 % 
and 19.3 % of the variation. 
The fungal community analysed by DGGE was also used to generate a second ordination 
plot in which DCA resulted in a 1° axis length of 3.745 (> 3 SD), therefore canonical 
correspondence analysis (CCA; a constrained unimodel ordination method) was utilised to 
investigate the relationship between the fungal taxa and seven environmental variables within 
cohort as above; age; FEV1% predicted; gender; GOLD COPD stage; height and smoking 
status. As before, full model Monte Carlo permutation execution of the fungal community 
present and the environmental variables resulted in no significant associations between the 
variance of the community profiles and the discreet and continuous variables (age (P= 0.456); 
FEV1% predicted (P = 0.75); gender (P = 0.526); GOLD COPD stage (P = 0.3); height (P = 
0.252) and smoking status (P = 0.596)). The first and second axes explained 31.8 % (x-axis) 
and 26.7 % (y-axis) variation observed in the dataset (Fig. 5.4). As previously, GOLD COPD 
stages II and III discreet variables were removed in the fungal CCA ordination plot for the 
purposes of clarity. 
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  Fig. 5.3: Redundancy analysis showing ordination plot of the bacterial community analysed by 
DGGE and environmental variables in COPD cohort. An association with the relationship between 
community structure and environmental variables was not significant. The x-axis explains 61.5 % 
of the variation, whereas the y-axis explains 19.3 % respectively. Environmental factors shown 
consisted of both continuous (height and FEV1% predicted) and indiscreet variables (smoking 
status and patient gender). CS.X, COPD subject number (● male; ○ female); ES, ex-smoker; F, 
female; FEV1 Pr, FEV1% predicted; M, male. 
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Fig. 5.4: Canonical correspondence analysis showing ordination plot of the fungal community 
analysed by DGGE and environmental variables in COPD cohort. Associations with the 
relationship between community structure and environmental variables were not significant. The 
x-axis explains 31.8 % of the variation, whereas the y-axis explains 26.7 % respectively. 
Environmental factors shown consisted of both continuous (height and FEV1% predicted) and 
indiscreet variables (smoking status and patient gender). CS.X, COPD subject number (● male; ○ 
female); ES, ex-smoker; F, female; FEV1 Pr, FEV1% predicted; M, male. 
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5.3.4 Metagenomic analysis by 454-pyrosequencing of bacterial 
community 
Analysis of the entire cohort by 454-pyrosequencing from extracted gDNA using the 
bacterial tag-encoded FLX-Titanium amplicon pyrosequencing (bTEFAP) method created 
16S rDNA amplicon libraries (Dowd et al., 2008). Following quality control procedures, 
pyro-amplicons consisting of 380 base pairs (bp) in length were obtained and then assigned to 
1,799 unique OTUs generated from the metagenomic data analysis. Following this, a 
rarefaction curve was generated to ascertain the diversity of the bacterial community present 
in the clinical samples analysed from the sampling effort (Fig. 5.5). The number of reads per 
sample and unique number of OTUs assigned are summarised below in table 5.1. 
Table 5.1: Number of reads and OTUs assigned per COPD subject from metagenomic 
analysis. 
COPD subject number Number of reads Number of unique OTUs assigned 
CS#1 2415 504 
CS#3 2715 532 
CS#4 2308 136 
CS#5 3536 447 
CS#6 2239 271 
CS#7 2657 55 
CS#8 1775 126 
CS#9 2122 182 
CS#10 2148 366 
CS#11 542 51 
CS#12 557 3 
 
We next investigated the most abundant bacterial genera represented within the 
community in cohort in rank order. A large number of unique OTUs (1,799) were generated 
from the 454-pyrosequencing reads therefore any OTUs assigned with < 100 reads per COPD 
subject were excluded from further analysis. Consequently, assignment of OTUs with > 100 
reads was included for further metagenomic analysis of cohort. After this meta-data analysis 
criterion was met, this resulted in 36 OTUs being designated at genus-level within the cohort, 
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of which 29 were classified bacterial genera and 7 designated unclassified (Fig. 5.6). Further, 
from the rankings attributed to the most abundant OTUs, the percentages of these OTUs per 
COPD subject was determined reflecting the bacterial community at genus level that was 
present at time of sampling (Fig. 5.7). In terms of abundance, Streptococcus, Arthrobacter, 
and Staphylococcus were the most prevalent. Strikingly, no OTUs representing the 
Pseudomonas genus were identified within cohort. Investigating individual COPD subjects 
displayed a heterogeneous bacterial population across the cohort when resolved to genus-
level. In samples CS#7, CS#11, and CS#12 the phylogenetic diversity was lower than that 
seen in the other COPD subjects. Both CS#7 and CS#11 had four bacterial genera present: 
Granulicatella Prevotella, Streptococcus, and Veillonella. CS#12 was comprised of only two 
dominant bacterial genera, Staphylococcus and Streptococcus respectively in the BAL sample 
analysed. The most abundant genus-level OTUs (i.e., 36) were then resolved to class-level in 
which 9 different bacterial classes were assigned: Acidobacteria; Actinobacteria; Bacilli; 
Bacteroidia; Clostridia; α-proteobacteria; β-proteobacteria; γ-proteobacteria and δ-
proteobacteria (Fig. 5.8). All COPD subjects were dominated with the Actinobacteria class, 
with the exception of CS#7, CS#11, and CS#12. These three patients were most prevalent for 
Bacilli class. The second most dominant bacterial class was that of the α-Proteobacteria, 
again though, this class was absent in patients CS#7, CS#11, and CS#12. 
Ordination analysis using the bacterial community at genus-level was performed. Using 
the most abundant OTUs generated from the metagenomic analysis (i.e., > 100 reads per 
OTU designated). An initial DCA was executed to analyse the relationship between the 
COPD subject bacterial genera in cohort against both discreet and continuous variables 
resulting in a 1° axis length of 10.776 (axis length > 3 SD). Therefore, canonical 
correspondence analysis was performed (data not shown as CCA ordination plot is indistinct) 
resulting in two significant environmental variables: gender (P = 0.026) and height (P = 
0.03). Other environmental variables investigated were not significant such as age (P = 
0.218), FEV1% predicted (P = 0.136), GOLD COPD stage (P = 0.076), and smoking status 
(P = 0.268). Following this, a further investigation of the bacterial community variance at 
class-level (Fig. 5.9) and their associations with the discreet and continuous variables was 
conducted in order to ascertain what were the dominant drivers in shaping the COPD 
community structure. Using CCA (DCA yielded a 1° axis length of 16.969 (> 3 SD)) and the 
above environmental variables against the nine different bacterial phylotypes represented at 
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class-level within cohort, two significant factors were identified: FEV1% predicted (P = 
0.002) and GOLD COPD stage (P = 0.04). Smoking status of the COPD subjects, i.e., ex-
smoker or current smoker approached significance (P = 0.05). The remaining continuous and 
discreet variables consisting of age, gender, and height from the CCA output were not 
significant as P-values of 0.186, 0.132, and 0.14 were all obtained. Both bacterial phylotypes 
and environmental variables in cohort by CCA (78.4 % (x-axis) and 12.1 % (y-axis) 
accounted for the percentage of variation explained) are shown in the final output (Fig. 5.9).
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Number of sequence reads 
Fig. 5.5: Rarefaction curve showing sample coverage diversity in COPD cohort 
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 [Type a quote from the document or the summary 
of an interesting point. You can position the text box 
anywhere in the document. Use the Text Box Tools 
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box.] 
Fig. 5.5: Rarefaction curve 
showing sample coverage 
diversity in COPD cohort. Both 
CS#3 and CS#5 displayed the 
highest amount of sample 
diversity, whereas CS#11 and 
CS#12 exhibited the lowest 
amount of diversity in their 
samples analysed. 
 128 
 
 
0
200
400
600
800
1000
1200
1400
S
tr
e
p
to
c
o
c
c
u
s
A
rt
h
ro
b
a
c
te
r
S
tr
e
p
to
c
o
c
c
u
s
S
ta
p
h
y
lo
c
o
c
c
u
s
V
e
ill
o
n
e
lla
C
ry
p
to
s
p
o
ra
n
g
iu
m
B
a
ln
e
im
o
n
a
s
N
it
ri
lir
u
p
to
r
P
ro
s
th
e
c
o
m
ic
ro
b
iu
m
A
c
ti
n
o
p
la
n
e
s
U
n
c
la
s
s
if
ie
d
G
ra
n
u
lic
a
te
lla
S
p
h
in
g
o
m
o
n
a
s
N
it
ro
b
a
c
te
r
C
ry
p
to
s
p
o
ra
n
g
iu
m
U
n
c
la
s
s
if
ie
d
P
im
e
lo
b
a
c
te
r
A
z
o
s
p
ir
ill
u
m
P
h
a
e
o
s
p
ir
ill
u
m
P
h
a
s
e
lic
y
s
ti
s
U
n
c
la
s
s
if
ie
d
U
n
c
la
s
s
if
ie
d
R
h
o
d
o
fe
ra
x
M
e
th
y
lo
s
in
u
s
U
n
c
la
s
s
if
ie
d
U
n
c
la
s
s
if
ie
d
R
h
iz
o
b
iu
m
R
u
b
e
lli
m
ic
ro
b
iu
m
A
z
o
s
p
ir
ill
u
m
A
llo
k
u
tz
n
e
ri
a
U
n
c
la
s
s
if
ie
d
N
o
c
a
rd
io
id
e
s
S
te
ro
id
o
b
a
c
te
r
S
p
h
a
e
ri
s
p
o
ra
n
g
iu
m
P
re
v
o
te
lla
P
ro
s
th
e
c
o
m
ic
ro
b
iu
m
N
u
m
b
e
r 
o
f 
re
a
d
s
 p
e
r 
O
T
U
 a
s
s
ig
n
e
d
 
Bacterial genera classification 
Fig. 5.6 Ranking of bacterial genera within COPD cohort 
Fig. 5.6: Ranking of bacterial 
genera within COPD cohort. 
The most abundant genera 
across cohort numbered 36 
after exclusion of those OTUs 
that generated < 100 reads 
per COPD subject. 
Streptococcus, Arthrobacter, 
and Staphylococcus were the 
most abundant bacterial 
genera present in patient 
cohort from the 454-
pyrosequencing analysis. 
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Fig. 5.7: Bacterial genus population in COPD cohort 
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  Fig. 5.7: Bacterial genus 
population in COPD cohort. A 
percentage population of the 
bacterial genera composition 
in the community of each 
COPD subject analysed from 
the 454-pyrosequencing data 
generated. With the exception 
of CS#7, CS#11, and CS#12, 
a heterogeneous population is 
shown in each of the COPD 
subjects. 
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Fig. 5.8: Bacterial class-level population in COPD cohort 
Acidobacteria
Beta-proteobacteria
Delta-proteobacteria
Actinobacteria
Bacilli
Bacteroidia
Clostridia
Alpha-proteobacteria
Gamma-proteobacteria
 Fig. 5.8: Bacterial class-level 
population in COPD cohort. 
Resolution of the 36 most 
abundant genera at class-level 
reveals that all of the COPD 
subjects with the exception of 
CS#7, CS#11, and CS#12 are 
populated in bacterial 
members comprised of the 
Actinobacteria and α-
proteobacteria. The Bacilli 
class completely dominates 
CS#12, but also constitutes a 
significant member of 
population bacterial class in 
CS#7 and CS#11. 
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Fig. 5.9: Canonical correspondence analysis of bacterial phylotypes resolved to class-level 
showing potential drivers of the COPD bacterial community in the COPD subjects analysed. 
Associations with the relationship between community structure and environmental variables were 
significant in FEV1% predicted (P = 0.002), GOLD COPD stage status (P = 0.04), and smoking 
status in patient (P = 0.05). The x-axis explained 78.4 % of the variation and the y-axis explained 
12.1 % of the variation respectively. Environmental factors shown consisted of both continuous 
(height and FEV1% predicted) and indiscreet variables (smoking status and patient gender). 
CS.X, COPD subject number (● male; ○ female); ES, ex-smoker; F, female; FEV1 Pr, FEV1% 
predicted; M, male. Bacterial class abbreviations: Acido, Acidobacteria; Actino, Actinobacteria; 
Bacteroi, Bacteroidia; Clostrid, Clostridia; α-proteo, α-proteobacteria; b-proteo, β-proteobacteria; 
g-proteo, γ-proteobacteria. 
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5.4 Discussion 
Although patient cohort was small (n = 11), using both a PCR-DGGE mediated approach 
in conjunction with 454-pyrosequencing metagenomic analysis we have been able to 
demonstrate several factors in COPD. We have identified the presence of a polymicrobial 
community in the RLL of the LRT not only comprised of multiple bacterial genera, but 
strikingly, also perhaps a fungal element. Further, comparison of the bacterial communities 
identified and their respective populations within each COPD subject demonstrate that they 
are heterogeneous in nature. Both the bacterial and fungal community generated when a 
PCR-DGGE culture-independent approach was taken has provided us with a ‘snapshot’ of the 
polymicrobial communities exhibited. Both of these community profiles and their respective 
ordination plots did not reveal any significant factors in the community structure. However, 
execution of a deep-sequencing strategy and the metagenomic data analysed in addition to the 
relationship between the bacterial community and patient phenotypes produced significant 
outcomes in terms of the community structure. The resolution of OTUs from 454-
pyrosquencing metadata at two levels, genus- and class-level, with CCA of the bacterial 
element in COPD subjects where environmental variables within cohort were related yielded 
varying results; gender and height were significant at bacterial genus-level. Resolution at 
class-level however revealed that lung function (FEV1% predicted) and either moderate or 
severe COPD progression were seen as significant in conjunction with smoking status of 
individuals. 
5.4.1 Bacterial community analysis in COPD cohort by PCR-DGGE 
From the PCR-DGGE bacterial community of all COPD subjects some qualitative 
observations can be made. Intense banding in the upper section of the gel at the top of the 
gradient suggests that the lungs of the COPD subjects are heavily colonised with bacteria that 
have a low GC-ratio genomic content such as H. influenzae, M. catarrhalis, P. aeruginosa, 
and S. pneumoniae (Fig. 5.1). Indeed, this has previously been shown in patients suffering 
from acute exacerbations in COPD as these same bacterial species were isolated from 
positive culture from expectorated sputa in 59 patients (Larsen et al., 2009). However, in this 
cohort, sampling strategy involved lower airway BAL from the RLL, not expectorated 
sputum. Additionally, our patient cohort on presentation at clinic was free of the symptoms 
associated with those of acute exacerbations. 
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It has been hypothesised that initial colonisation of pathogenic organisms in patients with 
COPD in the lower airways elicits an immune response to the pathogen in the host whilst 
inducing an acute exacerbation. However, acquisition of the same bacterial strain at a later 
encounter induces a less frequent and severe exacerbation strongly indicating that despite the 
impairment of the lung innate immune defences, there is still an adaptive immune response in 
play mediating partial protection against respiratory pathogens (Sethi et al., 2004). A study 
recently published, described that the lower airways in healthy individuals, i.e., control 
subjects in their patient cohorts respectively, were not sterile, challenging the bronchial tree 
sterility hypothesis (Hilty et al., 2010) reported by other authors (Stockley, 1998, Wilson et 
al., 1996). Hilty, et al., (2010) also analysed the microbial communities in 5 COPD patients, 
in which pathogenic Proteobacteria, particularly Haemophilus spp. were highly prevalent 
(Hilty et al., 2010). The sampling strategy adopted by Hilty, et al., (2010) utilised disposable 
sheathed cytology brushes and sampled the left upper and right lower lobes of the subject’s 
lungs allowing for a more extensive analysis of the lower airways. Our preliminary data from 
the PCR-DGGE profile (Fig. 5.1) would support these findings of a microbial community 
which is present in the LRT of COPD individuals, in particular low GC-count bacterial 
species like the above. 
Execution of a PCR-DGGE approach in this patient cohort yielded the detection of 23 
putative bacterial taxa across the 11 COPD individuals enrolled into this study, with a 
maximum of 88 bacterial taxa detected in total (Fig. 5.1). The use of DGGE in ascertaining 
these bacterial taxa are reputable as no sequencing data was obtained from any of the co-
migrated bands against the 16S standard ladder (SL) in each of the COPD subjects profiled. 
This is against the observed four bacterial species (H. influenzae, M. catarrhalis, S. 
pneumoniae, and C. indologenes) isolated from the BAL specimens using conventional 
microbiological techniques. However, despite the greater detection of microbial species using 
DGGE to investigate the bacterial community in our COPD cohort, this is insignificant to our 
own metagenomic analysis in which 1,799 unique OTUs were generated from 454-
pyrosequencing. This is in addition to several recently culture-independent studies 
investigating the lower airways of COPD patients in which the number of OTUs and 
sequence reads was far greater than both the PCR-DGGE and conventional microbiology 
approach presented here. Hilty, et al., (2010) identified ~ 3,000 sequence reads in their study 
(n = 5), Erb-Downward, et al., (2011) averaged ~12,000 sequences per sample (n = 14), Sze, 
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et al., (2012) identified > 1,400 OTUs (n = 8), and finally, Cabrera-Rubio, et al., (2012) 
generated ~ 1,033 sequences from the 16S rRNA gene metagenomic analysis corresponding 
to ~ 500 bacterial species per sample (n = 6). 
Comparing the bacterial organisms in the 16S SL against the bacterial taxa present in the 
DGGE profile (Fig. 5.1) several confounding factors can be demonstrated. In preparing the 
16S SL via PCR-DGGE of the bacterial isolates, an apparent observation was the 
heterogeneous nature of the 16S rRNA gene leading to multiple bands migrating through the 
denaturing gradient by an individual bacterial isolate. This finding has already been 
demonstrated, indicating that many bacterial species possess several copy numbers of the 16S 
rRNA gene which can lead to an overestimation of the bacterial community (Dahllöf et al., 
2000, Nübel et al., 1996). Additionally, when using 16S rRNA PCR-DGGE technique for 
microbial community analysis it has also been shown that amplicons from different bacterial 
species can migrate at the same rate (Jackson et al., 2000). This co-migration of different 
bacterial species can pose problems for the excision of bands for Sanger sequencing 
applications ― i.e., the retrieval of clean DNA sequences from individual bands (Muyzer and 
Smalla, 1998). No sequencing data was generated from our cohort using PCR-DGGE 
technique in both the bacterial and fungal communities investigated. Construction of the 16S 
SL by PCR-DGGE has revealed the above caveats, thus an accurate depiction of the 
microbial community detected in our COPD cohort is putative at best. 
Other drawbacks of using the 16S rRNA PCR-DGGE approach adopted here also need to 
be taken into consideration. The employment of a ‘semi-nested’ approach for PCR 
amplification of the V3 region could have led to additional biasing factors in the final DGGE 
profile produced (Fig. 5.1). Furthermore, the attachment of a GC-clamp to the 5′-end of either 
the forward or reverse primers tends to lower PCR amplification efficiency in addition to 
increasing the risk of artefact generation and heteroduplex formation (Ferris and Ward, 1997, 
Lee et al., 1996, Nocker et al., 2007, Ruano and Kidd, 1992). A critical issue in using PCR-
DGGE technique is its resolution, i.e., the maximum number of different DNA fragments in a 
microbial community that can be separated out in the denaturing gradient (Muyzer and 
Smalla, 1998). Bacterial populations that constitute ≥ 1 % of the total community can be 
detected by PCR-DGGE as previously shown (Murray et al., 1996, Muyzer et al., 1993), 
however, the rDNA amplicons obtained in PCR-DGGE mediated studies only reveals the 
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predominant species present in the community (Muyzer and Smalla, 1998), thus the total 
population analysed is misrepresented or biased. Nevertheless, despite these inherent 
limitations, DGGE is a useful technique in comparing community structural changes in 
response to perturbations or to identify differences observed when comparing bacterial 
communities in disparate micro-habitats (van der Gast et al., 2008). This would have been 
invaluable if the BAL samples from our COPD cohort were followed longitudinally as 
opposed to a cross-sectional enrolment. To date, no present study using a culture-independent 
approach has addressed this issue. 
Traditional culture-based techniques using bacterial morphology suffer from several 
drawbacks such as the inability of selective media to isolate fastidious and anaerobic bacteria 
(Staley and Konopka, 1985), in addition to the difficulty of differentiating colonial 
morphology on plates after swarming with the mucoid phenotype of P. aeruginosa (van 
Belkum et al., 2000). An over-reliance in routine diagnostic microbiology for assessment of 
the aetiology of microbial infections in COPD is concerning because of the differentiation 
between colonisation and infection in the host (Lentino and Lucks, 1987). In spite of these 
limitations, the conventional microbiology data presented here is strongly corroborated by 
several culture-dependent lower airway investigations in which both stable and exacerbating 
COPD patients were examined by using quantitative microbial culture methods on BAL 
samples (Cabello et al., 1997, Soler et al., 1999, Soler et al., 1998). As well as the established 
microbial agents associated with COPD exacerbations, the identification of C. indologenes in 
CS#6 is unusual as infection with this organism is rare as it is an environmental microbe 
(Hsueh et al., 1996). However, in a previous study, C. indologenes has been implicated in 
causing pneumonia in mechanically ventilated patients in a critical care unit (Bonton et al., 
1993), but there was no report of any patients enrolled into this study as being diagnosed with 
COPD. A recent retrospective study has been published in which Chen, et al., (2012) 
investigated 125 reported cases of C. indologenes being isolated from clinical samples. From 
their findings, C. indologenes was isolated in 91 cases of pneumonia, of which 19 patients 
presented with COPD as an underlying disease (Chen et al., 2012). The role of C. 
indologenes in stable and exacerbated COPD patients has not been fully investigated yet. 
As a comparison between culture-dependent and –independent methods, a recent study 
investigated clinically stable CF and COPD patients whose expectorated sputum samples 
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were then inoculated onto six different media. Using terminal restriction fragment length 
polymorphism (T-RFLP) profiling technique Rogers, et al., (2009) also harvested the 
bacterial growth on these plates for both RNA and DNA extraction, in addition to RNA and 
DNA being directly extracted from the same sputum sample. The authors concluded that 
when comparing conventional microbiology and T-RFLP, the former method was shown to 
be highly selective for the isolation of a small group of recognised respiratory tract 
pathogens. The use of T-RFLP from both the RNA and DNA directly harvested, in addition 
to the RNA and DNA extracted from the bacterial growth on diagnostic media, provided a 
more comprehensive profile of the bacterial species identified confirming that many bacterial 
taxa are present in sputum samples and that these may be clinically relevant (Rogers et al., 
2009b). From the study conducted by Rogers, et al., (2009) and the PCR-DGGE approach we 
employed against our conventional microbiology data, there is partial corroboration, although 
between out study and Rogers, et al., (2009) there is a distinct difference in the patient 
sampling methodologies and a lack of sequencing data. Furthermore, unlike that of Rogers, et 
al., (2005) only DNA was extracted from the clinical BAL samples, not RNA. Because of 
this factor, the profiling of the bacterial community represented in our COPD cohort does not 
indicate which bacterial taxa are metabolically active. This limitation was addressed in a 
previous study using extracted RNA to detect the presence of metabolically active bacteria in 
CF sputum samples using reverse transcribed 16S rRNA yielding cDNA amplicons which 
were analysed by reverse transcription T-RFLP (Rogers et al., 2005b). 
The identification of microbial communities has been demonstrated for several years in 
CF using culture-independent methodologies reported in numerous studies (Rogers et al., 
2005b, Rogers et al., 2003, Rogers et al., 2004, Rogers et al., 2006, Harris et al., 2007, Bittar 
et al., 2008) revealing the potential true number of bacterial isolates in CF infected 
individuals. The preliminary data generated from this small COPD cohort using a 16S rRNA 
PCR-DGGE methodology suggests that a microbial community in the lower airways is 
perpetuating host inflammatory responses and provides evidence supporting the vicious circle 
hypothesis (Murphy and Sethi, 1992). However, further analysis is required to indicate 
whether the bacterial genera in the lower bronchioles represent a core-microbiota in COPD 
patients as seen recently in CF (van der Gast et al., 2011). Investigations of this core-
microbiota in different respiratory disease states such as COPD, CF and non- CF 
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bronchiectasis could prove valuable for additional studies in the lower airways of individuals 
afflicted with these diseases. 
5.4.2 Metagenomic analysis of bacterial communities in COPD cohort 
As previously shown, we have identified a diverse bacterial community present in the 
LRT of the RLL in a cohort of eleven COPD subjects. Further, using constrained community 
ordination analysis we also have demonstrated that specific COPD phenotypic features 
significantly affect the community structure. Culture-dependent microbiological studies 
focusing in COPD have long been able to identify four main bacterial species, all thought to 
induce acute exacerbations in COPD: NTHI, M. catarrhalis, S. pneumoniae, and P. 
aeruginosa (Sethi and Murphy, 2001). Recently though, investigators using 16S rRNA 
community profiling techniques have revealed that the COPD lung microbiome is composed 
of a greater community richness than previously hypothesised (Erb-Downward et al., 2011, 
Hilty et al., 2010, Huang et al., 2010). Comparing these studies against the work performed 
here, interesting observations can be made. Huang and co-authors investigated a small cohort 
of eight COPD patients being managed for severe respiratory exacerbations. Using 16S rRNA 
PhyloChip technology on endotracheal aspirate (ETA) samples they were able to define 
1,213 bacterial taxa present of which 38 bacterial phyla and 140 distinct families were 
characterised in the lower airways of the COPD cohort investigated. Among the families 
detected were Alteromonadaceae, Burkholderiaceae, Comamonadaceae, Enterobacteriaceae, 
Helicobacteraceae, Pasteurellaceae, and Pseudomonadaceae respectively (Huang et al., 
2010). Further, despite all of the COPD subjects enrolled into the study being administered 
broad-spectrum antimicrobial therapies, the ETAs analysed from the patients harboured an 
average of 411 bacterial taxa. Although this patient cohort was very selective and small in 
number, it does confirm our current findings of a microbial community residing in the lower 
airways even though 16S rRNA profiling was determined by different culture-independent 
techniques. However, the diversity reported between our data and Huang, et al., (2010) 
differs dramatically. This difference can be attributed to the fact that in our cohort, sample 
extraction was performed on eleven clinically stable COPD patients, i.e., non-exacerbating. 
In contrast, Huang, et al., (2010) demonstrated that from their 16S rRNA community 
profiling analysis, patients were positive for the detection of P. aeruginosa (belonging to the 
bacterial family Pseudomonadaceae) in all subjects enrolled. Conversely, in our cohort the 
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detection of P. aeruginosa was not represented in any of the COPD subjects we analysed in 
significant numbers. 
Acquisition of new strains in P. aeruginosa has been previously shown to induce acute 
exacerbations in COPD individuals (Murphy et al., 2008). Additionally, using lower-airway 
protected brush sampling procedures, Rosell, et al., detected the presence of P. aeruginosa in 
their COPD cohort (Rosell et al., 2005); thus between the Huang COPD patient cohort and 
our study cohort, the absence of P. aeruginosa taxa from our metagenomic analysis could 
explain the clinically stable state of the COPD subjects we investigated. Another plausible 
reason for the organism’s absence from our own metagenomic analysis can be attributed to 
insufficient numbers present from the OTUs generated from the number of sequence reads. 
Strikingly, an absence of the Haemophilus genera has also been observed from our cohort. H. 
influenzae has long been implicated in COPD bacterial infections and a critical factor in the 
induction of acute exacerbations in COPD patients (Sethi and Murphy, 2008). The detection 
of the Haemophilus genera in insignificant numbers from the 454-pyrosequencing analysis 
could be again attributed to the stable state of cohort when sampling was undertaken. 
Retrospectively though, H. influenzae itself is notorious for persistent colonisation in the 
lungs of COPD sufferers with selected strains persisting for months to years (Murphy et al., 
2004). A common disease phenotype of COPD is chronic bronchitis and colonisation of the 
lower airways is usually associated with NTHI (Cabello et al., 1997) with new strain 
acquisition and colonisation of the lungs being a continuous and dynamic process (Samuelson 
et al., 1995). Indeed, such is the persistence of H. influenzae in COPD and other chronic 
pulmonary diseases, that a previous study investigated the distribution of H. influenzae in 
explanted lung tissues from individuals suffering from end-stage pulmonary diseases 
including COPD, CF and non-CF bronchiectasis (Möller et al., 1998). H. influenzae was 
detected both in the respiratory epithelium and sub-epithelial layers in the explanted lung 
tissues analysed from the pulmonary end-stage disease patients. This finding strongly 
suggests that H. influenzae plays an invasive role, but also persists in patients with severe 
lung disease, spreading throughout the pulmonary tree especially in COPD and CF patients 
(Möller et al., 1998). Additional previous studies have also shown that multiple strains of 
NTHI can colonise the respiratory tract in concert in chronic bronchitis settings (Murphy et 
al., 1999, Groeneveld et al., 1988). Excluding H. influenzae, both H. parainfluenzae and H. 
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haemolyticus are believed to play a role in COPD bacterial infection but their roles in acute 
exacerbations is uncertain (Sethi and Murphy, 2008). 
In another study of COPD subjects, Erb-Downward, et al., (2011) investigated the lung 
microbiome by using massively parallel 454-pyrosequencing of bacterial 16S amplicons from 
not only collected BAL samples but also in explanted lung tissues. They demonstrated three 
key findings: (i), that the bacterial lung microbiome is present and diverse, but different from 
the nasopharynx and oral cavity sites, (ii), that a decrease in pulmonary function is associated 
with a decrease in bacterial community diversity, i.e., the dominance of Pseudomonas spp., 
and (iii), the micro-anatomic sites sampled and analysed within the lung gave rise to disparate 
microbial communities between them. 
In their study, 14 subjects were analysed (7 ‘healthy’ smokers, 4 individuals with COPD 
(1 mild, 2 moderate, and 1 severe), and 3 non-smokers with no smoking history or evidence 
of lung disease) and from the metagenomic analysis performed in this cohort, the dominant 
phyla in the COPD subjects were the Bacteroidetes, Firmicutes, and Proteobacteria. At 
genus-level, the dominant bacterial genera in the COPD subjects were Pseudomonas, 
Streptococcus, Prevotella, Fusobacterium, and Veillonella respectively (Erb-Downward et 
al., 2011). In contrast, our meta-analysis demonstrated that the predominant bacterial genera 
were Streptococcus, Arthrobacter, and Staphylococcus indicating a very heterogeneous 
distribution of microbial diversity across COPD patients. However, in three of our COPD 
subjects, CS#7, CS#11, and CS#12, the diversity was limited; in particular CS#12 (moderate 
COPD) only the bacterial genera Streptococcus and Staphylococcus spp. were detected. This 
dominance of a very few bacterial genera could be attributed to the one sampling site (RLL) 
from where the BAL was taken in cohort. Erb-Downward, et al., (2011) also demonstrated 
that sampling from multiple micro-anatomical sites within the lungs demonstrated local 
differences in the bacterial communities inhabiting them highlighting that bacterial species in 
the lower airways of COPD patient’s exhibit differences not just globally, but also locally. 
The observations by Erb-Downward, et al., (2011) have only been recently partly 
corroborated by Sze, et al., (2012), although there is still contrasting data presented in their 
study. The authors of this study investigated the lung tissue microbiome in very severe COPD 
patients (GOLD stage IV (n = 4)) and compared them to other explanted lung tissues 
obtained from individuals who were non-smokers (n = 8) and current smoker control subjects 
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(n = 8). Lung tissue samples were also collected from CF patients (n = 8) acting as a positive 
control sub-group ― the lungs of CF individuals have been previously shown to contain 
bacteria and this finding is well documented, both in cross-sectional and temporal studies 
(Cox et al., 2010, Harris et al., 2007) ― for the culture-independent analyses that was carried 
out in this study. 
Executing an approach using terminal-restriction fragment length polymorphism (T-
RFLP) and pyrotag sequencing spanning the V1-V3 hypervariable regions within the 16S 
rRNA gene, Sze, et al., concluded that the lung tissue microbiome from the COPD GOLD 
stage 4 patients was significantly different from all of the other lung tissue sections 
investigated. Strikingly, from their metagenomic analysis in the study both the Lactobacillus 
and Burkholderia genera were significantly associated with the COPD GOLD IV explanted 
lung tissues. Additionally, both of the above genera represented the top five bacterial species 
within this sample group (i.e., two Burkholderia spp. and three Lactobacillus spp. were 
identified, although all were unclassified to species level) (Sze et al., 2012). The bacterial 
community composition within the GOLD 4 sub-group conflicts with that of the data shown 
in the Erb-Downward, et al., (2011) and Huang, et al., (2010) COPD microbiome studies. 
With our own meta-analysis a comparison cannot be deduced as no GOLD stage IV patients 
were recruited into our study. However, Sze, et al., (2012) state the differences in their study 
design and COPD patient selection in relation to the two aforementioned studies. They 
suggest that their investigation reflects the microbiome of lung parenchymal tissue as 
opposed to the above previous studies which examined the COPD lung bacterial community 
composition by BAL, ETA, and bronchial brushing collections respectively. Despite some of 
the conflicting data presented by Sze and co-authors, they conclude that a major limitation in 
their study was the exclusion of moderate and severe COPD patients (GOLD stages II and III 
respectively), and as thus, extrapolation of the Burkholderia and Lactobacillus genera found 
in their GOLD IV explanted lung tissue samples cannot be made across the other GOLD 
stages in COPD because of this constraint. 
A concerning factor from the metagenomic dataset shown across this patient cohort is the 
high prevalence of the bacterial genus Arthrobacter; in this study Arthrobacter spp. was one 
of the predominant bacterial genera present in all COPD subjects except CS#7, CS#11, and 
CS#12 (Fig. 5.7). Arthrobacter species that are implicated and isolated in clinical human 
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infection are rare as individuals are continually exposed to Arthrobacter strains in the 
environment (Funke et al., 1996). The first documented cases of Arthrobacter infection in 
patients isolated from clinical specimens by using 16S rRNA gene sequencing methods were 
reported in 1996 resulting in two new Arthrobacter species being identified: Arthrobacter 
cumminsu (isolated from a urine sample and skin swab) and Arthrobacter woluwensis 
(isolated from blood culture from a patient presenting with human immunodeficiency virus 
(HIV) infection) (Funke et al., 1996). Following this, Bernasconi et al., (2004) reported a 
case of infective endocarditis in a patient (HIV-seronegative habitual drug user) in which A. 
woluwensis was subsequently isolated and only identified through full-fragment 16S rDNA 
sequencing (Bernasconi et al., 2004). Initial laboratory diagnosis presumptively identified the 
organism as Corynebacterium aquaticum using conventional microbiology assays. In 
addition to the Bernasconi case report, there have been only five other documented cases of 
clinical disease involving Arthrobacter spp. none of which involved the pulmonary tree: 
bacteraemia (2 cases), severe phlebitis (1 case), post-operative endophthalmitis (1 case) and a 
patient presenting with Whipple’s syndrome (1 case) (Bodaghi et al., 1998, Esteban et al., 
1996, Hsu et al., 1998, Wauters et al., 2000). The rarity of cases pertaining to the 
Arthrobacter genus can be attributed to its relatively low pathogenicity and the challenges in 
its precise identification using conventional microbiological techniques such as the above, 
possibly biasing in a low recovery rate of Arthrobacter species (Bernasconi et al., 2004). In 
our COPD subjects, the dominance of the Arthrobacter genus in the metagenomic analysis 
could be from an environmental source either directly, i.e., Arthrobacter and 
Corynebacterium spp. may be a part of the human skin flora, or indirectly. This could be one 
reason why our metagenomic data-set conflicts with the other COPD lung microbiome 
studies and as such should be taken into consideration. 
In comparing the conventional microbiology data from the COPD cohort to our meta-
analysis, the application of a deep-sequencing strategy through 454-pyrosequencing yielded 
many different bacterial taxa across our COPD patient cohort, in which 1,799 unique OTUs 
were generated representative to genus-level. Conventional microbiology of patient BAL 
samples resulted in only four species being isolated: C. indologenes (CS#6), H. influenzae 
(CS#3, CS#8), M. catarrhalis (CS#8, CS#10), and S. pneumoniae (CS#1). Interestingly, from 
the meta-analysis employed in our study, none of the above genera were identified in our 
patient cohort from the data shown (Fig. 5.6 and Fig. 5.7) with the exception of the 
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Streptococcus genus (CS#7, CS#11, and CS#12). Nevertheless, Chryseobacterium (CS#11), 
Haemophilus (CS#7, CS#10, and CS#11), and the Moraxella (CS#10) genera were present in 
the COPD subjects analysed in this study (indicated in parentheses), but the assignment of 
OTUs pertaining to these three particular genera accounted for < 100 sequence reads per 
OTU. Strikingly, the detection of all the above genera by 454-pyrosequencing conflicts with 
the conventional microbiology data as Chryseobacterium, Haemophilus, and Moraxella spp. 
was not detected by culture-based methodologies in CS#7, CS#10, and CS#11 respectively. 
COPD subject #1 was positive for S. pneumoniae growth by culture, but the Streptococcus 
genus itself was not assigned to any OTUs in this individual from the meta-analysis 
performed. Only the isolation of M. catarrhalis by culture in CS#10 corroborates both the 
culture-dependent and metagenomic analysis performed, as the Moraxella genus was also 
present in CS#10, although the OTU assigned to this genus generated 80 reads. 
Historically, from earlier studies, bacterial infection in COPD was established as a 
potential driver in exacerbations in these patient populations (Burrows and Earle, 1969, Tager 
and Speizer, 1975). The application of conventional microbiological methods in COPD has 
primarily identified four organisms highly prevalent in exacerbating COPD patient 
populations: H. influenzae, M. catarrhalis, S. pneumoniae, and P. aeruginosa (Ko et al., 
2005, Larsen et al., 2009, Miravitlles et al., 1999, Sethi et al., 2002, Soler et al., 1998). 
Furthermore, several preliminary studies have been carried out on stable COPD patient 
cohorts investigating the bronchial tree bacteriologic flora (Brumfit et al., 1957, Lees and 
McNaught, 1959, Potter et al., 1968). Despite these earlier studies demonstrating the role of 
bacterial infection and exacerbations in COPD, this paradigm is still controversial. Earlier 
studies used sputum as a diagnostic measure for determining the role of bacterial infection in 
COPD (Gump et al., 1976, Lambert and Stern, 1972, McHardy et al., 1980). The execution of 
sputum as a diagnostic marker coupled with conventional microbiology is limited because of 
the complexity in the differentiation between colonisation and infection in the individual 
(Lentino and Lucks, 1987). Furthermore, culture-dependent microbiology of sputum also 
carries the risk of culturing those organisms that are residents in the URT, thus potentially 
leading to contamination of the culture plates being analysed. 
Comparison and interpretation of the data from the conventional microbiology approach 
employed here to other studies investigating the respiratory tract flora in stable COPD 
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patients are difficult because of the differences in microbiological methods and patient 
selections executed. Some comparisons can be made however from other studies. From our 
study, culture-dependent microbiology was conducted on BALF samples (with the exception 
of patient CS#11 in which BS were obtained instead) obtained from the RLL. Additionally, 
all individuals were stable at presentation before bronchoscopy was performed. The 
conventional microbiology data is in stark contrast to a study by Cabello, et al., (1997) in 
which they investigated the distal airways of 18 stable non-exacerbating COPD patients by 
using quantitative culture techniques on both bronchoscopic protected specimen brush (PSB) 
and BAL samples in the RLL. In their study, Cabello, et al., (1997) categorised any bacterial 
agents identified as either PPMs (potentially pathogenic micro-organisms) or non-PPMs 
(non-potentially pathogenic micro-organisms. The former being those micro-organisms well 
established in respiratory tract infections (Gram-positive cocci (S. aureus and S. 
pneumoniae); Gram-negative rods (P. aeruginosa); Enterobacteriaceae and Haemophilus spp; 
and Gram-negative cocci (M. catarrhalis)). The latter comprising of bacterial species such as 
Streptococcus viridans group, Neisseria spp., and Corynebacterium spp. which are normally 
associated with either the oropharyngeal or gastrointestinal flora, playing no role in 
respiratory infection in non-immunocompromised individuals (Cabello et al., 1997). 
Cultivation of micro-organisms using both PSB and BAL samples resulted in 22 non-
PPMs and 7 PPMs being isolated across 15 COPD patients in their cohort. From the BAL 
samples analysed, only two COPD patients yielded positive growth, S. pneumoniae and S. 
viridans, a PPM and non-PPM respectively. However, 15 COPD patients were positive for 
bacterial colonisation using PSB technique, resulting in the isolation of 27 micro-organisms, 
both comprising 5 PPMs (H. influenzae, S. pneumoniae, and S. aureus isolates) and 22 non-
PPMs (S. viridans, Neisseria spp., plasma-co-agulase S. aureus, and Corynebacterium spp. 
isolates) (Cabello et al., 1997). In our cohort, five patients yielded positive growth from the 
BAL samples cultured. Three bacterial species according to the Cabello, et al., (1997) 
categorisation were classified as PPMs: H. influenzae (CS#3, CS#8), M. catarrhalis (CS#8, 
CS#10), and S. pneumoniae (CS#1). It is also interesting to note that in the Cabello study, 
both M. catarrhalis and P. aeruginosa were negative for growth in both BAL and PSB 
samples analysed, unlike in our COPD cohort in which M. catarrhalis was present in CS#8 
and CS#10 by culture respectively. 
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Preceding Cabello, et al., (1997) are two earlier studies by Fagon, et al., (1990) and 
Monsó, et al., (1995) which both used PSB lower airway sampling technique and quantitative 
culture to characterise the lower airways in COPD patients. The former study by Fagon, et 
al., (1990) investigated the lower airways of COPD inpatient’s mechanically ventilated 
suffering from severe exacerbations, whereas the latter study by Monsó, et al., (1995) 
sampled the lower pulmonary tree in stable and moderately severe exacerbating COPD 
outpatients. Evidence for bacterial bronchial pathogens in 50 % of cases was confirmed by 
both studies using PSB, with the remaining 50 % of cases implying the absence of pathogens 
(Fagon et al., 1990, Monsó et al., 1995). A comparison in the validity of both study’s findings 
against other techniques such as BAL was not performed by Fagon, et al., (1990) and Monsó, 
et al., (1995) as BAL samples from the lower bronchial tree were not analysed in both COPD 
cohorts enrolled into both studies. Retrospectively, a comparison of our conventional 
microbiology culture data cannot be made, but both studies corroborate by culture-dependent 
techniques that the lower airways in COPD patients are colonised both in exacerbated and 
stable COPD populations. Indeed, other studies have shown that the lungs of stable COPD 
populations are colonised with bacteria and this has been subsequently demonstrated to 
contribute towards to the severity and frequency of patient exacerbations (Patel et al., 2002, 
Rosell et al., 2005, White et al., 2003, Wilkinson et al., 2003). 
From their original characterisation of the bronchial COPD pulmonary tree, Soler, et al., 
(1999) investigated 18 control (8 non-smokers and 18 smokers) and 53 stable COPD subjects 
(28 mild, 11 moderate, and 13 severe COPD phenotypes based on FEV1) using PSB and BAL 
sampling techniques. As before, a quantitative conventional microbiology approach was 
carried out as in the previous studies (Cabello et al., 1997, Soler et al., 1998) in which they 
found from the PSB and BAL sample analysis, the vast majority of PPMs isolated from both 
patient cohorts were community acquired, i.e., S. pneumoniae, S. aureus, H. influenzae, and 
M. catarrhalis. Indeed, from the COPD cohort subjected to culture-dependent microbiology, 
9 (mild), 11 (moderate), and 2 (severe) COPD patients respectively, was culture-positive for 
PPMs (Soler et al., 1999). In corroboration with the previous study by Soler, et al., (1997), 
the most prevalent non-PPM isolated was S. viridans. The findings by Soler, et al., (1999), 
partly confirm our findings both by culture-dependent and –independent means as they 
conclusively found that both patient cohorts analysed, in particular their COPD cohort by 
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BAL sample analyses, were frequently colonised by community acquired PPMs in the 
bronchial tree (Soler et al., 1999). 
The remaining COPD subjects (CS#4, CS#5, CS#7, CS#9, CS#11, and CS#12) in our 
study were all culture-negative from the conventional microbiology investigation. Although, 
from the 454-pyrosequencing approach employed, detection of many bacterial taxa was 
evident. This is clearly apparent in CS#4, CS#5, and CS#9, in which 136, 447, and 182 OTUs 
pertaining to bacterial genera respectively, were generated from the sequencing reads 
obtained (Table 5.1). In COPD subjects #7, #11, and #12, in which the number of bacterial 
genera detected by 454-pyrosequencing was much lower in comparison to the other COPD 
subjects, the number of OTUs observed is indicative of several bacterial species recovered 
from the RLL in the BAL samples analysed. Additionally, from the data presented in Fig. 5.7 
it is evident that the COPD subjects diagnosed as being culture-negative indeed harbour a 
lower airway bacterial population varying in diversity. 
Furthermore, despite this diagnosis by conventional microbiology, the use of BAL for 
culture-based microbiological detection is still advantageous over the culture-based methods 
using sputum as a diagnostic tool, although bronchoscopy itself is still a highly invasive 
examination technique. The main advantage being that BAL provides an in situ 
representation of the lower airways in healthy or diseased individuals (Reynolds, 2011). 
However, a previous initial study has demonstrated that recovery of BAL from patients for 
microbial culture can also yield oropharyngeal commensals; these can sometimes be 
designated as normal or mouth flora by an individual identifying bacterial species on culture 
media (Reynolds and Newball, 1974). This identification of normal or mouth flora could 
have been a biasing factor leading to the conflicting culture-dependent and metagenomic data 
presented above. The retrieval of BAL however, for the detection of bacterial infection in 
COPD alongside other investigations is still preferable over sputum due to the decreased risk 
of contamination from URT organisms in either the oro- or nasopharyngeal cavity. 
The use of conventional microbiology for analysis in COPD, and indeed other chronic 
respiratory diseases such as CF, is also limited in its detection due to the selective nature of 
the media employed; investigation of the LRT using traditional culture-based methodologies 
under standard conditions can only culture up to 30 % of bacteria (Suau et al., 1999), this is 
in addition to culture-dependent techniques being very labour intensive. Also, the 
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differentiation of bacterial strains isolated from the same species is a confounding factor as 
these strains cannot be detected by conventional microbiology. Thus detection of different 
bacterial strains can only be accomplished by molecular typing methods such as pulsed-field 
electrophoresis. As has been recently shown in the last decade, acquisition of different 
bacterial strains in COPD is strongly associated with the induction of acute exacerbations in 
these patient populations (Murphy et al., 2005, Murphy et al., 2007, Sethi et al., 2002, Sethi 
et al., 2007). 
Because of these limitations, many researchers investigating the lower bronchial tree in 
COPD are now using modern 16S rRNA molecular profiling techniques to reveal a bacterial 
diversity that is greater than previously imagined; this is now being realised (Cabrera-Rubio 
et al., 2012, Erb-Downward et al., 2011, Hilty et al., 2010, Huang et al., 2010, Pragman et al., 
2012, Sze et al., 2012). The preliminary research conducted in CF in the last decade using 
culture-independent techniques provides a foundation for much of the investigative work 
carried out in COPD. This approach has resulted in CF now being increasingly recognised as 
a polymicrobial disease (Rogers et al., 2009a). This is in addition to the complexity of the 
human oral microbiome and the just recently postulated core respiratory tract microbiome 
(Avila et al., 2009, Han et al., 2012). Culture-based detection in chronic respiratory tract 
diseases via expectorated sputum and bronchial washings are still essential for the diagnosis 
of acute infections or the determination of a carrier state in the patient (Reynolds, 2011). 
Despite the above limitations, traditional based cultivation of bacterial pathogens still has its 
advantages though. In CF this is particularly important as conventional microbiological 
methods enable the detection of the mucoid phenotype established by P. aeruginosa in 
chronically infected CF patients (Fegan et al., 1990, Hassett et al., 2002, Martin et al., 1993, 
Sokol et al., 1994, Yu et al., 2002). Differentiation between P. aeruginosa morphotypes is 
critical in a diagnostic microbiology laboratory as it has been demonstrated that within these 
morphotypes there is an inherent variability in their antimicrobial susceptibility patterns 
(Foweraker et al., 2005), thus this can affect the antibiotic treatment regimen of the CF 
patients concerned. 
5.4.3 Fungal community analysis in COPD cohort by PCR-DGGE 
The possibility of a fungal element in stable COPD patients has not been widely reported. 
Here our analysis revealed a significant and diverse fungal community. This raises several 
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questions. Does this fungal element contribute towards disease in the lower airways? Do 
fungi also drive an immunological response; inducing a host-pathogen antagonistic 
relationship thus contributing towards the vicious-circle hypothesis proposed nearly two 
decades ago using the bacterial paradigm (Murphy and Sethi, 1992)? Is there an interaction 
between fungal and bacterial populations that significantly affects disease pathology and 
severity? Published work on fungal interactions and infections in COPD patients is scarce. A 
report published several years ago detected the eukaryotic fungal pathogen Pneumocystis 
jiroveci in lung tissues from patients undergoing either lung resection or transplantation in 
COPD subjects (all GOLD classification stages) (Morris et al., 2004). Aetiology involving P. 
jiroveci infections are generally associated with pneumonia in immunocompromised hosts, 
specifically, patients infected with HIV (Goldenberg and Price, 2008). However, Morris, et al 
(2004) proposed that colonisation by P. jiroveci affected airflow obstruction in smokers, but 
was greatly pronounced in GOLD IV COPD subjects pointing towards a possible pathogenic 
link with COPD progression. These findings indicate that in the airways of COPD patients 
the increasing and irreversible airflow limitation, especially in more severe COPD, provides a 
more suitable environment for initial colonisation and inevitable proliferation of this fungal 
pathogen. In our study, FEV1% was not significant in relation to the fungal community 
present in the COPD subjects and thus a correlation with reduced airflow obstruction was not 
shown (Fig. 5.4). 
From the culture-dependent microbiology of the COPD subjects, only one patient (CS#3) 
was positive for fungal growth, identified to genus-level as a Candida spp. From the DGGE 
analysis presented in Fig. 5.2, co-migration of two possible fungal taxa detected in the BAL 
sample from this patient corresponded to the yeast-forming Candida genera, C. albicans and 
C. glabrata represented in the 28S SL qualitatively. Previous studies in CF individuals have 
detected numerous fungal species such as A. fumigatus, C. albicans, E. dermatitidis, and S. 
apiospermum (Bouchara et al., 2009, Phiet et al., 2009) some studies support the notion that 
the above fungal species can be an attributing factor in lung function decline in CF patients 
(Chotirmall et al., 2010, Haase et al., 1990, Amin et al., 2010, Cimon et al., 2000). However, 
in terms of COPD disease progression this is currently unproven, and investigations into 
fungal infections with COPD are unmet. Thus far, only P. jiroveci has been implicated in 
lung function decline in this regard (Morris et al., 2004, Norris and Morris, 2011). 
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All other environmental variables examined by CCA were not significant although this 
can be possibly attributed to the small cohort number. In terms of male and female 
phenotypic relationship to the fungal community only two females were enrolled into this 
study group, thus having an impact on the constrained community variance analysis 
performed. Additionally, the detection limits of PCR-DGGE of the fungal community must 
be considered, even though we have clearly demonstrated that fungal detection in cohort is 
much greater when using a culture-independent approach as opposed to traditional cultivation 
methods. Indeed, other culture-independent analysis of potential mycobiomes within diseased 
and healthy subjects has been previously shown in the oral cavity, but not in the lower 
airways of COPD patients as stated above. Two recent studies, the first a clone-library 
approach, investigated the oral cavity in HIV-infected patients using 18S rDNA primer sets 
demonstrating amplification of C. albicans and Saccharomyces cerevisiae in the subgingival 
plaque (Aas et al., 2007). The second demonstrated a greater coverage of the oral 
mycobiome, and thus a more comprehensive profile, by employing a novel Multitag 
Pyrosequencing approach using the pan-fungal internal transcribed spacer (ITS) regions 1 
and 2 nestled between the 18S and 28S rRNA gene sequences (Ghannoum et al., 2010). From 
the reads sequenced and subsequently analysed, 101 fungal species were identified, of which 
74 genera were culturable and 11 non-culturable in the oral cavity of healthy individuals. 
Moreover, the number of fungal species inhabiting the oropharynx in these subjects (n = 20) 
was between 9 and 23 in total with Candida being the most frequently isolated genera in 75 
% of subjects studied followed by Cladosporium, Aureobasidium, Saccharomycetales, 
Aspergillus, Fusarium, and Cryptococcus genera respectively (Ghannoum et al., 2010). 
Although these two studies focused predominantly on the oral cavity, it is interesting to note 
that the oral cavity contains this much fungal diversity successfully demonstrated by 
Ghannoum and colleagues, however, against this; a fungal element in the LRT in healthy 
individuals would be concerning as in nearly all cases of fungal isolation from the lungs 
points towards an underlying lung pathology, whether it be CF, AIDS in HIV-infected 
patients or atypical disease phenotypes. Conversely, would it be incorrect to presume that the 
lung microbiome does indeed contain a fungal element? To date, no metagenomic analysis 
examining BAL samples from healthy subjects have investigated the potential role fungi may 
play in the lung microbiome opening the door for other hypotheses. 
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Critically, the PCR-DGGE approach adopted here is constrained by the choice of primer 
set and the ‘semi-nested’ PCR performed. The DGGE profile in Fig. 5.2 representing the 
fungal community in cohort must be approached, to a degree, with caution. Firstly, the 
attachment of a GC-clamp to the reverse universal fungal primer U2R-GC may mirror the 
effects observed in GC-clamp attachment amplicon variation in PCR-DGGE studies of 
bacterial 16S rRNA gene community profiling leading consequently to artefactual production 
such as chimeras and heteroduplex formation (Muyzer and Smalla, 1998, Rettedal et al., 
2010). To counter these effects we used a single batch of primers to offset any potential bias 
that has been previously reported in using multiple batches of a single primer (Rettedal et al., 
2010). Additionally, during the PCR and subsequent amplification of the universal regions 
within the 28S rRNA gene, an additional 30 min during the final elongation step was 
implemented to further reduce the formation of any artefacts which could adversely affect the 
fungal community analysis (Janse et al., 2004). Thirdly, because cohort is small and only one 
clinical sample (either BAL or BS (in the case of CS#11)) was analysed the data at best can 
only attempt to provide a ‘snapshot’ of the microbial community identified. Longitudinal 
studies in this cohort using gDNA from BAL to generate both bacterial and fungal 
communities via PCR-DGGE profiles would have been complementary to the data presented. 
Additionally, no sequence data is available from the fungal community. 
Retrospectively in terms of a paradigm; fungal infection could have a role in disease 
progression in COPD subjects in relation to polymicrobial infection processes. Impaired 
innate lung defence mechanisms in the LRT in COPD induced primarily by smoking in 
addition to the fungal mycobiome in the oral cavity could predispose COPD patients to 
fungal infection. The action of smoking on the lower airways has been previously shown to 
cause defects in mucocilliary clearance thus effecting mucocilliary escalator function, and 
inducing surfactant abnormalities (Finley and Ladman, 1972, Vastag et al., 1985, Stanley et 
al., 1986, Verra et al., 1995, Honda et al., 1996). Both of these dysfunctional properties 
suggestively increase the probability of fungal colonisation in the LRT, as in bacterial 
colonisation, and in turn decrease the fundamental mechanisms necessary for pathogen 
clearance. 
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5.4.4 Microbial community profiles by ordination analysis 
Both the 16S and 28S rRNA PCR-DGGE techniques employed were used to investigate 
the lower airway microbial community in our COPD cohort. Additionally, the microbial 
communities detected by the above approach were then subjected to ordination analyses. 
However, the ordination analyses by the RDA and CCA performed did not show any 
significant community structure changes in relation to the COPD cohort patient phenotypes 
analysed (Fig. 5.3 and Fig. 5.4). Conversely, the assignment of OTUs from the metagenomic 
analysis at two different bacterial phylotypes (representative at class- and genus-level) 
revealed potential drivers of the bacterial community that we have identified in our COPD 
cohort by CCA. At class-level, associations with the relationship between community 
structure and patient phenotypic variables were significant in FEV1% predicted (P = 0.002), 
GOLD COPD stage status (P = 0.04), and smoking status (P = 0.05) (Fig. 5.9). At genus-
level, both patient gender (P = 0.026) and height (P = 0.03) phenotypes were shown to be 
significant in association with community structure (data not shown). These potential drivers 
of the community structure at genus-level are skewed as only two female individuals were 
enrolled into our COPD cohort versus nine males. Furthermore, an individual’s height and 
ethnicity can also affect their lung volume respectively (Cotes et al., 2006b, Cotes et al., 
2006a, Hughes, 2007). In our COPD cohort database, patient ethnicity was not disclosed for 
the purposes of this study. 
Previous longitudinal studies in CF have shown that in stable patients, there is a decline in 
FEV1 with age (Corey et al., 1997, Kerem et al., 1992). Additionally, Cox, et al., (2010) 
investigating an age-stratified CF cohort has shown that a decrease in bacterial diversity and 
community richness is correlated with an increase in patient age. These findings strongly 
suggest that bacterial colonisation in CF plays a major role in the frequency and severity of 
patient exacerbations via lung function decline. Although our cohort was a cross-sectional 
investigation, from our observations, lung function (FEV1% predicted) was shown to be 
significantly associated with bacterial community structure (P = 0.002). Two longitudinal 
studies in COPD have demonstrated lung function decline in stable COPD populations 
(Marin et al., 2010, Wilkinson et al., 2003). Wilkinson, et al., (2003) followed-up 30 stable 
COPD patients over 1 year and demonstrated that FEV1 decline was correlated with an 
increase in bacterial load and species change. Subsequently, Marin, et al., (2010) found that 
colonisation with H. influenzae, P. aeruginosa, enterobacteria spp. and neutrophilic 
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inflammatory response markers was significantly associated with a decrease in FEV1 in a 
cohort of 40 COPD patients over an eight month period. The studies by Wilkinson, et al., 
(2003) and Marin, et al., (2010) not only show interplay between bacteria and lower airway 
inflammation, but also importantly, that bacterial infection in COPD patients is not a static 
phenomenon (Beasley et al., 2012). Both the Wilkinson, et al., (2003) and Marin, et al., 
(2010) studies partly corroborate our findings in that bacterial colonisation in the LRT 
exhibits an effect on lung function in COPD individuals. 
A potential driver of the microbial community we have identified in our COPD cohort was 
significantly associated with GOLD stages II and III, i.e., moderate COPD and severe COPD 
respectively (P = 0.04). Chronic obstructive pulmonary disease severity is classified into four 
stages by spirometric diagnosis which is used to ascertain the severity of pathologic changes 
occurring in the patients assessed (Rabe et al., 2007). Recently, Pragman, et al., (2012) 
characterised and compared the lung microbiomes of both moderate (n = 14) and severe 
COPD (n = 8) patients, including a healthy control group (4 smokers and 6 non-smokers). As 
in other lung microbiome studies they executed a deep sequencing strategy of the V3 region 
of 16S rDNA amplicons and demonstrated that there was a significant increase in microbial 
diversity in both the moderate and severe COPD BAL samples analysed in comparison to the 
healthy control group (Pragman et al., 2012). Furthermore, from the metagenomic analysis 
performed by Pragman, et al., (2012), principle co-ordinates analysis (PCoA) revealed 
separation between the control and COPD cohorts investigated. However, no separation was 
observed by PCoA between the moderate and severe COPD BALF samples analysed in this 
study (Pragman et al., 2012). From our data, there is a clear separation in the patients and 
their GOLD stage COPD characterisation (i.e., 4 moderate (stage II) and 7 severe (stage III) 
COPD patients), in addition to the bacterial class phylotypes we have profiled (Fig. 5.9). 
In our cohort, eight patients were ex-smokers and three current smokers. These two 
phenotypic parameters were classified as smoking status in the patient and were significant 
(P = 0.05). A previous study has investigated the microbial communities of the URT 
(nasopharynx and oropharynx) using a deep sequencing approach comparing smoking (n = 
29) and non-smoking (n = 33) healthy asymptomatic adults (Charlson et al., 2010). Charlson, 
et al., (2010) found global community structure differences in bacterial taxa at both genus 
and phylum level. The smoker sub-cohort tended to exhibit disordered microbial community 
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structure than the non-smoking sub-cohort, including an increase in diversity in both the 
oropharyngeal and nasopharyngeal sites sampled (Charlson et al., 2010). Additionally, the 
smoker sub-cohort URT microbiome was also characterised by more bacterial genera 
potentially associated with respiratory tract disease. The data presented by Charlson, et al., 
(2010) is in agreement with our own data suggesting that smoking status in a COPD patient 
can exhibit an effect on the community structure, although in the above study only the URT 
was sampled not the LRT. 
5.5 Conclusions 
The culture-independent techniques against the conventional culture-based methods have 
enabled us to characterise the lung microbiome in a small cohort of moderate and severe 
COPD patients. We have also demonstrated that the lower airways in our COPD cohort are 
composed of a polymicrobial community using both a PCR-DGGE and deep sequencing 
strategy. Both these bacterial and fungal elements may drive the perpetuating immunological 
response playing a role in the vicious circle hypothesis. However, no sequencing data was 
obtained when using a 16S and 28S PCR-DGGE approach so the profiles we have generated 
using this technique is putative at best. 
The metagenomic data analysed from the 454-pyrosequencing reads has shown that each 
COPD subject was host to heterogeneous bacterial populations, with the most dominant 
genera being Streptococcus, Arthrobacter, and Staphylococcus spp. respectively. The deep 
sequencing approach has enabled us to characterise this COPD cohort to reveal a diverse 
population in the RLL of the pulmonary tree. The most prevalent bacterial genera we have 
identified conflicts with other metagenomic studies which have previously profiled the 
COPD lung microbiome in both stable and exacerbating COPD populations. However, all 
previous studies executed different sampling strategies involving their COPD cohorts 
respectively. 
From the ordination analyses, both bacterial and fungal communities identified by PCR-
DGGE exhibited no significance in terms of patient phenotype and community structure. 
However, from the metagenomic analysis, the bacterial community identified and resolved to 
genus-level, both gender and height are shown to be significant in community structure. 
Resolution at class-level revealed that lung function (FEV1% predicted), COPD disease 
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progression (GOLD stage II or III), and smoking status, were all associated with community 
structure in the cohort analysed. 
Molecular-based detection techniques in COPD could point the way towards a greater 
understanding of the microbial communities in colonised individuals and elucidate the 
complex mechanisms between host and microbe and their role in the induction of 
exacerbations. 
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Appendix 1: Chemicals and media 
A1.1 1 % (w/v) agarose gel 
1.  0.3 gm of agarose (MELFORD) was added to 30 mL of of 1× TAE buffer solution 
and boiled until fully dissolved. 
2. Five µL of SYBR® Safe DNA gel stain (10 000× concentrate in dimethyl sulphoxide 
(DMSO)) (Invitrogen™) was then added to the molten agarose, and mixed before 
being poured into the gel casting chamber. 
3. The gel was then left to set in order for the rest of the electrophoresis experiment to 
continue. 
A1.2 Molecular biology dyes 
A1.2.1 10 mL 6× bromophenol blue loading dye 
1. 0.025 g of bromophenol blue (SIGMA®) was added to 4 g of sucrose (SIGMA®) in 
an empty 25 mL plastic universal tube. 
2.  These two chemicals were then made up to 10 mL with dH2O. 
A1.2.2 10 mL DCode™ dye solution reagent 
1. 0.05 g of bromophenol blue (SIGMA®) was added to an empty 25 mL plastic 
universal tube. 
2. 0.05 g of xylene cyanol FF (SIGMA®) was then added to the universal tube. 
3. The contents of which were then made up to 10 mL with 1× TAE buffer solution. 
A1.2.3 10 mL 2× DCode™ gel loading dye 
1. 0.25 mL of a 2 % bromophenol blue solution (0.02 g of bromophenol blue 
(SIGMA®) made up to 1 mL with dH2O) was added to an empty 25 mL plastic 
universal tube. 
2. 0.25 mL of a 2 % xylene cyanol solution (0.02 g of xylene cyanol FF (SIGMA®) 
made up to 1 mL with dH2O) was then added to the universal tube. 
3. 7 mL of a 100 % glycerol solution (Fisher Scientific) was then added. 
4. This solution was then made up to 10 mL by the addition of 2.5 mL of dH2O. 
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A1.3 Denaturing solutions for DGGE experiments 
A range of denaturing solutions were utilised for DGGE analysis in a variety of different 
sample types. The reagent composition and amounts used in each denaturing solution are 
summarised below: 
100 mL denaturing solution (%age denaturant) 
Reagent 32.5 % 35 % 40 % 60 % 
40 % (v/v) 37.5:1 
acrylamide:bis-acrylamide 
(SIGMA® Life Sciences) 
30 mL 30 mL 30 mL 30 mL 
50× TAE 2 mL 2 mL 2 mL 2 mL 
Deionised formamide 
(SIGMA® Life Sciences) 
13 mL 14 mL 16 mL 24 mL 
Urea (electrophoresis 
grade) (MELFORD) 
13.65 g 14.7 g 16.8 g 25.5 g 
dH2O To 100 mL To 100 mL To 100 mL To 100 mL 
 
A1.4 10 % (w/v) ammonium persulphate (APS) 
1. 1 g of ammonium persulphate (SIGMA®) was weighed out and then decanted into an 
empty 25 mL plastic universal tube. 
2. This was then made to 10 mL using dH2O, before being aliquoted into 500 µL 
amounts in 1.5 mL microfuge tubes. 
3. These aliquots were then stored at -20 °C until further requirement. 
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A1.5 Running buffers for gel-based experiments 
A1.5.1 2 L 50× TAE solution 
1. 200 mL of a 0.5 M EDTA solution pH 8.0 was made up first (37.22 g EDTA made up 
to 200 mL of dH2O at pH 8.0 (this must be at pH 8.0 otherwise all of the EDTA will 
not entirely dissolve into solution)). 
2. 200 mL of the EDTA (0.5 M, ph 8.0) solution was then decanted into a 2 L 
DURAN® glass bottle before 484 gm of Tris-HCl (MELFORD) was added. 
3. Following this, 114.2 mL of glacial acetic acid (Fisher Scientific) was added. 
4. Then, the resulting solution was made up to 2 L using dH2O. 
A1.5.2 1 L 1× TAE solution 
1. 20 mL of 50× TAE solution was decanted into a 1 L DURAN® glass bottle. 
2. This was then made up to 1 L using dH2O. 
A1.6 Bacteriology and mycology media 
A1.6.1 Basic recipe for 1 L Luria-Bertani (LB) media and broth 
 10 g of tryptone (OXOID); 
 5 g of yeast (OXOID); 
 5 g of sodium chloride (NaCl) (SIGMA®); 
 15 g of agar bacteriological (agar no. 1) (OXOID); (omit this step from the recipe 
when making LB broth); 
 Made up to 1 L in an appropriate conical flask using dH2O; 
 Adjust the pH to 7.0 with NaOH; 
 Autoclave at 121 °C for 45 min, cool to 50 ° C and then pour 20 mL into each Petri 
dish. 
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A1.6.2 NADsens agar and broth 
This particular agar and broth was previously prepared at the Freeman Hospital, 
Microbiology Department, as a requirement of their routine media consortia by an 
appropriate member of staff. The agar and broth function as an isosensitest, used in antibiotic 
disk diffusion assays. Briefly, these components are all added together in the following order: 
hydrolysed casein, peptones, glucose, NaCl, starch, disodium hydrogen phosphate, sodium 
acetate, magnesium glycerophosphate, calcium gluconate, cobaltous sulphate, cupric 
sulphate, zinc sulphate, ferrous sulphate, manganous chloride, menadione, cyanocobalamin, 
L-cysteine hydrochloride, L-typtophan, pyridoxine, pantothenate, nicotinamide, biotin, 
thiamine, adenine, guanine, xanthine, uracil, and finally agar. These nutrients are all 
autoclaved at 121 °C for 60 min before cooling down to 50 °C and supplemented with 5 % 
whole horse blood and 20 mg/L NAD (nicotinamide dinucleotide). In making NADsens 
broth, as in LB broth, agar is omitted. 
A1.6.3 Basic recipe for 100 mL Sabourad broth 
1. 100 mL of Sabourad broth was implemented for each fungal strain. 
2. 3 g of Sabourad liquid medium (OXOID) was decanted into an appropriate conical 
flask before being made up to 100 mL with dH2O. 
3. Once Sabourad liquid medium was in solution, this was autoclaved at 120 °C for 45 
min. 
4. Once sterilised, these broths were now ready for inoculation by the fungal strains 
already described. 
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Appendix 2: Molecular base-pair markers 
Confirmation of successful PCR experiments and the resulting amplicons were confirmed by 
comparing the PCR fragments against a known set of molecular base-pair markers and 
standards shown below (Hyperladder I (BIOLINE)): 
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Appendix 3: Cross-sectional nCFBR cohort demographic data 
Part 1: Phenotypic data 
Patient 
number 
Sex Age FEV1 (L) FEV1% 
predicted 
Exacerbation 
present
a 
Recent
b
 
Abx
 
Current 
colomycin 
Current 
azithromycin 
Frequent 
exacerbators
c
 
1 F 61 0.67 30 Y N N Y Y 
2 M 67 1.42 46 Y Y N N Y 
3 F 62 1.32 64 Y Y N Y N 
4 M 59 2.02 63.8 N N Y N Y 
5 F 32 3 90 Y N N N Y 
6 F 80 1.35 94 Y N N Y Y 
7 F 63 1.1 49 N Y N Y Y 
8 M 64 2.8 84 N N N Y N 
9 M 58 2.3 70 Y Y N Y Y 
10 M 65 2.25 73 N N Y N N 
11 M 64 1.8 56 N Y N Y N 
12 F 60 1.55 60 N N N N N 
13 F 62 1.9 54 N N N Y N 
14 F 72 0.75 45 Y N N N N 
15 F 68 0.7 53 N N N N Y 
16 M 83 2.2 95 N N N N N 
17 M 68 1.6 52 N Y N N Y 
18 M 65 3.05 101 Y N Y Y Y 
19 F 64 0.5 25 Y N N Y N 
20 F 59 1.2 47 N Y Y Y Y 
21 F 62 2.1 112 Y N N Y Y 
22 F 55 2.5 93 N N N N Y 
23 M 58 0.85 23 N Y N Y Y 
24 F 68 1.65 70 N N N N N 
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25 M 35 1.6 39 N Y N N Y 
26 M 75 0.85 27 N N N N N 
27 F 56 0.7 32 N N N N Y 
28 M 58 0.8 24 N N N Y Y 
29 F 63 1.1 54 N N N Y N 
30 F 73 0.9 85 N N N N N 
31 F 62 0.75 33 N N Y Y N 
32 F 72 0.85 37 Y Y N N Y 
33 M 58 1.6 63 N N N Y N 
34 M 29 2.4 56 N N N N Y 
35 F 62 0.6 33 N N N N N 
36 F 79 0.4 27 N N N N N 
37 F 72 0.9 50 N N Y N N 
38 F 52 0.8 34.4 N N Y Y N 
39 F 48 2.5 114 N N Y Y Y 
40 F 71 0.45 25 N Y N Y N 
41 F 67 0.77 39 N N N N Y 
42 F 64 0.59 48 N N N Y Y 
43 M 61 1.27 41 N N Y Y N 
44 F 25 2.45 74 Y Y N Y Y 
45 F 76 1 56 N N N N Y 
46 F 70 0.95 42.3 N N N N Y 
47 F 64 1.05 44.5 N N N N Y 
48 F 72 0.9 50 N N N N N 
49 F 72 0.9 55 Y Y N Y Y 
50 F 71 0.65 41 N N N Y Y 
51 M 74 1 34 Y N N Y N 
52 M 74 0.6 21 Y Y Y Y Y 
53 M 59 2.6 84 N N N N N 
54 F 50 0.8 45 Y N N N Y 
55 F 58 2.4 102 Y N N Y Y 
56 M 60 0.85 28 N N N N Y 
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57 F 41 3.2 112 N N N Y N 
58 M 54 2.63 68.7 N N N N Y 
59 M 55 2.4 64 N N N Y N 
60 F 64 1.6 79 Y N N N N 
61 M 18 3.3 69.8 N N N N N 
62 F 33 ND ND N N N N Y 
63 F 60 1.55 69 N N N N Y 
64 F 79 0.9 65 N N N N N 
65 M 77 1.9 73 N N N N Y 
66 F 66 2 66 N Y N N N 
67 F 75 0.9 44.6 N N N N Y 
68 F 57 2 99 N Y N N Y 
69 F 66 1.85 96 Y N N N N 
70 F 66 0.55 27 Y N N N N 
a
 As defined by Pasteur, et al., (2010) at time of sampling. 
b
 Administration within one month of sampling, excluded patient who at the time were being treated with current colomycin and azithromycin 
therapy. 
c
 Defined as those individuals who presented with an exacerbation > 3 times in the last 12 months. 
Abbreviations: Abx, antibiotics; FEV1 (L), forced expiratory volume in one second; FEV1% predicted, forced expiratory volume in one second 
%age predicted; ND, not determined from patient’s medical notes. 
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Part 2: Conventional microbiology culture data 
Patient 
number 
Cuture-based detection
a 
Culture 
+ve
b
 
PA 
+ve 
HI 
+ve 
Chronic 
PA infection 
Intermittent 
PA infection 
No isolation 
of PA 
1 Mouth flora only N N N Y N N 
2 Haemophilus parainfluenzae Y N N N Y N 
3 Mouth flora only N N N N Y N 
4 Pseudomonas aeruginosa Y Y N N Y N 
5 Mouth flora, Haemophilus influenzae, Streptococcus pneumoniae 1 N Y N N Y 
6 Mouth flora only N N N N N Y 
7 Escherichia coli Y N N N Y N 
8 Candida spp. Y N N N N Y 
9 Haemophilus parainfluenzae and Staphylococcus aureus Y N N N Y N 
10 Pseudomonas aeruginosa and Streptococcus pneumoniae Y Y N Y N N 
11 Pseudomonas aeruginosa Y Y N Y N N 
12 Haemophilus influenzae Y N Y N Y N 
13 Pseudomonas aeruginosa X 2 Y Y N Y N N 
14 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
15 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
16 Mouth flora, Haemophilus parainfluenzae Y N N N N Y 
17 Pseudomonas aeruginosa and Achromobacter xylosoxidans Y Y N Y N N 
18 Mouth flora only N N N N N Y 
19 Mouth flora only N N N N N Y 
20 Mouth flora only N N N Y N N 
21 No growth N N N N N Y 
22 Mouth flora only N N N N Y N 
23 Mouth flora/ Stenotrophomonas maltophilia / MRSA Y N N Y N N 
24 Proteus spp. Y N N N N Y 
25 Mouth flora only N N N N Y N 
26 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
27 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
28 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
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29 Mouth flora, Serratia spp. Y N N N N Y 
30 Mouth flora, Pseudomonas aeruginosa, Klebsiella pneumoniae Y Y N Y N N 
31 Mouth flora, Haemophilus influenzae Y N Y N N Y 
32 Mouth flora / Aspergillus fumigatus Y N N N Y N 
33 Mouth flora, Haemophilus influenzae Y N Y N Y N 
34 Mouth flora, Haemophilus influenzae Y N Y N N Y 
35 Haemophilus influenzae Y N Y N Y N 
36 Pseudomonas aeruginosa Y Y N Y N N 
37 Pseudomonas aeruginosa and Staphylococcus aureus Y Y N Y N N 
38 Pseudomonas aeruginosa X 2 Y Y N Y N N 
39 Mouth flora only N N N N N Y 
40 Mouth flora only N N N Y N N 
41 Pseudomonas aeruginosa Y Y N Y N N 
42 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
43 Mouth flora, Pseudomonas species Y Y N Y N N 
44 Mouth flora, Haemophilus influenzae/Candida spp. Y N Y N N Y 
45 Escherichia coli Y N N N N Y 
46 Escherichia coli and Moraxella catarrhalis Y N N N N Y 
47 Pseudomonas aeruginosa X 2 Y Y N Y N N 
48 Mouth flora only N N N N N Y 
49 Mouth flora only N N N N Y N 
50 Mouth flora, Pseudomonas aeruginosa X 2 Y Y N Y N N 
51 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
52 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
53 Mouth flora and Staphylococcus aureus Y N N N Y N 
54 Mouth flora, Haemophilus influenzae Y N Y N N Y 
55 Mouth flora, Stenotrophomonas maltophilia Y N N N Y N 
56 Mouth flora only N N N N Y N 
57 Mouth flora only N N N N Y N 
58 Haemophilus influenzae Y N Y N N Y 
59 Morganella morganii Y N N N Y N 
60 Mouth flora, Haemophilus influenzae Y N Y N N Y 
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61 Mouth flora only N N N N N Y 
62 Mouth flora, Pseudomonas aeruginosa Y Y N Y N N 
63 Pseudomonas aeruginosa Y Y N N N Y 
64 Haemophilus influenzae Y N Y N N Y 
65 Mouth flora, Serratia liquefaciens Y N N N N Y 
66 Mouth flora only N N N N N Y 
67 Mouth flora only N N N N N Y 
68 Mouth flora and Staphylococcus aureus Y N N N N Y 
69 Mouth flora and Haemophilus influenzae Y N Y N N Y 
70 Mouth flora only N N N N N Y 
a
 Performed by Health & Care Professions Council registered Biomedical Scientists at the Freeman Hospital, Microbiology Department, 
Newcastle upon Tyne. 
b
 The culture of mouth flora in this study was defined as culture-negative. 
Abbreviations: HI, Haemophilus influenzae; PA, Pseudomonas aeruginosa. 
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Appendix 4: Microbiology Department 
at the Freeman Hospital SOP: 
Sputum and related samples 
Contained in the following appendix is the official SOP documentation relating to the 
processing of respiratory tract specimens carried out by the Freeman Hospital; This 
SOP was generously donated to the author by Prof. John Perry and Audrey Perry. 
Note that this document has been re-formatted and edited slightly from the original 
copy to ensure that it meets the requirements of thesis submission. 
Newcastle upon Tyne Hospitals NHS Trust:   MIFSOP003 
Microbiology Department:     Edition 6.0 26/06/2012 
Newcastle upon Tyne Hospitals NHS Trust:   MICRAF009 
Microbiology Department:     Edition 3.0 30/01/2012 
Location of SOP documentation:    Room 102 FH 
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Purpose and 
scope, 
applications 
 
Sputum samples and other samples such as Pleural fluid, Tissue, NPS 
BAL and cough swabs may be sent for examination. Samples are 
inoculated onto culture media and incubated in an appropriate 
atmosphere and temperature to allow the growth of micro-organisms. 
General guidance is presented in line with National SOPs. Specific 
requirements for specimen types are given in checklists. 
 
COSHH, 
Health and 
safety 
 
Before handling samples the following must be read and understood: 
COSHH assessments FH: F003, F007, F010, F017, F022, F032, 
F038, F042, F043. 
The following Risk Assessments must also be read :- FH : F001, F002, 
F012 also those specific to location : F009, R003. 
 
All respiratory samples must be processed in a Class 1 safety cabinet 
wearing appropriate gloves conforming to EN 166. 
The following documents should also be read before proceeding: 
Containment level 3 protocols MICH&SF010  
Category 3 room fumigation MICH&SF011 
Fumigation of Class 1 safety cabinet MICH&SF012 
 
Personnel All grades of BMS staff and Trainee staff under supervision may 
perform these procedures. 
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Introduction 
This document describes the isolation of organisms known to cause 
respiratory infection from associated specimens. Recovery and recognition of 
organisms responsible for pneumonia depends on 
• The adequacy of the lower respiratory tract specimen 
• Avoidance of contamination by upper respiratory tract flora 
• The use of microscopic techniques and culture methods. If these are 
suitable, fastidious organisms will grow 
• Current and recent antimicrobial treatment 
Distinction between tracheobronchial colonisation and true pulmonary 
infection can prove difficult. Ventilator associated pneumonia carries a high 
mortality but is difficult to diagnose clinically and microbiologically. The criteria 
which should be used for diagnosis remain controversial. The poor sensitivity 
and specificity of sputum culture in the diagnosis of pneumonia in hospitalised 
ventilated patients has led to the development of a variety of techniques for 
obtaining lower respiratory tract specimens either with or without the use of 
fibreoptic bronchoscopy. Specimens which may be received include 
bronchoalveolar lavage and protected brush specimens collected 
bronchoscopically, ‘blind’ protected brush specimens and non directed 
bronchoalveolar lavage. A pure bacterial count of greater than 103 cfu/ml in a 
brush specimen obtained bronchoscopically has been found to correlate with 
a histological diagnosis of pneumonia. Brush specimen results and 
bronchoalveolar lavage results are comparable if a cut off of 104 cfu/ml is used 
for the bronchoalveolar lavage although this is not recommended in this SOP 
because optional methodology, interpretation and clinical significance remain 
controversial. Non directed techniques have been found to give results 
comparable to bronchscopic methods. 
Types of specimen 
Bronchial aspirate 
These are collected by direct aspiration of material from the large airways of 
the respiratory tract by means of a flexible bronchoscope. 
Bronchial brushing 
This uses a protected brush catheter in the bronchoscope (a brush within two 
catheters sealed at the end with a polyethylene glycol plug) to tease material 
from the airways. 
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Bronchial washings 
Bronchial washings are collected in a similar fashion to bronchial aspirates, 
but the procedure involves the aspiration of small amounts of instilled saline 
from the large airways of the respiratory tract. 
Pleural fluid 
Pleural fluid is the accumulation of fluid between the inner and outer (visceral 
and parietal) layers of the pleura. 
Tracheal aspirate 
Tracheal aspirates are collected via the endotracheal tube. They are subject 
to the same limitations as sputum specimens. 
Transthoracic aspirate 
These samples are obtained through the chest wall, via a needle passed 
between the ribs. This procedure may be undertaken to sample, for instance, 
an aspergilloma, abscess or any focal lung lesion which is accessible. It is 
rarely used because of the risk of complications. 
Transtracheal aspiration 
Transtracheal aspiration is also a procedure which carries clinical risks and is 
therefore rarely performed in the UK. Its clinical usefulness in defining the 
aetiology of acute bacterial pneumonia has been described. The technique 
entails the insertion of a large bore needle containing a catheter through the 
cricothyroid space and into the trachea. The needle is then removed leaving 
the catheter in place. A syringe attached to the catheter is used to aspirate the 
secretions. If no material is obtained, 2-3 ml of sterile saline (without 
antibacterial additives) is injected and aspiration attempted again. 
Clinical associations 
Empyema 
Empyema is the collection of pus in the pleural cavity. It most often occurs as a 
complication of bacterial infection of the pulmonary parenchyma, either 
pneumonia or lung abscess. 
Any organism can be isolated from pleural fluid, in particular organisms 
associated with lower respiratory tract infection and organisms acquired by 
aspiration of the oropharyngeal flora, including oral streptococci and anaerobes. 
Unusual organisms such as L. monocytogenes have been reported. 
 
Organisms particularly associated with empyema in patients with acquired 
immune deficiency syndrome (AIDS) include: 
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• Cryptococcus neoformans 
• Mycobacterium avium-intracellulare  
• M. tuberculosis 
• Nocardia asteroides  
Other organisms which may cause infection in this group of patients include 
Pneumocystis carinii and Rhodococcus equi. 
Lower respiratory tract infection 
Lower respiratory tract infection (LRTI) is a major cause of morbidity and 
mortality. In the UK, about 50,000 people are admitted to hospital annually, of 
whom 10% die. The expression LRTI includes pneumonia, where there is 
inflammation of the lung parenchyma, and infections such as bronchiolitis, 
which affect the small airways. Lung abscess, where the lung parenchyma is 
replaced by pus filled cavities, and empyema, where pus occupies the pleural 
space, are less common manifestations of LRTI. 
Pneumonia can be classified according to whether it is community acquired or 
nosocomial (often defined as being acquired more than 48 hours after 
hospitalisation). It may be primary, occurring in a person without previously 
identified risk factors, or secondary. Many conditions are associated with an 
increased risk of pneumonia. Common risk factors include chronic lung 
diseases such as chronic obstructive pulmonary disease, diabetes mellitus, 
cardiac or renal failure and immunosuppression (either congenital or 
acquired). Reduced level of consciousness and weakness of the gag and 
cough reflexes are risk factors for aspiration pneumonia. Recent infection with 
respiratory viruses, particularly influenza, is also a risk factor. There are 
clinical signs and laboratory indices which can be used to assess the severity 
of pneumonia in an individual patient, some of which are predictive of an 
increased risk of death if present. 
Pleurisy  
Pleurisy is inflammation of the pleura, the serous membranes which cover the 
lungs and the inner aspect of the thoracic cavity. 
Pleural effusion is the accumulation of fluid between the inner and outer 
(visceral and parietal) layers of the pleura. It may arise as the result of 
pneumonia or of chronic heart failure or uraemia (when cultures will be 
negative), or by direct spread of infection, such as a primary tuberculous focus 
rupturing into the pleural cavity. Carcinomatous involvement of the visceral 
pleura is one of the more common causes of sterile pleural effusions. 
Effusion occurs early in the course of pneumonia representing the pleural 
response to an inflammatory reaction in the adjacent lung. Bacteria reach the 
pleural space by various routes: 
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• spread from an adjacent area of pneumonia 
• thoracic surgery or drainage 
• bacteraemia 
• chest trauma 
• trans-diaphragmatic spread from intra-abdominal infection 
Tuberculous pleural effusion usually arises as an extension of infection from a 
sub pleural focus. Only small numbers of bacilli are found in the effusion, as a 
result microscopy is rarely positive. Pleural biopsy is the specimen of choice. 
Pneumonia 
The aetiology of pneumonia varies according to whether it has been acquired 
in the community or in hospital and the risk factors present. Many of the 
bacteria found as colonisers of the upper respiratory tract have been 
implicated in pneumonia. Antibiotic treatment and hospitalisation affect the 
colonising flora, leading to an increase in numbers of aerobic Gram-negative 
bacilli. These factors affect the sensitivity and specificity of sputum culture as 
a diagnostic test and results must always be interpreted in the light of the 
clinical information. Many patients do not have a productive cough and are 
frequently unable to produce sputum. Sputum culture results are often 
unreliable and sensitivity of culture is poor for many pathogens. 
Community acquired pneumonia 
The commonest cause overall is Streptococcus pneumoniae, which is 
responsible for up to 60% of cases in community based surveys. It can affect 
individuals of any age, including those without known risk factors. Other 
bacterial pathogens tend to cause pneumonia in the presence of specific risk 
factors. Patients with COPD are additionally at risk of pneumonia caused by 
Haemophilus influenzae and Moraxella catarrhalis. Staphylococcus aureus 
pneumonia occurs either in the context of recent influenza infection or, less 
commonly, as a result of bloodborne spread from a distant focus, COPD or 
aspiration. Aerobic Gram-negative rods are rare causes of community 
acquired pneumonia. Occasionally, Klebsiella pneumoniae causes a severe 
necrotizing pneumonia, typically in patients with a history of alcohol abuse and 
homelessness (“Friedlanders” pneumonia). 
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Mycoplasma pneumoniae causes up to 20% of community acquired 
pneumonia, second only to Streptococcus pneumoniae. It tends to occur in 
epidemics every 4-5 years and affects younger age groups. Chlamydia 
pneumoniae is an exclusively human pathogen, but pneumonia caused by 
Chlamydia psittaci and Coxiella burnetii occurs in individuals with the relevant 
exposure history (birds and farm animals). These agents are responsible for a 
minority of cases. Legionella pneumophila is a rare cause of outbreaks of 
community acquired pneumonia and about 50% of cases seen in the UK give 
a recent history of travel. Respiratory viruses, such as RSV, influenza and 
adenoviruses may occasionally cause primary viral pneumonia. Other rare 
causes of community acquired pneumonia include Pasteurella species and 
Neisseria meningitidis. 
Hospital acquired pneumonia 
This is the second commonest type of nosocomial infection. Risk is increased 
by the presence of underlying disease and by various interventions and 
procedures. Mechanical ventilation is a major risk factor. Aerobic Gram-
negative bacilli, including members of the Enterobacteriaceae (such as 
Klebsiella and Enterobacter species) and Pseudomonas aeruginosa are 
implicated in up to 60% of cases. 
Pneumonia in special situations and patient groups 
Aspiration pneumonia: 
This occurs when oropharyngeal contents are introduced into the lower 
respiratory tract. Reduced level of consciousness, for instance following head 
injury or drug overdose is a risk factor, as are weak gag and cough reflexes 
which can follow a stroke or other neurological disease. True aspiration 
pneumonia usually has an insidious onset. Anaerobes such as 
Porphyromonas species, Fusobacterium, Prevotella and anaerobic 
streptococci are implicated and may be part of a mixed infection with aerobic 
bacteria. Lung abscess formation and empyema are common complications. 
Lung abscess: 
This may be secondary to aspiration pneumonia, in which case the right 
middle zone is most frequently affected. Other organisms may give rise to 
multifocal abscess formation and the presence of multiple small abscesses 
(<2cm diameter) is sometimes referred to as necrotising pneumonia. 
Pneumonia caused by S. aureus and K. pneumoniae may show this picture. 
Nocardiosis, almost always occurring in a setting of immunosuppression, may 
present as pulmonary abscesses. Abscesses as a result of blood borne 
spread of infection from a distant focus may occur in conditions such as 
infective endocarditis. Burkholderia pseudomallei may cause lung abscesses 
or necrotising pneumonia in those who have visited endemic areas (mainly 
south East Asia and northern Australia). 
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Lemierre's syndrome or necrobacillosis originates as an acute oropharyngeal 
infection. Infective thrombophlebitis of the internal jugular vein leads to septic 
embolisation and metastatic infection. The lung is most frequently involved 
and multifocal abscesses may develop. Fusobacterium necrophorum is the 
most common pathogen isolated from blood cultures in patients with this 
syndrome. 
Cystic fibrosis 
The major cause of morbidity and mortality in cystic fibrosis patients is 
progressive pulmonary disease associated with pulmonary infection. The 
major pathogens are S. aureus, H. influenzae, S. pneumoniae and 
pseudomonads, particularly mucoid P. aeruginosa strains. Strains of P. 
aeruginosa with differing antibiotic susceptibilities may be isolated from a 
single sample. Anaerobes may also be present. 
Resistance to antibiotics, particularly in Burkholderia cepacia, 
Stenotrophomonas maltophilia (both previously in genus Pseudomonas) and 
P. aeruginosa, limits the options for treatment. Transmission of B. cepacia 
between patients may occur and some patients succumb to "B. cepacia 
syndrome" which is a rapidly fulminating pneumonia sometimes accompanied 
by septicaemia. Nosocomial transmission of Burkholderia gladioli has also 
been reported. Fungi, particularly Candida and Aspergillus species have also 
been implicated in infections in cystic fibrosis patients. 
Fungal infections 
Exposure to environmental fungi is universal and the outcome of exposure is 
a function of the immune status of the individual and the intrinsic pathogenic 
potential of the fungus involved. Candida species are normal human 
commensals. Aspergillus species and Pneumocystis carinii have a worldwide 
distribution. Cryptococcus neoformans is also ubiquitous, but certain 
serotypes (C. neoformans var gattii) are restricted to tropical and subtropical 
areas. 
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Candida species are extremely rare causes of LRTI. Occasionally infection 
occurs as a result of haematogenous seeding. Diagnosis is difficult given that 
the airways may become heavily colonised in compromised patients. 
Aspergillus fumigatus is the commonest Aspergillus species to infect humans. 
Pulmonary manifestations in hosts without major impairment of cellular or 
humoral immunity include allergic bronchopulmonary aspergillosis in patients 
with asthma or cystic fibrosis and aspergilloma, which occurs when the 
organism colonises a pre-existing lung cavity or cyst. Invasive pulmonary 
aspergillosis may have an acute and rapid course in heavily 
immunosuppressed patients (e.g. allogeneic bone marrow transplant 
recipients) or a more chronic indolent progression in less compromised 
patients (e.g. chronic granulomatous disease, HIV infection). Pneumonia 
caused by P. carinii occurs in the setting of impaired cell-mediated immunity 
such as advanced HIV infection and solid organ or bone marrow 
transplantation. 
Cryptococcal pulmonary infection is unusual in the absence of immune 
dysfunction and may coexist with extrapulmonary cryptococcosis. Pneumonia 
may be severe and rapidly progressive in patients with advanced HIV infection 
but those with better immune function may have a more indolent and variable 
course. Several other fungi have been reported to cause pulmonary infection 
in immunocompromised patients, often as part of multisystem disseminated 
disease. Penicillium marneffei infection typically occurs in HIV-infected 
patients in areas of South East Asia where it is endemic. Pseudallescheria 
boydii, Fusarium, Alternaria and zygomycetes have been implicated in 
infections in patients being treated for haematological malignancy and in bone 
marrow transplant recipients. 
Some unusual fungal causes of LRTI are endemic to defined geographical 
areas. Although many infections are sub clinical, clinically apparent infections 
are occasionally imported into the UK. They occur in persons with normal 
immunity but tend to be more severe in the immunocompromised. The 
diagnosis should be considered in travellers returning from endemic areas 
who present with respiratory illness or pneumonia, particularly if they fail to 
respond to standard therapy. These infections include: histoplasmosis, 
caused by Histoplasma capsulatum (south east USA, Central America); 
coccidiodomycosis, caused by Coccidiodes immitis (south west USA, Central 
and South America) and blastomycosis caused by Blastomyces dermatidis 
(eastern USA, Africa). Although these infections have distinguishing 
characteristics, it is often difficult to differentiate them clinically from other 
causes of respiratory infection, particularly in their early stages. 
Paracoccidioidomycosis caused by Paracoccidioides brasiliensis (Central and 
South America) usually causes asymptomatic primary pulmonary infection, 
which may reactivate if immune function declines. 
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Immunosuppression 
Patients with congenital or acquired immune defects are susceptible to 
infection with unusual organisms which do not cause problems in the normal 
host. The range of organisms to which an individual is susceptible varies 
according to the nature of the immune defect. In addition, these patients 
remain at risk of infection with the common pathogens. Environmental 
bacteria such as Nocardia species, Rhodococcus equi, Legionella species 
and environmental mycobacteria may be implicated. Fungal pathogens such 
as Pneumocystis carinii and Aspergillus species are also important as are 
herpesviruses, particularly cytomegalovirus. Patients with advanced HIV 
disease and transplant recipients are susceptible to P. carinii pneumonia and 
mycobacterial infection. CMV infection often manifests itself as pneumonitis in 
heart, lung and heart/lung transplant recipients (but HIV infected individuals 
only rarely get CMV pulmonary disease). Invasive pulmonary aspergillosis is 
seen especially in patients who have had prolonged periods of 
granulocytopenia. 
Mycobacterial disease 
Primary pulmonary infection with Mycobacterium tuberculosis may lead to the 
formation of the ‘primary complex’, particularly in childhood. The pulmonary 
focus may be relatively small, but the draining hilar lymph nodes become 
greatly enlarged and may rupture, spreading infectious material into other 
areas of the lung. It is at this stage that miliary spread to other organs may 
occur via blood and lymphatics. Adolescents and adults may have 
asymptomatic primary infection, a typical primary complex or infection which 
progresses to typical chronic cavitating tuberculosis. Chronic cavitating 
disease is usually seen in reactivated primary infection and the lung apices 
are most commonly involved. The cough which accompanies this process 
produces aerosols of infectious particles which are the route by which other 
persons may become infected. 
Nocardia and Actinomyces infections 
Nocardiosis and actinomycosis are rare conditions which may affect other 
systems apart from the lungs. Nocardia is most often seen in the lung where it 
may cause acute, often necrotising, pneumonia. This is commonly associated 
with cavitation. It may produce a slowly enlarging pulmonary nodule and 
pneumonia which is often associated with empyema. Immune defects ranging 
from alcoholism to organ transplantation and HIV infection are present in the 
majority (60% plus) of patients presenting with nocardiosis. Actinomyces 
species cause a thoracic infection which may involve the lungs, pleura, 
mediastinum or chest wall. Cases often go unrecognised until empyema or a 
chest wall fistula develops. Aspiration of oral contents is a risk factor for the 
development of thoracic actinomycosis, thus predisposing conditions include 
alcoholism, cerebral infarction, drug overdose, general anaesthesia, seizure, 
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diabetic coma or shock. The appropriate specimens for investigation of both 
these organisms are pus, tissue and biopsy specimens. 
Parasitic infections 
Several helminth infections may give rise to a syndrome characterised by 
patchy pulmonary infiltrates and eosinophilia accompanied by symptoms of 
cough, fever and weight loss. These signs and symptoms are associated with 
passage of larval forms through the lungs and include Ascaris lumbricoides, 
hookworms and Strongyloides stercoralis. The lung fluke, Paragonimus 
westermanii has a wide distribution and is particularly prevalent in the far 
East, Indian subcontinent and West Africa. Human infection is acquired by 
consumption of uncooked freshwater crabs or crayfish, which harbour 
encysted metacercariae. Although infection may be asymptomatic, heavy 
infestations are manifested by pulmonary infiltrates as above which may 
progress to chronic productive cough with pleuritic chest pain. Ova of P. 
westermanii are demonstrable in sputum. Refer to parasite SOP for 
processing of samples for parasite examination. 
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Specimen processing 
 
SAMPLES SHOULD BE GRADED AS FOLLOWS: 
 
100% pus    - Purulent  
 
The sample is stuck to the container and does not move 
when it is inverted. 
 
 
75% pus / 25% saliva  - Mucopurulent 
 
 
 
50% pus / 50% saliva  - Mucopurulent 
 
 
 
25% pus / 75% saliva  - Mucopurulent 
 
 
 
100% saliva    - Mucoid 
 
The sample may be discarded as unsuitable using the Apex code MUCOID, 
unless it is from an ICU/HDU, cystic fibrosis or immunocompromised patient. 
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Preparation of Sputasol 
Carefully using forceps peel the metal foil from a fresh vial of Sputasol 
(Refrigerator Category 3 suite) and discard the foil into a Sharps box. 
Using a medical flat containing 100 ml of sterile de-ionised water pour in the 
vial of Sputasol and mix until dissolved. Using a sterile pipette place the 
contents of the vial into the remainder of the de-ionised water, tighten cap, mix 
and label with the current date. Sputasol must not be used if more than 48 
hours old. 
Store in the Blood Culture refrigerator. Discard the Sputasol glass vial into the 
Sharps box. 
Sputum Culture Protocol 
Before culture is commenced check the sample details match those on the 
request form and proceed to number the appropriate plates according to the 
tables at the back of the SOP, or the quick guide at the front of the SOP 
(MIFSOP 033). 
Carry the plates and samples into the Category 3 suite in carrier racks and 
place into the safety cabinet. Switch on the safety cabinet and ensure the air-
flow readings are within range before commencing. If not inform a Senior 
member of staff – DO NOT PROCEED UNTIL RECTIFIED. 
Put on relevant P.P.E (Disposable gloves and safety gown) 
Using a sterile pipette, add an equal volume of Sputasol to the samples, 
discard the pipette to waste. Tighten the lids securely and vortex until the 
sample is fully homogenised.  
Using a 10 μl loop place a level loopful of sample into 5 ml of sterile de-
ionised water, and vortex to homogenise. Discard loop to waste jar. 
Using a separate sterile 10 µl loop, inoculate the appropriate plates and 
spread for single colonies. Discard the loop into the discard jar. 
Incubate the plates in appropriate atmospheric conditions for 24 hours, and 
examine for typical bacterial pathogens as contained in the tables. Re-
incubate as required according to the tables. 
Store samples in the cold room when finished. 
Wipe down the safety cabinet with Terminex after culturing a batch of 
samples, discard gloves into clinical waste bags and remove gown. 
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Pleural Fluids Culture Protocol 
Upon arrival in the laboratory check that the sample details match those on 
the request form. In the category 3 suite, place the sample into the sealed 
centrifuge buckets and balance ready for centrifugation. Spin the sample for 
10 minutes at 3000 r.p.m. Turn on the safety cabinet and check readings are 
acceptable before proceeding.  
Pour off the sample supernatant into a labelled sterile universal. Number up 
the plates as per protocol and place 5 drops of spun deposit onto a vial of 
sterile saponin (Blood Culture Refrigerator) using a sterile Pasteur pipette. 
Vortex to mix. Using a 10 µl loop apply 10 µl to the culture plates and spread 
for single colonies. Discard loop and pipette into discard waste. Incubate the 
plates under the appropriate atmospheric conditions overnight before 
reading. See tables for list of appropriate pathogens. Re-incubate as 
required. 
Tissues and Biopsies Culture Protocol 
Upon arrival in the laboratory check that the sample details match those on 
the request form. Label the plates as appropriate and transfer to the safety 
cabinet. Pour Terminex into autoclavable container and place into the cabinet. 
Switch on the safety cabinet and ensure the air-flow readings are within range 
before commencing. If not inform a Senior member of staff – DO NOT 
PROCEED UNTIL RECTIFIED. 
Put on relevant P.P.E (Disposable gloves and safety gown) 
Place the sample into a tissue grinder, add 3 drops of sterile de-ionised water, 
and grind the sample ideally until a smooth homogenous suspension is 
achieved. Occasionally the sample may be difficult to grind, in such cases 
grind the sample for at least 10 minutes. Using a 10 µl loop place a loopful of 
the ground tissue suspension onto each plate and spread for single colonies. 
Discard loop into discard waste. Upon completion of all cultures and 
enrichments place the grinder into the disinfectant and using a pipette ensure 
the grinder is filled. Leave to stand overnight before autoclaving. 
Incubate the plates under the appropriate atmospheric conditions overnight 
before reading. See tables for list of appropriate pathogens. Re-incubate as 
required. 
Respiratory Swab Culture Protocol 
Occasionally swabs of respiratory samples are sent. These are often from CF 
patients, lung Tx donors or from anastomosis sites. These are cultured 
according to the quick guide. The sample is checked to ensure the details 
match those on the request form. Number the plates as appropriate and 
inoculate the swab onto the plates and spread for single colonies. Place swab 
into appropriate rack in cold room upon completion. Incubate the plates under 
the appropriate atmospheric conditions overnight before reading. See tables 
for list of appropriate pathogens. 
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BAL Samples 
Introduction 
It is possible to recover bacteria, viruses, protozoa and fungi responsible for 
pulmonary infection from BAL specimens. Although isolation of Aspergillus 
species from BAL is of value in patients with invasive disease, it is only 30% 
sensitive. BAL specimens are particularly useful in the diagnosis of 
Pneumocystis carinii pneumonia, pneumonia caused by Legionella 
pneumophila and for the detection of Mycobacterium tuberculosis presenting 
as pneumonia. 
Bronchoalveolar lavage (BAL)  
A segment of lung is `washed' with sterile saline after insertion of a flexible 
bronchoscope, thus allowing recovery of both cellular and non-cellular 
components of the epithelial surface of the lower respiratory tract. It is a 
reliable method for making a definitive aetiological diagnosis of pneumonia 
and other pulmonary infections. 
Non directed bronchoalveolar lavage (NBL) 
A suction catheter, preferably a protected BAL catheter to minimise 
contamination, is passed down the endotracheal tube until resistance is met. 
An aliquot of sterile saline is injected and then aspirated. This method 
provides a lower respiratory tract sample without the need for bronchoscopy 
and without the attendant risks of transtracheal aspiration. 
Culture of BAL samples 
Before culture is commenced check the sample details match those on the 
request form and proceed to number the appropriate plates according to the 
tables at the back of the SOP, or the quick guide at the front of the SOP 
(MIFSOP 030). 
Carry the plates and samples into the Category 3 suite in carrier racks and 
place into the safety cabinet. Switch on the safety cabinet and ensure the air-
flow readings are within range before commencing. If not inform a Senior 
member of staff – DO NOT PROCEED UNTIL RECTIFIED. 
Put on relevant P.P.E (Disposable gloves and safety gown). 
Place the sample into the sealed centrifuge buckets and balance ready for 
centrifugation. Spin the sample for 10 minutes at 3000 r.p.m. In the safety 
cabinet transfer the supernatant into a labelled plastic universal. Add 20 ml of 
sterile de-ionised water to the deposit and vortex. Centrifuge the sample again 
and discard the supernatant to another labelled plastic universal. Vortex. The 
sample is now ready for culture. 
Lavages from patients are cultured as neat onto the appropriate plates by 
placing 10 µl of sample onto the plates and spreading for single colonies. 
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Lavages from patients with cystic fibrosis and bronchiectasis may also be 
diluted by placing a 10 µl loopful into 5 ml of sterile de-ionised water and 
inoculating this diluted sample onto a chocolate plate only. Discard loops into 
discard waste. 
Incubate the plates under the appropriate atmospheric conditions overnight 
before reading. See tables for list of appropriate pathogens. Re-incubate as 
required. 
Interpretation guidelines 
This applies to all routine samples from FRH, RVI, Clinics, Outpatients and 
GP’s. It excludes samples from both Critical Care sites, CF patients and 
bronchiectasis. 
Sensitivities are performed on Pseudomonas spp, Coliforms and S. aureus 
when: 
- Heavy and pure from a purulent sample 
- Or accompanied by good clinical details 
 
Sensitivities are suppressed. The medical staff may add a further comment if 
necessary. 
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Charts 
BAL Samples (Diagnostic/Donor/Recipient) 
Clinical 
details/ 
Conditions 
Standard media Incubation Cultures 
read 
Target organism(s) 
  
Temp 
(
o
C) Atmos Time 
  
Culture neat 
only 
Blood agar 
 
35-37 5-10% 
CO2 
24-48 h Daily 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Other organisms in pure growth may be 
significant. 
 
CBAC 35-37 5-10% 
CO2 
24-48 h Daily Haemophilus sp 
Enterobacteriaceae 
Pseudomonads sp. 
Capnocytophagia 
 
Legionella media 35-37 CO2 10 days Daily Legionella sp. Nocardia 
 Gram stain     Any organisms and cellular examination 
 
Send sample to 
HPA for TB 
culture 
    Mycobacteria 
 
Sab  35-37 Air 5 Days Daily Candida sp. 
Aspergillus sp. Other fungi. 
If the patient 
has cystic 
fibrosis then 
add the 
following: 
      
 
B. cepacia 
media 
35-37 Air 5 days 
10-day 
terminal 
read 
Daily B. cepacia, B. gladioli 
Atypical Mycobacteria 
 
SAID 35-37 Air 24-48 h Daily S. aureus 
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Sputum 
General guidance on Culture media, conditions and organisms  
Clinical 
details/conditions 
Standard 
media 
Incubation Cultures 
read 
Target organism(s) 
  Temp 
(
o
C) Atmos Time 
  
Routine sputum 
samples, 
NB, dilute 10 μl of 
sample into 5 ml 
water 
NP and ET 
secretions 
 
Blood 
agar 
 
35-37 5-10% 
CO2 
24-48 h 
 
Routine 
GP 
samples 
24 h 
 
Daily 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Other organisms in pure growth may be 
significant. 
 CBAC 35-37 5-10% 
CO2 
24-48 h Daily Haemophilus sp 
Enterobacteriaceae 
Pseudomonads sp. 
Capnocytophagia 
Culture all samples even if mucoid from all FH, RVI Critical Care and CF patients. 
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Bronchiectasis sputum 
 
  
Clinical 
details/conditions 
Supplementary 
media 
Incubation Culture
s read 
Target organism(s) 
  Temp 
(
o
C) Atmos Time 
  
Dilution Chocolate agar 35-37 CO2 24-48 h Daily 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Pseudomonas sp 
Neat culture Blood agar  35-37 CO2 24-48 h Daily 
 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Other organisms in pure growth 
may be significant. 
 CBAC 35-37 CO2 24-48 h Daily 
 
Haemophilus sp 
Enterobacteriaceae 
Pseudomonads sp. 
Capnocytophagia 
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Cystic fibrosis sputum 
 
  
Clinical 
details/conditions 
Supplementary 
media 
Incubation Cultures read Target organism(s) 
  Temp 
(
o
C) Atmos Time 
  
Dilution Chocolate agar 35-37 CO2 24-48 
h 
Daily 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Pseudomonas sp 
Neat culture Blood agar  
 
35-37 CO2 24-48 
h 
Daily 
 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Other organisms in pure growth 
may be significant. 
 CBAC 
 
 
35-37 CO2 24-48 
h 
Daily 
 
Haemophilus sp 
Enterobacteriaceae 
Pseudomonads sp. 
Capnocytophagia 
 CLED 35-37 Air 24-48 
h 
Daily 
 
Enterobacteriaceae 
Pseudomonas sp 
 Sab 35-37 Air 5 days Daily Aspergillus sp. And other fungi 
Candida sp. 
 SAID 35-37 Air 24-48 
h 
Daily 
 
S. aureus 
 B. Cepacia 
media 
30 Air 5 
Days 
Daily 
10-day Terminal 
Read 
B. cepacia, B. gladioli 
 
Atypical Mycobacteria 
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Cough swabs 
Clinical 
details/conditions 
Standard 
media 
Incubation Cultures 
read 
Target organism(s) 
  Temp 
(
o
C) Atmos Time 
  
Cough swab 
Not cystic fibrosis 
Blood agar  
 
35-37 5-10% 
CO2 
24- 48 h Daily 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Other organisms in pure growth may be 
significant 
 CBAC 
 
35-37 CO2 24-48 h Daily Haemophilus sp 
Enterobacteriaceae 
Capnocytophagia 
Pseudomonas sp. 
Cystic fibrosis Cepacia  
media 
30 Air 5 days 
10 day 
terminal 
read 
Daily B. cepacia 
B .gladioli 
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Pleural fluids 
* TB Sent only on request 
  
Clinical 
details/Conditions 
Supplementary 
media 
Incubation Cultures 
read 
Target organism(s) 
  Temp 
(
o
C) Atmos Time 
  
Centrifuge Saponise 
Chocolate agar 
Blood agar 
35-37 CO2 24-48 h Daily 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Pseudomonas sp 
 
Blood agar 35-37 An 24-48 h Daily Anaerobes 
On request only 
Legionella plate 35-37 CO2 10 days Daily 
 
Legionella sp. 
All samples from 
Freeman Wards 23 
and 28 
Pneumocoocal 
antigen testing 
    Forward sample to serology for 
testing. 
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Lung tissue samples, biopsy and PM materials, empyema 
  
Clinical 
details/Conditions 
Supplementary 
media 
Incubation Cultures read Target organism(s) 
  Temp 
(
o
C) Atmos Time 
  
Grind sample in 
tissue grinder as 
appropriate 
Choc 35-37 CO2 24-48 h Daily Haemophilus sp 
Enterobacteriaceae 
Pseudomonads sp. 
Capnocytophagia 
 
Blood agar 
 
35-37 CO2 24-48 h Daily 
 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Other organisms in pure 
growth may be significant. 
 
Sab 35-37 Air 5 Days Daily 
 
Candida sp. 
Aspergillus sp. and other 
fungi. 
 
Blood Agar 
and FAA Neo 
+ Mz 5 discs 
35-37 An 5 Days After 48 hours in 
cabinet then at 5 
days 
 
Anaerobes 
 
Enrichment if 
required 
Robertsons 
Cooked Meat 
broth 
35-37 Air 48 hours Subculture at 48 
hours 
Anaerobes. 
Any other pathogenic sp. 
 
Legionella plate 
Not neonates 
35-37 CO2 10 days Daily Legionella sp. 
 
TB culture 
Not neonates 
    On Empyema samples on 
Medical Request only 
Empyema 
     Send to Serology for Pn 
Antigen 
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Lung abscess and aspiration pneumonia sputum 
  
Clinical 
details/conditions 
Standard 
media 
Incubation Cultures read Target organism(s) 
  Temp 
(
o
C) Atmos Time 
  
Culture Sample 
Neat 
Blood agar 
 
35-37 5-10% 
CO2 
24-48 h Daily 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Other organisms in pure growth 
may be significant 
 CBAC 35-37 5-10% 
CO2 
24-48 h Daily Haemophilus sp 
Enterobacteriaceae 
Pseudomonads sp. 
Capnocytophagia 
Not required for 
aspiration 
pneumonia 
Sab 35-37 Air 5 Days Daily Candida sp. 
Aspergillus sp. and other fungi. 
 Blood Agar 
and FAA Neo 
+ Mz 5 discs. 
35-37 An 5 Days After 48 hours in 
cabinet then at 5 
days. 
Anaerobes 
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Transplant assessment and post lung transplant sputum 
 
Clinical 
details/Conditions 
Supplementary 
media 
Incubation Cultures 
read 
Target organism(s) 
  Temp 
(
o
C) Atmos Time 
  
Culture Neat 
CBAC 35-37 CO2 24-48 h Daily Haemophilus sp 
Enterobacteriaceae 
Pseudomonads sp. 
Capnocytophagia 
 
Blood agar 35-37 CO2 24-48 h Daily 
 
S. pneumoniae 
M. catarrhalis 
S. aureus 
Other organisms in pure growth 
may be significant 
 
CLED 35-37 Air 24-48 h Daily 
 
Use on CF only. 
 
Sab agar 35-37 Air 5 Days Daily Aspergillus sp and other fungi 
Culture dilute onto 
Chocolate agar 35-37 CO2 24-48 h Daily H. influenzae, S. pneumoniae 
 
      
If CF patient add in  
the following: 
B. cepacia 
Medium 
35-37 Air 5 days 
10-Day 
Terminal 
read 
Daily B. cepacia, B. gladioli 
 
Atypical Mycobacteria 
 
SAID 35-37 Air 24-48 Daily S.aureus  
If cystic fibrosis 
Tx Assessment 
TB culture     Forward to HPA Newcastle 
 
If cystic fibrosis 
TX assessment 
B. cepacia broth 35-37 Air Plate after 
48 hrs onto 
B. cep. 
media 
Read after 
72 hrs 
B. cepacia 
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Respiratory Sample Quick Guide 
CODE SPECIMEN BA CBAC CHOC CLED 
2D 
SAB 
5D 
SAB 
AN 
BA SAID CEP 
LEG 
Full 
plate 
5D AN 
(FAA/BA) ROB STB H.D.A COMMENTS 
R1 Sputum:- Routine Dil Dil              
                 
R2 Sputum:- Routine Critical Care  Y Y            Y Use 1/4 HDA plate 
 All CC, ITU, HDU and PICU                
                 
R5 
SCIDS/Immunosuppressed 
Sputum/ETS/NPS etc 
RVI:- GNCH03, 04, 14, 35SCBU Y Y   Y          Use 1/4 SAB plate 
                 
R12 Sputum, Bronchiectasis Y Y Dil             
                 
R4 Sputum, CF Y Y Dil Y  Y  Y Y     CC Use 1/4 SCID plate 
                 
R12 Sputum, Post LTx Y Y Dil           Y  
R13 Sputum, Post LTx, CF Y Y Dil Y    Y Y     Y  
R11 Sputum, Tx Assessment Y Y Dil   Y        Y  
R4A Sputum, Tx Assessment, CF Y Y Dil Y  Y  Y Y    Y Y Add B.cepacia broth 
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R9 
Sputum, asp.pneumonia/lung 
abscess  Y Y    Y     Y   CC  
                 
R2 ETS/NPS Y Y            CC  
                 
R2 Cough Swab Y Y             Includes bronchiectasis 
R6 CF Cough swabs Y Y       Y      Use 1/4 CEP plate for C/S 
                 
R7 Pleural Fluid Y  Y    Y       CC < 18-John P. 
R10 Pleural Fluid, Empyema Y  Y   Y Y   Y Y  Y CC All get Pn Ag < 18-John P. 
                 
R14 BAL* Y Y    Y    Y   Y CC Gram: Donor/Recip Tx** 
R17 BAL*, CF Y Y  Y  Y  Y Y Y   Y CC Gram: Donor/Recip Tx** 
                 
R8 Lung biopsy/tissue Y  Y   Y    Y Y Y Y CC 10 day AN (Nali/BA) 
R18 Neonatal death tissue Y  Y    Y    Y     
R16 Anastomosis specimens/wash Y Y    Y        CC  
R2 Airways/bronchus swab Y Y            CC  
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*
 BALS from the same lung can be pooled, but BALs from different lungs must be processed separately. 
**
 Label hospital number as GDON + hospital No. and names as DONOR + surname of recipient. Inform Prof. Gould/Crit Care cover with 
Gram-stain result direct sens may be required. 
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Appendix 5: COPD cohort demographic data 
Phenotypic and conventional microbiology culture data 
Sample number Sex Age Height (m) FEV1% 
predicted 
GOLD 
stage 
Ex-smoker Current 
smoker 
BAL microbiology data
a
 
CS#1 M 71 1.58 43 III Y N Streptococcus pneumoniae 
CS#3 M 67 1.61 49 III Y N Candida spp., & Haemophilus influenzae 
CS#4 M 52 1.64 68 II Y N No pathogens isolated 
CS#5 M 63 1.73 39 III N Y No pathogens isolated 
CS#6 M 64 1.83 49 III Y N Chryseobacterium indologenes 
CS#7 M 63 1.83 60 II Y N No pathogens isolated 
CS#8 M 69 1.67 43 III N Y Moraxella catarrhalis & Haemophilus influenzae 
CS#9 F 73 1.22 65 II Y N No pathogens isolated 
CS#10 M 61 1.74 43 III N Y Moraxella catarrhalis 
CS#11 M 62 1.73 36 III Y N No pathogens isolated 
CS#12 F 70 1.61 57 II Y N No pathogens isolated 
a
 CS#11 culture data was based on a bronchial secretion sample as patient was unable to produce BAL sample. 
Abbreviations: BAL, bronchoalveolar lavage; CS#X, COPD subject number; FEV1% predicted, forced expiratory volume in one second 
percentage predicted; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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